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General introduction 
Cancer is a major threat to public health. Last decades the global burden 
of cancer increased, due to a growing and ageing population. Currently, 
most developed countries face a phenomenon called double-ageing, 
elderly people are not only increasing in number but their life expectancy 
increased too.[1] As cancer is primarily a disease of older age this phenom-
enon will result in a further increase of absolute incidence rates. In the 
Netherlands, the most frequently diagnosed cancers are prostate cancer 
and breast cancer in men and women respectively.[2] 
 
Incidence of gastrointestinal cancer
Gastrointestinal malignancies represent a substantial proportion of the newly 
diagnosed cancers as well (figure 1). Colorectal cancer for instance, is the second 
most common cancer in both men and women. The high incidence rates of 
colorectal cancer have been attributed to the western lifestyle, including phys-
ical inactivity, smoking, alcohol consumption and a high consumption of red 
and processed meat.[3] Even so, gastric cancer is  an important health problem, 
being the fourth most common cancer and the second leading cause of cancer 
death worldwide. Fortunately, in western European countries the burden of 
gastric cancer decreased, most likely as a result of the eradication of Helicobacter 
Pylori. Helicobacter Pylori is the most common chronic bacterial infection 
in humans, affecting approximately 50% of the global population.[4] A large 
prospective Japanese study investigating the association between Helicobacter 
Pylori infection and the development of gastric cancer, found that 2.9% of the 
infected patients developed gastric cancer. Patients  with severe atrophy and 
intestinal metaplasia had an even higher risk.[5] Esophageal cancer is the eight 
most common cancer worldwide and the sixth leading cause of cancer-related 
mortality. Globally, squamous cell carcinoma is the predominant histologic 
subtype, however in the Netherlands the incidence of adenocarcinomas signifi-
cantly increased and now exceeds the incidence of squamous cell cancers. The 
most important risk factors for the development of esophageal adenocar-
cinomas include gastro-esophageal reflux disease and obesity. In contrast to 
gastric cancer, an inverse relationship was found between Helicobacter Pylori 
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infection and esophageal adenocarcinomas. The risk of developing esophageal 
cancer seems to be reduced in patients with a Helicobacter pylori infection.[6] 
In the Netherlands, pancreatic cancer is the tenth most common cancer 
and in developed countries it ranks the fourth leading cause of cancer related 
deaths.[7] Most patients present with advanced disease. In  our dataset 55% 
of the patients presenting with pancreatic cancer between 2009 and 2013 
had metastases at time of diagnosis. In general, 27% percent of the patients 
diagnosed with gastrointestinal malignancies had metastases at time of diag-
nosis. This percentage increased from 23% in 1989 to 30% in 2013. The lowest 
percentage of metastatic disease was found in patients with colorectal cancer, 
23% of these patients had metastases at time of diagnosis, compared to 37% 
in patients with gastroesophageal cancer and 55% in patients diagnosed with 
pancreatic cancer. 
Advances in systemic treatment 
Last decades, major changes have been made in the systemic treatment of 
advanced cancers. The first cytotoxic agent, nitrogen mustard, an alkylating 
agent was introduced shortly after World War II. However, for a long time 
researchers were very sceptic about the usefulness of chemotherapeutic 
agents. The turning point came when Li et al. demonstrated in 1958 that metho-
trexate, an antimetabolite, could cure women suffering from choriocarcinomas 
Figure 1  Proportion of newly diagnosed cancer patients presenting with 
gastrointestinal malignancies in the Netherlands 
Gastroesophageal cancer
Colorectal cancer
Pancreatic cancer
Other gastrointestinal malignancies
Other malignancies
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or related trophoblastic disease.[8] The evolution of chemotherapy in gastroin-
testinal cancers started in that period with the discovery of the antimetabolite 
fluorouracil, nowadays still the cornerstone in the treatment of  many gastroin-
testinal malignancies.[9] After the antimetabolites, antitumor antibiotics were 
introduced. These agents, derived from micro-organisms, were initially intro-
duced to treat infections.[10] Subsequently, they appeared to have an antitumor 
effect.[11] 
The antimitotic agents, including taxanes and vinca alkaloids, were discov-
ered in the 1960s as well. The taxanes had a difficult start.[8] Paclitaxel, the 
first taxane reached it's approval in 1992, almost three decades after its initial 
discovery.[10] Another subgroup of chemotherapeutic agents with a difficult 
start were the camptothecins. The first derivative of camptothecin, a topoisom-
erase I inhibitor, that achieved approval was irinotecan for the treatment of 
metastatic colorectal cancer in 1996.[8] Shortly after the introduction of irino-
tecan the cytotoxic agent oxaliplatin, a platin derivative showed to have effi-
cacy in colorectal cancer.[12]
Besides the increasing number of chemotherapeutic agents over time, new 
indications and drug combinations arose.  In the 1960s, it was shown that admin-
istering multiple drugs simultaneously  resulted in better outcomes. Nowadays 
drug combinations, dosing and scheduling have been carefully refined to maxi-
mize effectiveness and minimize side effects.[13] 
Initially, chemotherapy was solely prescribed in patients with metastatic 
disease. Around 1970, the first studies were initiated to investigate the role of 
chemotherapy after complete surgical resection in an attempt to reduce recur-
rence rates. The first large study investigating the effect of adjuvant chemo-
therapy in patients with resected colon cancer was published in 1990.[14] The 
study concluded that levamisole combined with 5-fluorouracil reduced the recur-
rence rate and improved overall survival of patients with Dukes C colon cancer. 
Anno 2016, adjuvant chemotherapy and neoadjuvant strategies are standard for 
the treatment of  breast cancer, colorectal cancer, gastroesophageal cancer and 
pancreatic cancer.
In the 21th century, a stagnation occurred in the discovery of new clini-
cally relevant cytotoxic agents. However, new insights in the development 
of tumors led to the development of an entire new class of drugs, known as 
‘targeted-agents’.[8,15] These agents inhibit specific targets such as growth 
factors, signaling molecules and molecules that promote angiogenesis.[8] 
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Targeted agents can be subdivided in monoclonal antibodies and small mole-
cules. Monoclonal antibodies target specific antigens on the cell surface such as 
transmembrane receptors or extracellular growth factors. Small molecules do 
not act on the surface of the cell but can penetrate through the cell membrane 
to interact with target proteins or enzymes. 
 One of the landmark events in the ‘targeted therapy’ revolution was the 
introduction of bevacizumab, an angiogenesis inhibitor, approved in 2004 for 
the treatment of  metastatic colorectal cancer. Bevacizumab is a monoclonal 
antibody directed against the vascular endothelial growth factor and is designed 
to slow down the growth of new blood vessels to the tumor.[16] Nowadays, 
bevacizumab is used in the systemic treatment of metastatic colorectal cancer, 
cervical cancer, ovarian cancer, non small cell lung cancer and breast cancer. 
A second class of monoclonal antibodies shown to be effective in metastatic 
colorectal cancer, are antibodies directed against the epidermal growth factor 
receptor (EGFR). The EGFR inhibitors (cetuximab, panitumumab) disrupt the key 
signaling pathway that is controlled by EGFR.[15] 
Trends in the prescription of systemic treatments 
The advances in cancer treatment had an enormous impact on clinical prac-
tice. In 1989 only 9% of all patients with solid malignancies in the Netherlands 
received chemotherapy, this percentage more than doubled to 22% in 2013. 
Together with the growing burden of cancer, the increased prescription rates 
resulted in a more than four-fold increase in absolute patient number, from 
4,800 patients in 1989 to 21,000 patients in 2013. 
Trends in prescription of systemic treatments in patients 
with non-metastatic malignancies 
In patients with non-metastatic malignancies, the prescription rate of (neo) 
adjuvant chemotherapy increased from 8% in 1989 to 18% in 2013. Significant 
increases were observed in patients with gastrointestinal malignancies, lung 
cancer and breast cancer. The prescription rate of adjuvant chemotherapy 
increased from 1% in 1989 to 60% in 2013 in patients with stage III colon cancer. In 
1996, the Dutch national guidelines recommended 5-fluorouracil based chemo-
therapy in patients with stage III colon cancer resulting in a sharp increase in the 
prescription of adjuvant chemotherapy (figure 2).[17] Prescription rates increased 
after the publication of two important trials. In 2004, the published MOSAIC trial 
 13
General introduction, outline and data sources     1
demonstrated that adding oxaliplatin to 5-fluorouracil further reduced recur-
rence rates in patients with stage III colon cancer after surgical resection.[18] 
One year later in 2005, the published X-ACT trial showed that oral capecitabine 
was at least as effective as intravenous fluorouracil. Furthermore, capecitabine 
was more patient convenient and associated with significantly fewer adverse 
events.[19] 
The management of locoregional esophageal cancer had undergone a major 
evolution over the past 15 years. For a long time, survival was poor after surgical 
resection due to locoregional or metastatic recurrence. Several studies have 
been conducted to improve outcome, investigating the effectiveness of periop-
erative chemotherapy and chemoradiotherapy. An important study in esopha-
geal cancer was the Dutch CROSS study, which compared chemoradiotherapy 
followed by surgery with surgery alone in patients with esophageal or esoph-
agogastric junction cancer. From March 2004 through December 2008, 368 
patients were randomly assigned to chemoradiotherapy, with weekly adminis-
tration of carboplatin and paclitaxel for 5 weeks with concurrent radiotherapy 
41.4 Gy in 23 fractions, followed by surgery or to surgery alone. The study found 
that preoperative chemoradiotherapy significantly improved the median overall 
survival from 24 months to 49 months. Furthermore, the regimen was associ-
ated with acceptable adverse-event rates.[20] 
One of the landmark trials in resectable gastric cancer was the British 
MAGIC trial, published in 2006. This trial evaluated the efficacy of perioperative 
chemotherapy in patients with resectable adenocarcinomas of the stomach. 
Five hundred and three patients were randomly assigned to perioperative 
chemotherapy and surgery or surgery alone. Chemotherapy consisted of three 
preoperative and three postoperative cycles, including epirubicin, cisplatin and 
fluorouracil. Patients treated with perioperative chemotherapy had a signifi-
cantly higher likelihood of progression-free survival and overall survival, with 
five-year survival rates of 36% compared to 23% in patients who underwent 
surgical resection alone.[21] Significant increased prescription rates were 
observed after the publication of this trial.
For the treatment of resectable pancreatic cancer some progress has been 
made with the introduction of adjuvant chemotherapy. In 2004 the results of 
the ESPAC-1 study were published, which found that adjuvant chemotherapy 
with 5-fluorouracil resulted in an improvement of median overall survival from 
15.5 months (5-year survival rate 8%) to 20.4 months (5-year survival rate 8%).[22] 
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In 2007, Oettle et al. found an improvement of disease free survival in patients 
treated with adjuvant gemcitabine. In 2008 the final result of this study 
showed a significant improvement of overall survival.[23] Gemcitabine became 
the reference adjuvant regimen in resectable pancreatic cancer.
Trends in prescription of systemic treatments in patients with 
metastatic malignancies 
In the period 1989-2013 a more than twofold increase in prescription rate was 
seen in patients with metastatic solid tumors, rates increased from 16% in 1989 
to 39% 2013. 
A sixfold increase was seen in the prescription of palliative chemotherapy in 
patients diagnosed with metastatic colorectal cancer (figure 3). Major advances 
have been achieved in the systemic treatment of colorectal cancer. Currently, 
there are several active drugs for patients with metastatic disease: fluorouracil, 
oxaliplatin, irinotecan, bevacizumab, cetuximab, panitumumab, aflibercept and 
regorafenib. The choice of the systemic regimen, single agent or combination 
Figure 2 Proportion of newly diagnosed patients with non-metastatic gas-
trointestinal cancers, treated with chemotherapy in the Nether-
lands from 1989-2013 
Pr
op
or
tio
n 
of
 p
at
ie
nt
s t
re
at
ed
 
w
ith
 ch
em
ot
he
ra
py
 (%
)
198
9
199
1
199
3
199
5
199
7
199
9
200
1
200
3
200
5
200
7
200
9
201
1
201
3
0
20
40
60
Stage III colon cancer
Non-metastatic pancreatic cancerNon-metastatic gastric cancer (non-cardia)
Non-metastatic esophageal cancer
 15
General introduction, outline and data sources     1
therapy with or without targeted therapy, depends on the goals of the treatment, 
the type and timing of prior treatment, the mutational profile of the tumor, the 
toxicity profiles of the drugs and patient related factors (e.g. comorbidity, age).
[24] Guidelines recommend a combination of a fluorpyrimidine, oxaliplatin and/
or irinotecan, with or without targeted agents in first line. The ongoing introduc-
tion of successful agents resulted in an impressive increase in prescription rates. 
 Although for other metastatic gastrointestinal malignancies, such as meta-
static esophageal cancer, gastric cancer and pancreatic cancer, advances in the 
systemic treatment were limited, a significant increase in prescription rates 
was observed. Trends in treatment of patients with metastatic upper gastroin-
testinal malignancies will be discussed more detailed in this thesis. 
Figure 3 Proportion of newly diagnosed patients with metastatic gastroin-
testinal cancers, treated with chemotherapy in the Netherlands 
from 1989-2013 
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Trends in survival of patients diagnosed with 
gastrointestinal malignancies 
The 5-year relative survival rate after diagnosis of cancer in the Netherlands 
improved. Among men, the relative 5-year survival rate increased from 41% in 
1989-1993 to 54% in 2003-2007. Among women, the rate increased from 57% 
to 63% in the respective periods.[1] The increased survival rate in men is mainly 
attributable to an increase in the incidence of prostate cancer and a decreased 
incidence of highly fatal cancers such as lung and gastric cancer. In women the 
increased survival is the result of the increased incidence of breast cancer with 
a relatively favorable survival. 
The overall survival in patients diagnosed with colon and rectal cancer 
improved, from respectively 54% in 1999-2001 to 58% in 2005-2007 for colon 
cancer and from 52.1% in 1999-2001 to 57.6% in 2005-2007 for rectal cancer.
[2] The advances in the systemic treatment of metastatic colorectal cancer are 
likely to attribute to the improved survival in these subgroups of patients. In the 
era of single agent fluorouracil overall survival was approximately 12 months 
in patients with metastatic colorectal cancer. Nowadays, the median overall 
survival is more than two years.[25]
Only modest improvement of the very poor overall survival was achieved 
in gastroesophageal cancer. In Europe, the five year relative overall survival for 
patients diagnosed with esophageal cancer increased from 9.8% in 1999-2001 
to 12.6% in 2005-2007. The relative five year overall survival in gastric cancer 
increased from 23.3% in 1999-2001 to 25.1% in 2005-2007. In Europe, the survival 
of these subgroup of patients remained dismal, especially when compared to 
the survival of patients diagnosed with gastric cancer in Asia.[26] 
Five-year relative survival in patients diagnosed with small bowel cancer 
increased from 41% in 1999-2001 to 49% in 2005-2007.[26] Presumably, the 
improvement in survival is partially explained by centralization of the surgery. 
Although this centralization occurred for pancreatic cancer as well, the 5-year 
relative overall survival of patients diagnosed with pancreatic cancer in Europe 
increased with only 1%, from 5% in 1997-2001 to 6% in 2005-2007. 
The improvements in survival of patients diagnosed with tumors of the 
upper gastrointestinal tract are mainly the result of advancements in the treat-
ment of non-metastatic disease, such as centralization of surgery, neoadjuvant 
chemoradiotherapy in resectable esophageal cancer, perioperative chemo-
therapy in resectable gastric cancer and adjuvant chemotherapy in resectable 
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pancreatic cancer. 
However, a significant proportion of the patients presents with metastatic 
upper gastrointestinal cancer varying from 32% esophageal cancer to 59% in 
pancreatic cancer. In this thesis, we will focus on these subgroups of patients. 
We will investigate the impact of treatment advances on overall survival in 
patients with metastatic upper gastrointestinal malignancies. 
Hospital variation & volume-outcome relationship 
Previous research showed that the care for cancer patients varied between 
hospitals. Guidelines recommend adjuvant chemotherapy including oxaliplatin 
combined with fluorouracil plus leucovorin or capecitabine. Steenbergen et al. 
showed that the initiation of adjuvant chemotherapy varied widely between 
ten community hospitals in the southern Netherlands. In patients < 65 years 
the prescription rate of adjuvant chemotherapy varied from 82% to 96%, in 
patients aged between 65-74 years the rate varied from 59% to 78% and in 
patients older then 75 years the rate varied between 9% and 25%.[27] 
In patients with metastatic upper gastrointestinal cancers, guidelines state 
that palliative chemotherapy can be considered. We want to investigate if this 
consideration also leads to variation in the prescription of palliative chemo-
therapy between ten community hospitals.  
During the past decade, centralization of high complex upper gastrointes-
tinal surgery has been discussed extensively. Multiple publications showed that 
centralization positively impacts the overall survival of patients diagnosed with 
resectable gastroesophageal and pancreatic cancer. It has been hypothesized 
that this improvement is not explained solely by the experience of the surgeon. 
Different aspects of the hospital structure such as the presence of an inten-
sive care unit, interventional radiology, experienced gastroenterologists and 
medical oncologists are hypothesized to influence the outcome as well.[28] In 
this thesis ,we investigate if being diagnosed or being treated in a high-volume 
center improves the survival of patients with metastatic pancreatic cancer. 
18
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Outline of this thesis 
This thesis presents an analysis of trends in incidence, treatment and overall 
survival in patients diagnosed with tumors along the upper gastrointestinal 
tract, with a focus on metastasized disease. The four anatomical subsites 
discussed in detail are the esophagus, stomach, pancreas and small intestine. 
The main objectives of the studies described in this thesis were:
• To investigate trends in treatment and overall survival of patients diagnosed 
with metastatic upper gastrointestinal cancers, including esophageal cancer, 
gastric cancer, small bowel cancer and pancreatic cancer. 
• To investigate hospital variation in the prescription of palliative chemo-
therapy in patients with metastatic gastric and pancreatic cancer. 
• To investigate the influence of incidence volume and treatment volume on 
median overall survival of patients diagnosed with metastatic pancreatic 
cancer. 
In chapter 2, the trends in treatment and overall survival of patients with 
synchronous metastatic esophageal cancer have been studied. Factors influ-
encing the likeliness of receiving external beam radiotherapy, brachytherapy, 
chemoradiotherapy or chemotherapy were analyzed and the impact of these 
treatment modalities on overall survival was studied. 
In chapter 3.1 an overview of the descriptive epidemiology of metastatic 
gastric cancer in the south of the Netherlands is given. Besides the influence 
of different patient and tumor characteristics on the prescription of pallia-
tive chemotherapy, this chapter investigates if there is an inter-hospital varia-
tion in the prescription of palliative chemotherapy. Chapter 3.2 reports on the 
subgroup of patients with peritoneal carcinomatosis of gastric origin. 
Chapter 4 provides an overview of the incidence, treatment and overall 
survival of patients diagnosed with an adenocarcinoma of the small bowel in 
the Netherlands. 
Trends in chemotherapeutic treatment in patients with metastatic pancre-
atic cancer and the effect of treatment on population-based survival are evalu-
ated and reported in chapter 5.1. Studying pancreatic cancer we observed that 
a large proportion of the pancreatic cancer patients did not have pathological 
verification of their tumor. Currently the guidelines in pancreatic cancer recom-
mend pathological verification for patients with suspected pancreatic cancer, 
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except for those with resectable disease where a biopsy prior to surgery is not 
always necessary. However, obtaining tissue for verification can be very diffi-
cult, therefore we conducted a population-based study to assess the relevance 
of pathological verification in chapter 5.2. Data of the studies represented in 
chapter 5.1 and 5.2 showed that only a small proportion of the patients had 
an overall survival exceeding two years. In chapter 5.3, we questioned whether 
long-term survival actually exists in pancreatic cancer. 
In an attempt to improve survival of patients diagnosed with resectable 
pancreatic cancer the surgical care for these patients is centralized in high 
volume centers. Different studies showed that centralization of pancreatic 
surgery positively impacted overall survival. In chapter 5.4 we hypothesize 
that being diagnosed or being treated in a high-volume incidence and/or high-
volume treatment center might influence the prognosis of patients with meta-
static pancreatic cancer. 
Data sources
Eindhoven cancer registry
The Eindhoven Cancer Registry (ECR) started in 1955 as part of a program for 
nationwide cancer registration. In the beginning, the registry comprised of data 
from three hospitals located in Eindhoven, which covered an area with almost 
1 million inhabitants. The area gradually expanded, since 1986 it covers almost 
the entire province Noord-Brabant and the northern part of Limburg. This area 
now hosts 2.4 million inhabitants and is served by 10 community hospitals, two 
radiotherapy institutions and six pathology laboratories. The pathology labo-
ratories participate in the nationwide automated pathological archive (PALGA) 
which notifies the cancer registry on all newly diagnosed malignancies. Within 
6-18 months after notification, information on patient characteristics, tumor 
characteristics and treatment is routinely extracted from medical records by 
trained registrars working on behalf of the cancer registry. 
Netherlands Cancer Registry
With the exception of the Eindhoven cancer registry, the other regional registries 
discontinued their activities, until a new nationwide program was established in 
1984. Since 1989 the entire Dutch population is covered by nine regional cancer 
registries, together establishing the Netherlands Cancer Registry, governed by 
20
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the Association of Comprehensive Cancer Centers. The Netherlands Cancer 
Registry is also notified by the national automated pathological archive, PALGA. 
The trained registrars collect information on the patients' past and current 
health status. Information on the vital status of patients was obtained from civil 
municipal registries and the central bureau for genealogy, which collect data on 
all deceased Dutch inhabitants. 
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Abstract
Background: We assessed the use of external beam radiotherapy, 
brachytherapy, chemoradiotherapy and chemotherapy in patients with 
metastatic esophageal cancer and evaluated the effect on overall survival.
Methods: We included all patients diagnosed with synchronous metastatic 
esophageal cancer in the south of the Netherlands between January 1, 1994 
and December 31, 2013. Proportions of patients treated with external beam 
radiotherapy, brachytherapy, chemoradiotherapy and chemotherapy 
were described with respect to the period of diagnosis, patient and tumor 
characteristics. Independent risk factors for death were discriminated.
Results: A total of 1,020 patients were included, 61.5% of these patients 
received palliative treatment with external beam radiotherapy, chemo-
radiotherapy, brachytherapy and/or chemotherapy. The use of external 
beam radiotherapy decreased from 44.5% in 1994 to 22.2% in 2013 (p=0.0001), 
whereas the use of chemoradiotherapy increased from 2.9% in 1994 to 19.1% 
in 2013 (p<0.0001). The prescription of systemic chemotherapy as a single 
modality increased from 13.9% to 30.5% (p<0.0001). The use of brachytherapy 
decreased from 20.9% in 1994 to 7.4% in 2013 (p=0.0013). The odds of receiving 
external beam radiotherapy, brachytherapy, chemoradiotherapy and 
chemotherapy, were influenced by different tumor and patient characteris-
tics such as age, gender, histologic subtype and number of metastatic sites. 
The median overall survival in patients with metastatic esophageal cancer 
significantly improved over time from 18 weeks (one-year survival rate 
14.4%) in 1994–1998 to 25 weeks (one-year survival rate 22.4%) in 2009–2013. 
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Patients treated with chemoradiotherapy had the most favorable prognosis, 
followed by patients treated with chemotherapy as a single modality.
Conclusion: The median overall survival of patients diagnosed with meta-
static esophageal cancer improved from 18 weeks in 1994–1998 to 25 weeks 
in 2009–2013. Although this increase could be attributed to stage migration, 
our population-based study suggests that major changes in treatment strat-
egies and appropriate patient selection might play a role as well.
Introduction
About 35% of the patients with esophageal cancer present with metastatic 
disease.[1] These patients have an extremely poor prognosis, with a 1-year 
survival rate of 18%.[2] Treatment of patients with metastatic esophageal 
cancer is complex, due to a wide range of local and systemic treatment options. 
In order to achieve adequate locoregional palliation, different modalities can be 
used, such as external beam radiotherapy, brachytherapy, chemoradiotherapy 
or endoscopic stent placement. Historically, external beam radiotherapy has 
played an important role in the management of locoregional disease. However, 
in 1992 the radiation therapy oncology group (RTOG) published a landmark trial 
(RTOG-85-01), which showed that chemoradiotherapy was superior to external 
beam radiotherapy in terms of survival and locoregional control in patients 
with locally advanced esophageal cancer.[3,4] The benefit of both treatments is 
often slow in onset, whereas a more rapid relief of dysphagia can be achieved 
with brachytherapy or endoscopic stent placement. Brachytherapy is recom-
mended for patients with a life expectancy between 3 and 6 months. In patients 
with a shorter life expectancy or those with a firm stenosing tumor, endoscopic 
stent placement is preferred, which offers instant relief of symptoms.[5-7]
Systemic chemotherapy can provide palliation, improve quality of life, and 
prolong survival in patients with metastatic gastroesophageal cancers.[8,9] 
There is no consensus regarding which regimen should be used in first line. 
Most guidelines advise that patients with a good performance status should 
be offered combination chemotherapy, including a platinum and fluoropyrimi-
dine derivative.[5,10] Population-based data on the use of the above mentioned 
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modalities in patients with metastatic esophageal cancer are sparse. In 2007, 
Cronin-Fenton et al. assessed trends over time for treatment of esophageal and 
gastric cancer. They observed an increased use of chemotherapy and radio-
therapy in surgically and non-surgically treated patients. However, they were 
unable to distinguish between curative and palliative treatments.[11] 
In the present population-based study we aimed to assess the use of 
external beam radiotherapy, brachytherapy, chemoradiotherapy and chemo-
therapy in patients with metastatic esophageal cancer. We evaluated which 
factors were associated with the use of the different modalities and assessed 
the effect on overall survival. 
Methods 
Data collection 
We obtained data from the Eindhoven Cancer Registry (ECR), which is main-
tained by the Comprehensive Cancer Centre Netherlands. The ECR is a popu-
lation-based registry that collects data on all patients with newly diagnosed 
cancer in the southern part of the Netherlands. The registry area comprises 
about 2,4 million inhabitants and encompasses 10 general hospitals, 2 large 
radiotherapy institutions and 6 pathology laboratories. These pathology labo-
ratories participate in the nationwide automated pathological archive (PALGA), 
which notifies the cancer registry on all newly diagnosed malignancies. Within 
6 to 18 months after notification, information on patient and tumor character-
istics are extracted from medical records, including age, gender, comorbidity 
(modified version of the Charlson comorbidity index), socioeconomic status 
(defined at neighborhood level, combining mean household income and mean 
value of the house/apartment), date of diagnosis, hospital of diagnosis, subside 
of primary tumor (International Classification of Diseases for Oncology (ICD-O) 
topotopography codes), morphology (ICD-O morphology codes), tumor stage 
(TNM classification staged following recommendations of the International 
Union Against Cancer in the respective period (4th-7th edition)), tumor grade and 
subsite of metastasis (ICD-O topography codes).
We included all patients diagnosed with esophageal cancer (ICD-O topo-
graphy codes C15.0-C15.9) in the south of the Netherlands between January 
1, 1994 and December 31, 2013. Our inclusion was limited to adenocarcinomas 
(ICD-O morphology codes 8140, 8142, 8144, 8145, 8210, 8211, 8255, 8260-8263, 
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8480, 8481, 8490, 8560, 8570, 8574) and squamous cell carcinomas (ICD-O 
morphology codes 8070-8076, 8078) of the esophagus. Other morphology 
codes were excluded or did not occur during the study period.
In this study, we focused on the treatment and survival of patients with 
metastatic adenocarcinomas or squamous cell carcinomas of the esophagus. 
We did not classify cervical and celiac lymph node involvement (M1a in the 
5th and 6th TNM edition) as metastatic disease, since after the introduction of 
the 7th TNM edition in 2010 these nodal metastases, regardless of the primary 
tumor location, are no longer regarded as distant metastatic disease.
The Eindhoven Cancer Registry contains information on primary therapies 
defined as therapies administered or planned within 6 months after the initial diag-
nosis. Trends in treatment with external beam radiotherapy, brachytherapy, chemo-
radiotherapy and chemotherapy over time are shown using three-year moving 
averages. Unfortunately, no information is available on endoscopic stent placement. 
To establish survival, patients’ vital status at January 1, 2015 was assessed 
through linkage with civil municipal registries and the central Bureau for 
Genealogy, which collects data on all deceased Dutch Citizens. 
Statistical analyses 
We described proportions of patients treated with external beam radiotherapy, 
brachytherapy, chemoradiotherapy and chemotherapy according to different 
patient and tumor characteristics. Trends in time were analyzed by means of 
a Cochran-Armitage trend test. Multivariable logistic regression analysis was 
used to identify predictive factors. Variables included in the analysis were sex, 
age, comorbidity, socioeconomic status, histologic subtype, number of meta-
static sites and period of diagnosis. 
Survival time was defined as the time from diagnosis till death or till 
January 1, 2015 for patients still alive. Survival was calculated based on all-cause 
mortality. Differences between survival curves were evaluated by means of a 
log-rank test. Independent risk factors for death were discriminated by means 
of multivariable proportional hazard regression modeling. To investigate the 
effect of different treatment modalities on the hazard ratios (HRs) of death, we 
built the model with and without treatment variables. 
Statistical analyses were carried out using SAS statistical software. (Version 
9.4, SAS institute, Cary, NC, U.S.A.). For all analyses, a two sided p-value p<0.05 
was considered statistically significant. 
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Table 1 Characteristics of patients with metastatic esophageal cancer, 
diagnosed between 1994 and 2013 in the southern Netherlands 
(N = 1,020)
Number Percentage
Sex
 Male 
 Female
810
210
79.4
20.6
Age (yrs.)
 <50 
 50-59
 60-69
 70-79
 ≥80 
72
237
341
270
100
7.0
23.2
33.4
26.5
9.8
No. of comorbid conditions 
 0
 1
 2 or more 
 Unknown 
463
343
159
55
45.4
33.6
15.6
5.4
Social economic status (SES)
 Low 
 Intermediate 
 High 
 Institutions 
 Unknown 
245
415
281
46
33
24.0
40.7
27.6
4.5
3.2
Histologic subtype
 Adenocarcinoma
 Squamous cell carcinoma
718
302
70.4
29.6
No. of metastatic sites
 1
 2
 3 or more 
704
227
89
69.0
22.3
8.7
Period of diagnosis 
 1994-1998
 1999-2003 
 2004-2008 
 2009-2013
111
214
307
388
10.9
21.0
30.1
38.0
Treatment 
 No treatment 
 External beam radiotherapy (EBRT)
 Brachytherapy (BRT) 
 Chemoradiotherapy (CRT)
 Chemotherapy (CT) 
393
247
178
99
218
38.5
24.2
17.5
9.7
21.4
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Figure 1 Percentage of patients presenting with metastases and number 
of affected organs, in patients with esophageal cancer diagnosed 
between 1994 and 2013 in the southern Netherlands (N=1,020)
Figure 2 Percentage of patients treated with external beam radiotherapy, 
brachytherapy, chemoradiotherapy and chemotherapy over time 
in patients with metastatic esophageal cancer, diagnosed between 
1994 and 2013 in the southern Netherlands (N=1,020)
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Results 
Between 1994 and 2013, 3,349 patients were diagnosed with esophageal cancer 
in the south of the Netherlands, of whom 1,020 (30,5%) were diagnosed with 
synchronous metastases. The characteristics of patients presenting with meta-
static disease are depicted in table 1. Overall, 79,4% of these patients were 
male and the median age at time of diagnosis was 66 years (range 31-93). 
Adenocarcinoma was the predominant subtype of esophageal cancer in 
our study (70,4%). In the course of time the proportion of adenocarcinomas 
increased from 48,7% in 1994-1998 to 75,8% in 2009-2013. 
The proportion of patients presenting with metastatic disease also increased 
over time from 21,9% in the period 1994-1998 to 32,1% in 2009-2013 (figure 1). 
Of the patients with metastatic disease, 69,0% had single site metastases, in 
22,3% 2 organs were affected and in the remaining 8,7% 3 or more organs were 
affected. The proportion of patients presenting with metastases in multiple 
organs increased significantly over time, from 10,8% in 1994-1998 to 37,4% in 
2009-2013 (p<0.0001). The most often affected sites were the liver (42,6%), the 
extra regional lymph nodes (44,5%) and the lungs (22,7%). 
Of the patients with metastatic esophageal cancer, 61,5% received external 
beam radiotherapy, chemoradiotherapy, brachytherapy and/or chemotherapy. 
The proportion of patients receiving treatment increased from 55,9% in 1994-
1998 to 69,9% in 2009-2013 (p=0.0001). Trends over time are depicted in 
figure 2. The use of external beam radiotherapy decreased during the study 
period from 44,5% in 1994 to 22,2% in 2013 (p=0.0001). Similarly, the use of 
brachytherapy decreased from 20,9% in 1994 to 7,4% in 2013 (p=0.0013). The use 
of chemoradiotherapy increased from 2,9% in 1994 to 19,1% in 2013 (p<0.0001). 
Chemotherapy as a single treatment modality increased from 13,9% to 30,5% 
(p<0.0001). Within the first 6 months after diagnosis, 82,6% of the treated 
patients (N=518) received treatment with one modality. Multiple modalities 
were used in 17,4% of the treated patients (N=109); 42 patients (6,7%) received 
external beam radiotherapy and brachytherapy, 22 patients (3,5%) received 
brachytherapy and chemotherapy and 38 patients (6,1%) received chemoradio-
therapy and chemotherapy. The majority of patients treated with chemoradio-
therapy and chemotherapy was treated between 2009 and 2013. 
Table 2a and 2b  present the crude percentages and adjusted odds ratios 
for the use of external beam radiotherapy, brachytherapy, chemoradio-
therapy and chemotherapy. Young patients (<50 yrs.) were more often treated 
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Table 2a Crude percentages and odds of receiving external beam radio-
therapy, brachytherapy and chemoradiotherapy in patients with 
metastatic esophageal cancer, diagnosed between 1994 and 2013 
in the southern Netherlands (N=1,020)  
Crude
% EBRT
Odds ratio 
(95% CI)
Crude 
% BRT
Odds ratio
(95% CI)
Crude 
% CRT
Odds ratio
(95% CI)
 Sex 
 Male 
 Female 
22.7
30.0
1.00 (reference) 
1.33 (0.93-1.90)
18.9
11.9
1.00 (reference)
0.58 (0.37-0.93)
9.6
10.0
1.00 (reference) 
1.05 (0.59-1.87)
Age (yrs.)
 <50 
 50-59 
 60-69 
 70-79 
 ≥80 
8.3
23.2
23.8
30.7
22.0
0.25 (0.10-0.62)
0.89 (0.59-1.33)
1.00 (reference) 
1.52 (1.04-2.21)
1.03 (0.58-1.81)
18.1
22.8
13.8
17.0
18.0
1.41 (0.70-2.87)
1.80 (1.15-2.80)
1.00 (reference)
1.30 (0.82-2.06)
1.55 (0.83-2.89)
13.9
12.7
12.9
5.6
0.0
1.55 (0.68-3.53)
1.13 (0.66-1.94)
1.00 (reference)
0.33 (0.17-0.53)
Not applicable
No. of comorbid 
conditions 
 0
 1 
 2 or more 
 Unknown 
24.0
27.4
20.8
16.4
1.00 (reference)
1.07 (0.77-1.51)
0.68 (0.43-1.09)
0.54 (0.25-1.17)
18.6
17.2
17.0
10.9
1.00 (reference)
1.04 (0.71-1.53)
1.07 (0.64-1.78)
0.48 (0.20-1.18)
19.2
17.6
14.9
10.0
1.00 (reference)
1.19 (0.71-1.97)
1.07 (0.53-2.16)
0.53 (0.12-2.39)
Social economic 
status (SES)
 Low 
 Intermediate 
 High 
 Institutions 
 Unknown
26.1
24.8
23.8
10.9
24.2
0.98 (0.67-1.43)
1.00 (reference)
1.02 (0.70-1.47)
0.34 (0.13-0.90)
1.13 (0.48-2.67)
17.1
18.1
16.7
13.0
24.2
0.98 (0.63-1.50)
1.00 (reference)
0.94 (0.62-1.43)
0.68 (0.27-1.70)
1.72 (0.72-4.12)
8.6
10.4
11.7
2.2
3.0
0.97 (0.54-1.74)
1.00 (reference)
1.10 (0.66-1.85)
0.31 (0.04-2.44)
0.23 (0.03-1.81)
Histology
 Adenocarcinoma
 Squamous-cell  
 carcinoma
21.2
31.5
1.00 (reference)
1.52 (1.10-2.11)
18.0
16.2
1.00 (reference)
0.92 (0.63-1.35)
9.3
10.6
1.00 (reference)
1.12 (0.67-1.86)
No. of 
metastatic sites
 1
 2
 3 or more 
26.4
21.6
13.5
1.00 (reference) 
0.82 (0.56-1.18)
0.58 (0.30-1.11) 
18.2
17.6
11.2
1.00 (reference) 
1.01 (0.67-1.51)
0.58 (0.29-1.18)
11.2
7.5
3.4
1.00 (reference)
0.49 (0.28-0.88)
0.15 (0.05-0.52)
Period 
 1994-1998
 1999-2003
 2004-2008
 2009-2013
36.0
30.8
17.3
22.7
1.00 (reference)
0.69 (0.41-1.15)
0.41 (0.24-0.70)
0.40 (0.24-0.66)
16.2
22.0
23.1
10.8
1.00 (reference)
1.40 (0.75-2.58)
1.55 (0.86-2.81)
0.60 (0.32-1.12)
2.7
2.3
7.5
17.5
1.00 (reference)
0.91 (0.21-3.94)
3.91 (1.13-13.54)
11.82 (3.55-39.36)
* EBRT: External Beam Radiotherapy, BRT: Brachytherapy, CRT: chemoradiotherapy 
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Table 2b Crude percentages and odds of receiving chemotherapy in 
patients with metastatic esophageal cancer, diagnosed between 
1994 and 2013 in the southern Netherlands (N =1,020) 
Crude % CT Odds ratio (95% CI) 
Sex
 Male 
 Female 
23.2
14.3
1.00 (reference)
0.75 (0.47-1.19)
Age (yrs.)
 <50 
 50-59 
 60-69 
 70-79
 ≥80
43.1
29.5
26.1
9.3
3.0
2.37 (1.31-4.31)
1.37 (0.92-2.04)
1.00 (reference)
0.24 (0.15-0.40)
0.07 (0.02-0.22)
No. of comorbid conditions 
 0
 1
 2 or more 
 Unknown 
26.6
19.5
13.2
12.7
1.00 (reference)
0.92 (0.63-1.35)
0.78 (0.44-1.37)
0.59 (0.25-1.43)
Social economic status (SES)
 Low 
 Intermediate 
 High 
 Institutions 
 Unknown
18.0
20.7
25.6
10.9
33.3
1.04 (0.66-1.62)
1.00 (reference) 
1.15 (0.77-1.72)
0.76 (0.27-2.16)
1.73 (0.71-4.22)
Histology
 Adenocarcinoma
 Squamous cell carcinoma
26.2
9.9
1.00 (reference)
0.30 (0.19-0.48)
No. of metastatic sites
 1 
 2
 3 or more 
20.5
23.8
22.5
1.00 (reference) 
0.96 (0.64-1.44)
0.62 (0.34-1.13)
Period of diagnosis
 1994-1998
 1999-2003
 2004-2008
 2009-2013
12.6
12.6
18.9
30.7
1.00 (reference)
0.83 (0.40-1.73)
1.57 (0.80-3.10)
3.56 (1.84-6.89)
* CT: chemotherapy 
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Table 3 Crude median overall survival, crude 1-year survival and risk 
of dying (hazard ratios) of patients with metastatic esophageal 
cancer, diagnosed between 1994 and 2013 in the southern 
Netherlands (N = 1,020) »
with chemotherapy, whereas external beam radiotherapy was prescribed 
less frequently to young patients. Patients aged 70 or older had lower odds of 
receiving chemotherapy and chemoradiotherapy. Histologic subtype was associ-
ated with the receipt of chemotherapy and external beam radiotherapy, patients 
with squamous cell cancers were more often treated with external beam radio-
therapy and less often with chemotherapy compared to patients with adenocar-
cinomas. In patients with metastases in multiple organs, the odds of receiving 
chemoradiotherapy were lower. 
The median overall survival in patients with metastatic esophageal cancer 
improved from 18 weeks (1-year survival rate 14,4%) in 1994-1998 to 25 weeks 
(1-year survival rate 22,4%) in 2009-2013. Table 3 shows the results of a propor-
tional hazard regression analysis. This improvement in survival was no longer 
observed after adjusting for treatment. Also, we found that the different ther-
apeutic approaches had different survival outcomes. The worst survival was 
found in ‘untreated’ patients, who had a median overall survival of 9 weeks 
(1-year survival rate 4,6%). Patients treated with external beam radiotherapy 
and brachytherapy had a comparable prognosis of approximately 21-23 weeks 
(1-year survival rate 9,4%-15,0%). Superior survival was seen in patients treated 
with chemotherapy, with a median survival of 42 weeks (1-year survival rate 
36,0%). Patients treated with chemoradiotherapy had the most favorable prog-
nosis, with a median survival of 51 weeks (1-year survival rate 50,0%). A separate 
multivariable analysis demonstrated a survival benefit of chemoradiotherapy 
over systemic chemotherapy (HR 0.63, 95% CI 0.45-0.89, p=0.0086).
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Crude median 
survival
(weeks)
Crude 1-year 
survival
(%)
HR (95% CI) 
without  
treatment
HR (95% CI) 
with  
treatment
Sex
 Male 
 Female
21.0 
20.1
16.8
19.5
1.00 (reference)
0.94 (0.80-1.11) 
1.00 (reference)
0.92 (0.78-1.08) 
Age 6 (yrs.)
 <50 
 50-59
 60-69
 70-79
 ≥80
30.6
25.6
22.6
19.5
11.0
36.1
21.5
17.0
13.7
5.0
0.72 (0.55-0.95)
0.86 (0.73-1.02)
1.00 (reference) 
1.26 (1.07-1.49)
2.38 (1.88-3.02)
0.65 (0.49-0.85) 
0.84 (0.70-0.99) 
1.00 (reference) 
0.97 (0.82-1.15) 
1.64 (1.29-2.09) 
No. of comorbid conditions 
 0
 1
 2 or more 
 Unknown
24.1
18.7
17.4
17.4
20.3
16.6
12.0
12.7
1.00 (reference) 
1.02 (0.88-1.18) 
1.20 (0.99-1.45) 
1.24 (0.93-1.65) 
1.00 (reference)
0.98 (0.85-1.14) 
1.08 (0.89-1.31)
0.97 (0.73-1.29) 
Social economic status (SES)
 Low 
 Intermediate 
 High 
 Institutions 
 Unknown
21.1
20.7
21.3
16.1
26.0
16.3
17.1
19.2
8.7
24.2
0.94 (0.80-1.11) 
1.00 (reference) 
1.03 (0.88-1.20) 
1.17 (0.86-1.61) 
0.74 (0.50-1.08) 
0.97 (0.82-1.14)
1.00 (reference) 
1.07 (0.91-1.25)
0.79 (0.57-1.09) 
0.83 (0.57-1.23)
Histology
 Adenocarcinoma
 Squamous cell carcinoma
21.0
20.6
17.6
16.9
1.00 (reference)
1.03 (0.89-1.19) 
1.00 (reference)
1.05 (0.90-1.21)
No. of metastatic sites
  1 
 2
 3 or more 
24.3
17.4
10.3
19.7
12.8
10.1
1.00 (reference)
1.46 (1.25-1.71) 
2.00 (1.58-2.52)
1.00 (reference)
1.52 (1.30-1.78) 
1.87 (1.48-2.37)
Period of diagnosis 
  1994-1998
  1999-2003
  2004-2008
  2009-2013
18.3
19.2
19.3
25.1
14.4
13.1
15.0
22.4
1.00 (reference) 
0.96 (0.75-1.21)
0.85 (0.68-1.06)
0.63 (0.50-0.79) 
1.00 (reference) 
0.99 (0.78-1.25)
0.93 (0.74-1.17)
0.87 (0.68-1.10) 
Treatment 
 No treatment
  External beam Radiotherapy
  Brachytherapy 
  Chemoradiotherapy
  Chemotherapy
  BRT and EBRT 
  BRT and CT
  CRT and CT 
9.4
23.3
20.7
50.6
41.9
29.6
32.4
40.4
4.6
15.0
9.4
50.0
36.0
26.2
27.3
34.2
not applicable
not applicable
not applicable
not applicable
not applicable
not applicable
not applicable 
not applicable
2.46 (2.05-2.96)
1.00 (reference) 
1.23 (0.97-1.57)
0.40 (0.29-0.56)
0.63 (0.50-0.80)
0.87 (0.62-1.23)
0.75 (0.47-1.20) 
0.49 (0.23-1.05) 
* EBRT: External Beam Radiotherapy, BRT: Brachytherapy, CRT: chemoradiotherapy, CT: chemotherapy 
proportional 
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Discussion 
We assessed the use of external beam radiotherapy, brachytherapy, chemora-
diotherapy and chemotherapy in 1,020 patients diagnosed with synchronous 
metastatic esophageal cancer. Over time, the prescription rate of chemo-
therapy and chemoradiotherapy increased drastically. Together with appro-
priate patient selection and stage migration these increases resulted in an 
improved median overall survival for patients with metastatic esophageal 
cancer, from 18 weeks in the period 1994-1998 to 25 weeks in 2009-2013.
During the study period, the proportional incidence of synchronous metastases 
in esophageal cancer increased from 21,9% to 32,1%. The most likely explana-
tion for this phenomenon is stage migration.[12] Earlier and increased detec-
tion of metastases was facilitated by the evolution of diagnostic techniques, 
for instance the improvement of the computed tomography scan (CT) and the 
introduction of 18F-fluorodeoxyglucose PET.[5] This explanation is supported by 
the observation that in our study the number of metastatic sites increased in 
the course of time. 
For patients with metastatic esophageal cancer there are several thera-
peutic options aiming to improve the quality of life and/or prolong survival. 
The use of the various treatment modalities changed drastically. Since 2004 the 
use of chemoradiotherapy has increased.[2] In the past decade, several studies 
demonstrated that chemoradiotherapy in non-metastatic disease resulted in 
a survival benefit and an impressive downsizing of the primary tumor.[11,13,14] 
In 2004 the Dutch CROSS trial started investigating the role of preoperative 
chemoradiotherapy with weekly administration of carboplatin (AUC 2) and 
paclitaxel (50 mg/m2) during 5 weeks with concurrent radiotherapy (41.4 Gy, 
in 23 fractions, 5 days per week).[15] This preoperative chemoradiation scheme 
improved overall survival and was very well-tolerated. We hypothesize that 
this well-tolerated scheme has been administered increasingly to patients with 
limited metastatic esophageal cancer as well. However, no additional infor-
mation on the scheme or dosage of radiotherapy was available in our popula-
tion-based study. 
The use of systemic chemotherapy as a single modality also increased during 
the study period.[2,11] This increase, especially seen after 2006, parallels the 
increased use of palliative chemotherapy in metastatic gastric cancer.[16] The 
palliative chemotherapy schedules of esophageal, esophagogastric junctional 
and gastric cancer are identical and are often discussed in the same guidelines. 
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These guidelines state that patients with advanced esophageal cancer derive 
the same benefits from systemic chemotherapy as patients with gastric cancer.
[5] Unfortunately, our dataset contained no additional information on the 
prescribed agents or combinations. 
Our logistic regression analysis showed that treatment choice was not 
only influenced by the period of diagnosis, but also by patient characteristics. 
We found that younger patients had lower odds of receiving external beam 
radiotherapy and higher odds of receiving chemotherapy. Physicians seem 
reluctant to use chemotherapy in the elderly, either as a single modality or 
in combination with radiotherapy. This treatment selection according to age 
has been described previously. Cronin-Fenton et al. stated that the effect of 
age was explained by the existence of comorbidities.[11] However, after adjust-
ment for comorbidity in our logistic regression analysis, age-related differences 
persisted. Treatment choice was also influenced by tumor characteristics such 
as histological subtype and extent of disease. We observed that fewer patients 
with metastasized squamous cell cancers received chemotherapy. It has been 
reported that the results achieved with palliative chemotherapy in patients 
with squamous cell esophageal cancer are inferior to the results achieved in 
esophageal adenocarcinomas.[10] Another explanation could be the worse 
physical condition of patients with metastatic squamous cell cancer compared 
to patients with metastatic adenocarcinomas of the esophagus. Ninety percent 
of all squamous cell cancers in the developed world are caused by substantial 
alcohol intake and smoking.[17] Both are well known risk factors for a variety 
of comorbidities, in particular cardiovascular and pulmonary comorbidities, 
which might have negatively influenced the prescription of chemotherapy. 
Consistent with findings of previous studies, we found that external beam 
radiotherapy was offered less frequently to patients with adenocarcinomas, 
possibly because less effect is expected from radiation of adenocarcinomas 
compared to squamous cell tumors.[11,18] Furthermore, patients with metas-
tases in multiple organs had lower odds of receiving chemoradiotherapy. It 
seems that this modality was preserved for patients with limited metastatic 
disease.[19] Chemoradiotherapy requires treatment during several weeks and 
has substantial side effects which, for patients with more advanced disease 
and a limited lifespan, may not outweigh the potential benefits. We found that 
the choice of brachytherapy was not influenced by extent of disease, nor by 
any other patient or tumor characteristic. Single-dose brachytherapy is a safe 
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modality, with an acceptable toxicity profile and a rapid relief of dysphagia. 
Therefore it can be widely used in patients with metastatic esophageal cancer 
with symptomatic stenosis.[20-22]
The survival of patients with synchronous metastatic esophageal cancer 
increased from 18 weeks in 1994-1998 to 25 weeks in 2009-2013. This finding 
has been reported before in another Dutch population-based study.[12] The 
authors suggested that the increase in survival can be attributed to stage 
migration. It is indeed likely that improved diagnostic accuracy leads to earlier 
detection of metastases, resulting in a smaller tumor load at time of diagnosis 
and an improvement of overall survival. Still, the prolonged survival may also 
have been due to the major changes in treatment strategies, as the beneficial 
influence of time was not observed anymore after adjusting for treatment in 
our multivariable hazard regression analysis. In our study, the median overall 
survival of patients treated with chemoradiotherapy was 51 weeks (1-year 
survival rate of 50,0%), versus 23 weeks in patients treated with external beam 
radiotherapy (1-year survival rate of 15,0%). Furthermore, we found a survival 
benefit of chemoradiotherapy over chemotherapy (median survival 42 weeks, 
1-year survival rate of 36,0%). However, no survival benefit of palliative chemo-
radiotherapy, even over radiotherapy, was found in the TROG 03.01-NCIC CTG 
ES2 multinational phase III study, which compared palliation of dysphagia and 
survival in patients treated with radiotherapy or chemoradiotherapy.[23] Our 
results seem to reflect appropriate patient selection rather than a true effect 
of treatment. Patients with advanced metastatic disease (metastases in two or 
more organs) were less likely to be treated with chemoradiotherapy, whereas 
the extent of disease did not influence the prescription of external beam radio-
therapy or chemotherapy. In our study, it was impossible to correctly adjust 
for extent of disease due to the lack of important variables, such as number 
of metastases, size of metastases, disease related symptoms and perfor-
mance status. We hypothesize that chemoradiotherapy was more likely to be 
prescribed in the fitter patients with a limited number and size of metastases 
and thus a predetermined improved survival. 
The evolving therapeutic options for the treatment of patients with meta-
static esophageal cancer, together with appropriate patient selection and stage 
migration resulted in a prolonged overall survival. Therefore, optimal treatment 
for patients with metastatic esophageal cancer requires intensive cooperation 
between different specialists and it is of utmost importance that all patients 
are discussed in dedicated multidisciplinary teams.
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Abstract
Background: Gastric cancer often presents in a metastasized stage. We 
conducted a population-based study to evaluate trends in systemic treat-
ment and survival of metastatic non-cardia gastric cancer. 
Methods: All patients with a non-cardia adenocarcinoma of the stomach, 
diagnosed between 1990 and 2011 in the southern Netherlands were 
included (N=4,797). We conducted a multivariable logistic regression anal-
ysis to evaluate trends in administration of palliative chemotherapy and a 
multivariable proportional hazards regression analysis to evaluate trends 
in crude overall survival.
Results: The proportion of patients presenting with metastatic gastric 
cancer increased from 24% in 1990 to 44% in 2011 (p<0.0001). The use of 
palliative chemotherapy increased, from 5% in 1990 to 36% in 2011, with a 
strong increase in particular after 2006 (p<0.0001). Younger patients (<50 
yrs: (adjusted odds ratio (ORadj) 3.9, (p<0.001;  50-59 yrs, ORadj 1.7, p=0.01) 
and patients with a high socioeconomic status (ORadj 1.7, p=0.01) received 
chemotherapy more often. In contrast, older patients (70-79 yrs ORadj 0.3, 
p<0.001; 80+ yrs ORadj 0.02, p<0.001), patients with comorbidity (ORadj 0.6, 
p=0.03), linitis plastica (ORadj 0.5, p=0.03) and multiple distant metas-
tases (ORadj 0.5, p=0.01) were treated with chemotherapy less often. A large 
inter-hospital variation was observed in the administration of pallia-
tive chemotherapy (9-27%). Median overall survival remained constant 
between 15 (95% CI 11.9-17.7) and 17 (95% CI 15.0-20.0) weeks (p=0.10).
Chapter 3.1
No improvement in median survival for patients 
with metastatic gastric cancer despite increased 
use of chemotherapy
 
N. Bernards, G.J.M. Creemers, G.A.P. Nieuwenhuijzen, K. Bosscha, J.F.M 
Pruijt, V.E.P.P. Lemmens. Annals of Oncology 2013 Dec;24(12):3056-60
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Conclusion: The increased administration of chemotherapy in patients 
with metastatic gastric cancer did not lead to an increase in popula-
tion-based overall survival. Identification of the subgroup of patients 
which benefits from palliative chemotherapy is of utmost importance to 
avoid unnecessary treatment. 
Introduction
Due to lack of early symptoms, gastric cancer often presents in an metastasized 
stage, characterized by poor survival.[1,2] Several studies have shown that palli-
ative chemotherapy is superior to ‘best supportive care’ for selected patients, 
in terms of prolonged survival, reduction of disease-related symptoms and 
improved quality of life.[3] Although most studies were small and of moderate 
methodological quality, this evidence has led to the implementation of pallia-
tive chemotherapy into national guidelines on the treatment of gastric cancer.
[4-6] The NCCN guideline Gastric Cancer for instance, recommends chemo-
therapy with a two or three drug regimen for patients with metastatic gastric 
cancer.[5] The Dutch guideline corresponds to the NCCN guideline and recom-
mends a combination including epirubicine, a platinum derivative, and a fluoro-
pyrimidine as first-line palliative treatment.[4]
A recent population-based Dutch study showed that adherence to national 
guidelines for resectable gastric cancer was suboptimal, only 47% and 56% of 
the patients received recommended preoperative and postoperative chemo-
therapy.[7] Data on the prescription of palliative chemotherapy for patients 
diagnosed with metastatic gastric cancer on daily practice are scarce. In this 
study we examined trends in the use of chemotherapy for patients metastatic 
(non-cardia) gastric cancer, diagnosed between 1990 and 2011 in the southern 
part of the Netherlands. In addition, we assessed to which extent patient and 
tumor related factors influenced the administration of chemotherapy and 
if there was any variation in prescription between ten community hospitals. 
Finally, we evaluated trends in overall survival for patients with metastatic 
gastric cancer. 
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Methods
Data collection 
Data were obtained from the Eindhoven Cancer Registry in the Netherlands 
which collects data on diagnosis, staging and treatment of all patients with 
newly diagnosed cancer. Registration takes place within 6-9 months after 
diagnosis by specially trained administrators. The Eindhoven Cancer Registry 
serves approximately 2,4 million inhabitants, about 15% of the Dutch popula-
tion. It contains data of six pathology departments, the medical records of ten 
community hospitals and two radiation therapy institutes. 
Patients diagnosed with non-cardia adenocarcinoma of the stomach 
between January 1st 1990 and December 31st 2011 were included. Topography and 
morphology were coded according to the International Classification of Disease. 
The following morphology codes were used to classify tumors as adenocarci-
noma: 8140-8145, 8210, 8211, 8255, 8260-8263, 8480-8481, 8490, 8560, 8570. 
Other morphologies were excluded or did not occur during the study period. 
Tumors were classified according to the TNM classification and staged following 
the recommendations of the International Union Against Cancer in the respec-
tive period (4th-7th edition). Clinical stage was used in case of missing patholog-
ical stage. If tumor stage was unknown, it was classified as X. 
Since 1993, clinically relevant comorbidities were registered according to a 
slightly modified version of the Charlson comorbidity index. The social economic 
status (SES) of individual patients was defined at neighbourhood level using 
postal codes (17 households on average), combining mean household income 
and mean value of the house/apartment. Postal codes were assigned to three 
SES categories: low (1st-3rd deciles), intermediate (4th-7th) and high (8th-10th).[8]
Vital status of patients at January 1st 2012 was assessed through linkage with 
civil municipal registries and the central Bureau for Genealogy, which collects 
data on all deceased Dutch Citizens. Survival was calculated based on all-cause 
mortality. 
Statistical analyses
Differences in the prescription of systemic chemotherapy between periods of 
diagnosis, hospitals of diagnosis and other subgroups were tested by means of 
a χ2 test. The independent influence of hospital, patient and tumor characteris-
tics on the administration of palliative chemotherapy was evaluated by means 
of a logistic regression analysis. 
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Survival time was defined as the time from diagnosis to death, patients still alive 
at January 1, 2012 were censored. A log rank test was carried out to evaluate signifi-
cant differences between survival curves. To discriminate independent risk factors 
for death a multivariable proportional hazard regression analysis was used. 
All tests were two-sided and considered statistically significant if p-values < 
0.05. SAS Statistical software (version 9.3) was used to perform all analyses.
Results
Patients with non-cardia gastric cancer diagnosed between January 1st 1990 
and December 31st 2011 in the southern part of the Netherlands were included. 
The final cohort consisted of 4,797 patients, 2,865 men (60%) and 1,932 women 
(40%) with a median age of 72 years (range 13-100) at the time of diagnosis. 
The incidence rate of non-cardia gastric cancer in the above mentioned region 
decreased in the last two decades, from 27 per 100,000 in 1990 to 13 per 
100,000 in 2010. A significant proportion of patients with non-cardia gastric 
cancer presented with metastatic disease at the time of diagnosis (N=1,618). In 
total, 40% of the patients with metastatic gastric cancer presented with liver 
metastases with or without concomitant metastases elsewhere, and 44% with 
peritoneal dissemination. The proportion of patients presenting with meta-
static disease at time of diagnosis increased from 24% in 1990 to 44% in 2011 
(p<0.0001). 
 Overall, the proportion of patients with metastatic gastric cancer receiving 
palliative chemotherapy increased from 5% in 1990 to 36% in 2011 (figure 1). 
A remarkable increase was seen after 2006. Table 1 shows the odds of 
receiving chemotherapy for patients with metastatic gastric cancer adjusted 
for age, gender, SES, comorbidity, histologic subtype, tumor grade, pres-
ence and location of distant metastasis, period and hospital of diagnosis. 
After adjustment, elderly patients (70-79 yrs, ≥80 yrs), patients with concom-
itant comorbidity and those with multiple distant metastases or linitis plas-
tica received chemotherapy less often. In contrast, chemotherapy was 
administered more frequently to young patients (< 60 yrs) and patients with 
a higher SES. Furthermore a large inter-hospital variation was seen in the 
proportion of patients receiving chemotherapy, varying from 9% to 27%. 
No improvement in overall survival was observed in the last two decades 
(figure 2). 
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The median survival for patients with metastatic gastric cancer remained 15-17 
weeks (p=0.10). The overall survival for patients not treated with chemotherapy 
worsened. Initially, the median survival for untreated patients with metastatic 
gastric cancer was 16 weeks, whereas in 2008-2011 the median overall survival 
was only 9 weeks (p<0.001). For patients treated with chemotherapy, the overall 
survival remained stable between the 32-37 weeks (p=0.39). In a multivariate 
model chemotherapy was positively associated with survival. After adjustment, 
male gender, a poor or undifferentiated tumor, the presence of liver or multiple 
metastases were negative prognostic factors (table 2).
Table 1 Crude percentages and adjusted odds for receiving chemotherapy 
among patients diagnosed with metastatic gastric cancer, in the 
southern Netherlands between 1990 and 2011 (N=1,618)
Crude % 
treated with chemo
Odds ratio 
(95% CI)
Sex
 Male 
 Female
18.2
16.0
1.00 (reference)
0.89 (0.64-1.23) 
Age
 <50 
 50-59
 60-69
 70-79
 ≥80 
44.9
28.7
22.4
10.6
 1.2
3.90 (2.31-6.59)
1.71 (1.11-2.64)
1.00 (reference)
0.30 (0.20-0.45)
0.02 (0.01-0.08)
Social economic status (SES)
 Low 
 Intermediate
 High
12.3
17.8
24.4
1.00 (reference)
1.30 (0.86-1.95)
1.75 (1.16-2.64)
Comorbidity b
 0 
 1
 ≥2
27.0
17.0
16.3
1.00 (reference)
0.65 (0.44-0.96)
0.82 (0.54-1.25)
Histologic subtype
 Adenocarcinoma
 Signetcell carcinoma
 Linitis plastica 
16.3
22.8
18.1
1.00 (reference)
0.84 (0.54-1.31)
0.52 (0.29-0.93)
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Crude % 
treated with chemo
Odds ratio 
(95% CI)
Tumour grade
 Well/moderate 
 Poor/undifferentiated
 Unknown
16.4
50.7
32.9
1.00 (reference)
0.93 (0.60-1.44)
1.03 (0.63-1.69)
Metastasis 
 Lung
 Liver
 Peritoneum 
 Extra regional nodes
 Other 
 2 organs 
 3+ organs 
30.8
15.8
16.8
19.0 
14.7
18.3
28.9
2.69 (0.60-12.09)
1.00 (reference)
0.66 (0.42-1.02)
0.94 (0.54-1.63)
0.51 (0.27-0.97)
0.54 (0.33-0.86)
0.83 (0.35-1.99)
Period of diagnosis
 1990-1995 
 1996-2001
 2002-2007
 2008-2011
7.4
12.6
20.8
33.9
1.00 (reference)
1.10 (0.64-1.87)
2.72 (1.64-4.54)
7.89 (4.58-13.59)
Hospital of diagnosis
 Hospital A
 Hospital B
 Hospital C 
 Hospital D
 Hospital E 
 Hospital F
 Hospital G
 Hospital H
 Hospital I
 Hospital J
 
8.9
16.5
17.4
9.1
20.5
16.0
27.2
17.3 
25.2
15.7
1.00 (reference) 
2.84 (1.28-6.31) 
2.58 (1.27-5.22) 
0.92 (0.36-2.33) 
3.68 (1.82-7.46) 
2.69 (1.48-4.88) 
5.18 (2.92-9.19)
3.37 (1.71-6.65) 
5.52 (2.88-10.59) 
1.98 (0.96-4.08)
a Adjusted for all variables listed. Included in the analysis but results not shown for SES institutions, 
SES unknown, comorbidity unknown and tumor grade unknown.
b Comorbidity is registered since 1993 
Table 1 Continued
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Figure 2 The overall survival in weeks of patients diagnosed with meta-
static non-cardia gastric cancer between 1990 and 2011 in the 
southern Netherlands according to the period of diagnosis (N=1,618)
Figure 1 Prescription of chemotherapy in patients diagnosed with meta-
static non-cardia gastric cancer over time 1990-2011 (N=1,618)
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Table 2 Risk of dying (Hazard ratios)a for patients with metastatic non-car-
dia gastric cancer, diagnosed between 1990 and 2011 in the South 
of the Netherlands (N=1,618)
HR (95% CI) 
Sex
 Male 
 Female
1.00 (Reference)
0.83 (0.74-0.92)
Age
 <50 
 50-59
 60-69
 70-79
 ≥80
0.98 (0.79-1.22)
0.86 (0.73-1.02)
1.00 (Reference) 
1.06 (0.93-1.20)
1.12 (0.94-1.33)
SES 
 Low 
 Intermediate
 High
1.00 (Reference)
0.94 (0.83-1.07)
0.95 (0.83-1.09)
Comorbidity 
 0 
 1
 ≥2
1.00 (Reference) 
0.96 (0.84-1.11)
0.99 (0.85-1.15)
Histologic subtype
 Adenocarcinoma
 Signetcell carcinoma
 Linitis plastica 
1.00 (Reference)
1.00 (0.86-1.16)
1.21 (0.99-1.47)
Tumour grade
 Well/moderate 
 Poor/undifferentiated
 Unknown
1.00 (Reference)
1.33 (1.15-1.53)
1.28 (1.09-1.50) 
Location metastasis 
 Lung
 Liver
 Peritoneum 
 Extra regional nodes
 Other locations 
 2 > locations 
 3 > locations 
0.40 (0.22-0.71)
1.00 (Reference) 
0.63 (0.54-0.72) 
0.45 (0.37-0.54) 
0.70 (0.57-0.87)
0.96 (0.82-1.13)
0.83 (0.60-1.15)
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HR (95% CI) 
Period of diagnosis
 1990-1995 
 1996-2001
 2002-2007 
 2008-2011
1.00 (Reference) 
1.08 (0.92-1.27) 
1.09 (0.93-1.27)
1.38 (1.14-1.67)
Hospital of diagnosis
 Hospital A
 Hospital B
 Hospital C 
 Hospital D
 Hospital E 
 Hospital F
 Hospital G
 Hospital H
 Hospital I
 Hospital J
1.00 (Reference) 
1.27 (0.99-1.63) 
1.24 (0.99-1.54) 
1.08 (0.84-1.38)
1.26 (1.00-1.57) 
1.17 (0.98-1.40)
1.01 (0.84-1.21) 
1.18 (0.95-1.45) 
1.13 (0.92-1.39) 
1.29 (1.04-1.61)
Chemotherapy 
 No
 Yes 
1.00 (Reference) 
0.50 (0.43-0.59)
a Adjusted for all variables listed. Included in the analysis but results not shown for SES institutions, 
SES unknown, comorbidity unknown, and tumor grade unknown.
b Comorbidity is registered since 1993 
Discussion
An increasing percentage of patients with gastric cancer is diagnosed with 
metastatic disease. Although the proportion of patients treated with palliative 
chemotherapy increased drastically, it did not lead to an increase in the popula-
tion-based overall survival in patients with metastatic gastric cancer.
The proportion of patients presenting with metastatic disease at time of diag-
nosis increased from 25% in 1990 to 44% in 2011. Improved staging procedures 
have played an important role. The modern improved computed tomography 
Table 2 Continued
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scan (CT) sometimes in combination with positron emission tomography (PET 
scan) further enhanced the diagnostic process.[9,10] These evolving technol-
ogies presumably led to stage migration by earlier and increased detection 
of distant metastases, mostly occurring in liver and peritoneum.[10] In addi-
tion, altered and more aggressive biological behavior of gastric cancer, could 
also be related to the rising proportion of patients presenting with metastatic 
disease. Nevertheless, to our knowledge no data are available on this subject 
and further investigation is needed.
Several randomized trials have shown that systemic chemotherapy can 
reduce disease related symptoms and improve median survival, from approxi-
mately 4 months to 11 months in selected patients with metastatic gastric 
cancer.[3] This benefit of palliative chemotherapy over best supportive care 
alone was already reported in several studies in the early nineties.[3] The last 
Cochrane review on chemotherapy for advanced and metastatic gastric cancer 
concluded that combination regimens including 5-FU or capecitabine and oxal-
iplatin or cisplatin, with or without an anthracycline, or docetaxel  and irinotec-
an-based regimens can be considered as reasonable treatment options.[3] 
The newly introduced agents, oxaliplatin, docetaxel and irinotecan have an 
altered and often a more favorable toxicity profile, but provide similar overall 
survival as previous studied agents. Despite modest changes for the treat-
ment of  metastatic gastric cancer, the administration of palliative chemo-
therapy increased drastically, in particular after 2006. In 1990, 5% of patients 
with metastatic gastric cancer was treated with palliative chemotherapy. 
Gradually, the percentage increased to 20% in 2006, and even 36% in 2011. In 
2005, Cunningham published the results of the REAL-2 trial in which capecit-
abine and oxaliplatin were established as equal substitutes of fluorouracil and 
cisplatin in triplet regimens for the treatment of metastatic gastric cancer.[11] 
Furthermore, in 2006 Cunningham et  al published the MAGIC trial in which 
they demonstrated that perioperative chemotherapy with a regimen of epiru-
bicin, cisplatin and infused fluorouracil (ECF) significantly improved progres-
sion-free and overall survival for patients with resectable gastric cancer.[12] 
Presumably, the growing experience with combination chemotherapy for the 
treatment of  gastric cancer has led to a stronger increase in the administration 
of palliative chemotherapy in the past years.. 
The current study demonstrates that patients with a lower socio-eco-
nomic status (SES), advanced age and comorbidity were less likely to be treated 
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with chemotherapy. In addition, tumor-related factors such as metastases in 
multiple organs and linitis plastica were adversely related to the prescription 
of chemotherapy as well. The increased hazard of death for patients with linitis 
plastica, although of borderline significance, suggests that this is a negative 
prognostic factor. The presence of metastases in multiple organs was not asso-
ciated with an increased risk of dying compared to patients with liver metas-
tases only. However, due to the population-based nature of our data we do 
not know to which extent above mentioned conditions had impact on perfor-
mance status, nutritional status etc and in this manner influenced the prescrip-
tion of chemotherapy. The reluctance to prescribe chemotherapy for elderly 
patients has already been described in previous studies.[13,14] Also, treatment 
selection according to SES has frequently been reported for curative cancer 
treatments.[15-17] However, only a few studies have reported the effect of SES 
on treatment decisions in the palliative setting. Recently, Swedish investigators 
established high education level as an important socioeconomic variable, asso-
ciated with more intensive treatments.[18] In a multivariate model adjusting 
for case-mix, a marked hospital variation was found in the prescription of palli-
ative chemotherapy, varying between 9-27%. Decisions concerning the use of 
chemotherapy in patients with metastatic cancer are complex.[19,20] A recent 
study found that the physicians’ individual treatment recommendations were 
strongly influenced by the amount of experience and their judgment about the 
benefit of the treatment and biological age of the patient.[20] 
Despite the increased prescription of palliative chemotherapy and the 
presumed stage migration, the overall survival of all patients with metastatic 
gastric cancer did not change over time. Median survival of patients with meta-
static disease remained poor, between 15 and 17 weeks. As expected, poor/
undifferentiated tumors and the presence of multiple metastases were asso-
ciated with poor survival.[21] Consistent with previous reports, in case of single 
site metastases, dissemination to the liver was identified as an independent 
adverse prognostic factor as well.[22] In addition to tumor related prognostic 
factors, there was a significant effect of gender on overall survival. We found 
that women with metastatic gastric cancer had a better survival compared to 
their male counterparts. According to the study of Yang et al, using the data of 
the SEER registry, this difference was associated to race and limited to African 
Americans and White patients. This race specific gender difference in survival 
is possibly related to sex hormones, their receptor expression and possible 
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interaction with her2neu receptor pathways.[23] Our data do not confirm the 
finding from Yang et al that younger patients with metastatic gastric cancer 
have an improved overall survival. However, the SEER registry lacks information 
on systemic chemotherapy.[24] 
Survival of patients treated with systemic chemotherapy in the last two 
decades remained stable between 32 and 37 weeks. This may reflect the lack 
of a major breakthrough in the efficacy of the cytotoxic drugs used for the 
treatment of  gastric cancer. The survival of patients not treated with palliative 
chemotherapy worsened in the last two decades, from an initial survival of 16 
weeks to a survival of only 9 weeks in the most recent period. This is probably 
due to selection bias, patients who are medically fit are more likely to be treated 
with palliative chemotherapy. The oldest and/or most frail patients remain 
untreated. Due to the population-based nature of our data, detailed infor-
mation on the patients health and nutritional status were not available. Even 
so, information concerning established prognostic factors such as body mass 
index, ECOG performance status of the patient and symptoms like ascites are 
lacking in our database.[25,26] These factors influence prognosis and presum-
ably the administration of chemotherapy in daily practice. 
Conclusion
In conclusion, the increased administration of chemotherapy for patients with 
metastatic gastric cancer did not lead to an increased population-based overall 
survival. A subgroup of patients might benefit from palliative chemotherapy, 
but more research is necessary to establish prognostic and in particular predic-
tive factors for patients with metastatic gastric cancer. 
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Chapter 3.2 
Chemotherapy as palliative treatment for 
peritoneal carcinomatosis of gastric cancer
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Introduction
Gastric cancer is known for its aggressive behavior. Most patients present with 
advanced, inoperable or metastatic disease. In the absence of curative treatment 
modalities, systemic chemotherapy can be considered as a reasonable treatment 
option for these patients. Previous studies showed that, in selected patients, 
chemotherapy is superior to ‘ best supportive care ’ in terms of prolonged 
survival, reduction of disease-related symptoms and improved quality of life.[1] 
Therefore, international guidelines recommend palliative chemotherapy with a 
two or three drug regimen for patients with metastatic gastric cancer.[2,3] 
In patients with gastric cancer, dissemination to the peritoneum is common. 
Up to 14% of all newly diagnosed patients presents with peritoneal carcino-
matosis (PC).[4] The efficacy of palliative chemotherapy in patients with PC 
from gastric origin has not been well studied. It is hypothesized that the effect 
of intravenous chemotherapy on peritoneal metastases is limited due to the 
peritoneal blood barrier. Peritoneal dissemination is therefore thought to be 
an adverse prognostic factor.[5] Comprehensive data regarding the use and 
effectiveness of systemic chemotherapy for this subset of patients is virtu-
ally absent. The aim of this population-based study was to evaluate trends in 
systemic treatment and survival of patients with PC of gastric origin. 
Methods
Data collection
The Eindhoven Cancer Registry registers all newly diagnosed cancer patients 
in the southern part of the Netherlands, including ten community hospitals, 
six pathology departments and two radiotherapy institutions, comprising 2.4 
million inhabitants. All patients diagnosed between 1995 and 2011 with an 
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adenocarcinoma of gastric origin were included. Information on patient and 
tumor characteristics was extracted from the medical records by specially 
trained administrators of the cancer registry. Anatomical sites of distant metas-
tases are registered according to the International Classification of Disease-
Oncology (ICD-O). Chemotherapy (yes vs. no) was defined as receiving cytostatic 
drugs of any kind. By means of an independent case ascertainment method, 
the completeness of the registration is estimated to exceed 95%.[6] The vital 
status of all patients was assessed on January 1, 2012 through merging with 
the Municipal Administrative Databases in which all deceased and emigrated 
persons in the Netherlands are registered. 
Statistical analyses 
Statistical analysis differences between patients who were treated with palliative 
chemotherapy and patients who were not, were tested by means of a χ2 -test. To 
investigate trends in treatment and survival, patients were categorized into four 
groups by period of diagnosis: 1995 – 1998, 1999 – 2002, 2003 – 2006 and 2007 
– 2011. Survival time was defined as the time from cancer diagnosis until death; 
patients still alive at January 1, 2012 were censored. Crude survival was determined 
by the Kaplan-Meier method and compared using a log-rank test. Cox regression 
analysis, adjusting for age, gender, period of diagnosis, co-morbidity, tumor differ-
entiation grade, tumor stage, lymph node stage, and surgery, was used to deter-
mine the relationship between chemotherapy and two-year mortality among 
patients with PC. A hazard ratio (HR) was provided with the 95% confidence 
interval (CI). All tests of statistical significance were two sided. SAS/STAT statistical 
software (SAS system 9.3, SAS Institute, Cary, NC, USA) was used for all analyses.
Results
Between 1995 and 2011, 5,220 patients were diagnosed with gastric cancer, of 
whom 2,029 patients (39%) had metastatic disease at presentation[4]. Of these 
patients, 706 patients (34%) were diagnosed with PC, of whom 491 patients 
had PC as the only metastatic site and 215 patients had PC combined with other 
metastases. In total, 168 patients (24%) were treated with palliative chemo-
therapy. Younger patients, patients with less co-morbidities and patients with 
lower N-stage were significantly more likely to be treated with chemotherapy 
(table 1).
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Table 1 General characteristics of patients diagnosed between 1995 and 
2011 in the south of the Netherlands with peritoneal carcinomato-
sis of gastric origin (N=706)
Chemotherapy No chemotherapy P-value
N = 168 % N = 538 %
Age (years) <.0001
<60 82 40 121 60
60-69 51 25 150 75
70-79 34 16 182 84
>80 1 1 85 99
Gender 0.743
Male 102 24 319 76
Female 66 23 219 77
Peritoneal carcinomatosis 0.586
without other metastases 114 23 377 77
with other metastases 54 25 161 75
Period of diagnosis <.0001
1995-1998 20 11 155 89
1999-2002 24 16 130 84
2003-2006 28 19 123 81
2007-2011 96 42 130 58
Number of comorbid conditions 0.006
0 71 32 153 68
1 77 20 308 80
≥2 12 18 56 82
Unknown 8 28 21 72
Localization of the primary tumor 0.002
Cardia 29 32 63 68
Fundus of stomach 2 20 8 80
Body of stomach 24 30 55 70
Gastric antrum 19 15 112 85
Pylorus 3 9 31 91
Lesser curvature 4 13 28 87
Greater curvature 9 43 12 57
Overlapping lesions/ NOS 78 25 229 75
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Chemotherapy No chemotherapy P-value
N = 168 % N = 538 %
T stage of the primary tumor 0.086
T0 0 0 1 100
T1 1 20 4 80
T2 17 22 59 78
T3 27 27 73 73
T4 30 21 115 79
Tx 93 25 286 75
N stage of the primary tumor 0.012
N0 33 35 62 65
N1 9 14 57 86
N2 11 18 50 82
Nx 115 31 260 69
Differentiation grade of the primary tumor 0.061
Well/moderately 21 18 97 82
Poorly/ undifferentiated 87 23 294 77
Unknown 60 29 147 71
Tumor histology 0.483
Adenocarcinoma 97 22 341 78
Signet ring cell 45 28 116 72
Linitis plastica 22 25 65 75
Other 4 20 16 80
Resection 0.081
Yes 25 18 113 82
No 143 75 425 25
PC: peritoneal carcinomatosis; NOS: not otherwise specified
Table 1 Continued
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Figure 1 Percentage of patients treated with chemotherapy in patients 
diagnosed with peritoneal carcinomatosis of gastric cancer ori-
gin only, peritoneal carcinomatosis combined with other metas-
tases and non-metastatic gastric cancer according to period of 
diagnosis
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Table 2 Median overall survival for patients with peritoneal carcino-
matosis from gastric origin, diagnosed between 1995-2011 in the 
South of the Netherlands, according to treatment (N=706)
Chemotherapy No chemotherapy Total
N MS (95%CI) N MS (95%CI) N MS (95%CI)
1995-2011 168 7.7 (6.8-8.6) 538 3.4 (3.0-3.7) 706 4.1 (3.7-4.6)
1995-1998 20 5.7 (4.1-9.7) 155 4.3 (3.6-5.8) 175 5.1 (3.8-5.8)
1999-2002 24 7.5 (4.4-8.9) 130 3.8 (3.0-5.2) 154 4.5 (3.4-5.3)
2003-2006 28 7.7 (5.8-11.0) 123 3.2 (2.3-3.7) 151 3.7 (2.8-4.5)
2007-2011 96 7.9 (6.8-10.5) 130 2.2 (1.7-2.7) 226 4.0 (3.1-4.8)
P log-rank 0.310 <.0001 0.740
MS: median survival in months, CI: confidence interval
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Table 3 Risk of dying (hazard ratios) for patients with peritoneal carcino-
matosis from gastric origin, diagnosed between 1995-2012 in the 
South of the Netherlands (N=706) 
HR (95%CI)
Age
<60 1.0 (reference)
60-69 1.0 (0.8-1.2)
70-79 1.2 (1.0-1.5)
≥80 1.4 (1.1-1.9)
Gender
Male 1.0 (reference)
Female 0,9 (0.7-1.0)
Period of diagnosis
1995-1998 1.0 (reference)
1999-2002 1.0 (0.8-1.3)
2003-2006 1.1 (0.9-1.4)
2007-2011 1.3 (1.0-1.7)
T stage of primary tumour
T1,2 1.0 (reference)
T3 0,8 (0.6-1.1)
T4 0,9 (0.7-1.2)
TX 1.5 (1.1-2.0)
N stage of primary tumour
N0 1.0 (reference)
N+ 1.4 (0.7-2.8)
Nx 1.8 (0.7-4.3)
Differentiation grade of primary tumour
Well/moderately 1.0 (reference)
Poorly/undifferentiated 1.4 (1.1-1.8)
Unknown 1.4 (1.1-1.8)
Surgery
Yes 0.6 (0.3-1.2)
No 1.0 (reference)
Chemotherapy
Yes 0.5 (0.4-0.6)
No 1.0 (reference)
HR: hazard ratio; CI: confidence interval
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Furthermore, the percentage of patients treated with chemotherapy increased 
over time (p<0.001, figure 1). In the period 1995 – 1998, 11% of the patients with 
PC were treated with chemotherapy as compared with 42% in the most recent 
period. 
 Median survival of patients with PC was 4 months. For those receiving 
chemotherapy, this was 7.7 months compared to 3.4 months in patients 
receiving best supportive care (p<0.001, table 2). Crude median survival did 
not significantly increase over time among all PC patients and among patients 
treated with chemotherapy (p=0.740 and p=0.310, respectively). Crude survival 
of patients who did not receive chemotherapy decreased over time (p<0.0001). 
After adjusting for age, gender, period of diagnosis, co-morbidity, tumor differ-
entiation grade, tumor stage, lymph node stage, and surgery, patients with PC 
who were treated with palliative chemotherapy had a reduced risk to die within 
two years after gastric cancer diagnosis (HR=0.48, 95% CI 0.38 – 0.60, table 3). 
Discussion
Gastric cancer is the second most common cause of cancer-related death in the 
world.[7] Although the age-standardized incidence rates have decreased in the 
Netherlands, a growing proportion of patients presents in a more advanced 
or metastatic disease stage.[8] Peritoneal dissemination is the most common 
metastatic site. 
There has been a strong increase in the prescription of combination chemo-
therapy in patients with advanced gastric cancer, especially after publication 
of the REAL-2 trial in 2005 and MAGIC trial in 2006.[9,10] Despite the increased 
prescription rates of palliative chemotherapy in patients with peritoneal carci-
nomatosis, crude median overall survival did not improve over time. This might 
suggest that palliative chemotherapy is of limited value for gastric cancer 
patients suffering from PC. As mentioned previously, the effect of intravenous 
chemotherapy in this subgroup of patients might be limited due to the perito-
neal blood barrier. Ross et al. revealed that systemically treated patients with 
PC had a response rate of 15% compared to 43% in patients with metastases of 
other origin.[11] The theory of Ross seems to be in conflict with our multivari-
able logistic regression analysis showing a reduced risk of dying for PC patients 
treated with palliative chemotherapy compared to non-treated PC patients. 
However, this study also showed that younger patients, patients with less 
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co-morbidities and patients with a lower N-stage were more likely to be treated 
with chemotherapy, which is in line with previous studies, as is the reluctance 
to prescribe chemotherapy to old and frail patients.[12] Therefore, the reduced 
risk of dying might also be attributed in part by a selection bias. Younger and 
fitter patients, those with a better overall survival beforehand, are more likely 
to be treated with chemotherapy. We hypothesize that other patient charac-
teristics such as performance status, nutritional status and disease related 
symptoms played a role as well. Unfortunately, due to the population-based 
character of our study we were unable to adjust for these possible confounders. 
Few clinical studies have reported on the effect of chemotherapy in patients 
with peritoneal carcinomatosis from gastric cancer. One study, including 172 
PC patients, found that treatment with chemotherapy improved the one-year 
survival rate from 4.6% to 23.9%. However, after correction for tumor and patient 
characteristics this survival benefit was not reproduced in a multivariate analysis 
(p<0.082).[13] A promising agent for the treatment of  advanced gastric cancer 
might be S-1. Shigeyasu et al. found a median overall survival of 15.3 months in a 
small phase II study, including 19 patients with PC of gastric origin. In this study 
S-1 was combined with docetaxel.[14] Izuishi et al. reported a survival benefit 
of S-1 over 5-FU in patients with peritoneal carcinomatosis of gastric origin.[15] 
Although S-1 has proven to be a useful alternative to 5-FU for patients with 
advanced gastric cancer, it is mainly prescribed in Asian countries.[16]
Furthermore, it might be effective to combine cytoreductive surgery 
with intra-peritoneal chemotherapy. A systemic review by Gill et al. showed 
an improvement of median overall survival from 7.9 months to 15 months in 
patients with PC from gastric origin.[17] 
Conclusion
In conclusion, the use of chemotherapy increased in patients with PC of gastric 
origin. However, this did not result in prolongation of median overall survival on 
a population-based level. The beneficial effect of current chemotherapy regi-
mens remains questionable in this subgroup of patients. Given the poor prog-
nosis of these patients if left untreated, further research should be performed 
to optimize therapy, which may include multi-modality treatment with intra-
peritoneal chemotherapy.
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Abstract
Background: We conducted a population-based study to establish the inci-
dence, treatment and overall survival over time of patients with small 
bowel adenocarcinoma.
Methods: All patients diagnosed with small bowel adenocarcinoma in 
the Netherlands between 1999 and 2013 were included (N=1,775). Age-stan-
dardized incidence rates were calculated per 100.000 person-years using 
the European standardized population rate. The influence of patient 
and tumor characteristics on the administration of chemotherapy was 
analyzed by means of a multivariable logistic regression analysis. The 
Cochran-Armitage trend test was conducted to evaluate trends in treat-
ment and survival and the cox proportional hazards model was used to 
identify prognostic factors of overall survival. 
Results: The incidence of small bowel adenocarcinomas increased, 
mainly due to an almost twofold increase of duodenal adenocarci-
nomas. Patients with locoregional duodenal tumors were less likely to 
undergo surgery (58%), compared to 95% of the locoregional jejunal and 
ileal tumors (p<0.0001). The use of chemotherapy doubled for adjuvant (7 
to 15%) and palliative chemotherapy (19 to 37%). Median overall survival 
of patients with locoregional disease increased from 19 to 34 months 
(p=0.0006), whereas median overall survival of patients with metastatic 
disease remained 4-5 months. Favorable prognostic factors in locoregional 
disease, identified by multivariable survival analysis, included age < 60 
years, tumor stage I or II, diagnosis in 2009-2013, surgical treatment and 
Chapter 4.1 
Trends in incidence, treatment and survival of 
small bowel adenocarcinomas between 1999-2013: 
A population-based study in the Netherlands
L. M. Legué, N. Bernards, S.L. Gerritse, T.R. van Oudheusden, I.H.J.T. de 
Hingh, G.J.M. Creemers, A.J. ten Tije, V.E.P.P. Lemmens Acta Oncol. 2016 
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treatment with chemotherapy. Favorable prognostic factors in metastatic 
disease were age < 50 years, jejunal tumors, surgical treatment and treat-
ment with chemotherapy. 
Conclusion: Small bowel adenocarcinomas are rare tumors with an 
increasing incidence. The administration of adjuvant and palliative 
chemotherapy doubled, but median overall survival only increased for 
patients with locoregional disease. Given the rarity and dismal prognosis, 
it is important to develop international studies to determine the optimal 
treatment for these patients.
Introduction
Small bowel tumors are rare malignant tumors, accounting for less than 5% of 
all gastrointestinal tumors, but the incidence is rising.[1] Small bowel tumors 
have an unequal distribution in the small intestine. The preferred location 
depends on the histological subtype. The four major subtypes of small bowel 
tumors are adenocarcinomas, neuroendocrine tumors (including carcinoids), 
gastro-intestinal stromal tumors (GIST) and lymphomas.[2] Adenocarcinomas 
and neuroendocrine tumors are the most common subtypes in the small intes-
tine, both accounting for approximately 40% of small bowel tumors.[3-5] 
Patients with small bowel adenocarcinomas merely present with non-spe-
cific symptoms, such as vague abdominal pain, weight loss, nausea and vomiting, 
bowel obstruction, gastrointestinal bleeding or anemia, which challenges the 
diagnosis. Known predisposing risk factors for these tumors are autoimmune 
disorders including celiac disease, Crohn’s disease and several hereditary cancer 
syndromes, including familial adenomatous polyposis (FAP), hereditary nonpol-
yposis colorectal cancer (HNPCC) and the Peutz-Jeghers syndrome. These 
predisposing genetic disorders also play a role in the pathogenesis of colon 
cancer. Although the precise pathogenesis of small bowel adenocarcinomas is 
unknown, most available data suggest a carcinoma sequence driven multistep 
process of specific genetic changes similar to colorectal cancers.[5-9] 
Due to the rarity of the disease, data about small bowel adenocarcinomas are 
scarce, diverse and contradictory. Therefore we conducted a population-based 
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study to establish the incidence, treatment and overall survival over time of 
patients with a small bowel adenocarcinoma in the Netherlands between 1999 
and 2013.
Methods
Data collection
For this study, data were retrieved from the Netherlands Cancer Registry (NCR), 
which is managed by the Comprehensive Cancer Organization the Netherlands. 
The nationwide NCR covers nearly 17 million inhabitants and comprises popu-
lation-based data on all newly diagnosed malignancies. Primary source of noti-
fication of the NCR is the automated nationwide pathological archive (PALGA), 
supplemented with data from the National Registry of Hospital Discharge 
Diagnoses. Required information on diagnosis, treatment, patient- and tumor 
characteristics are routinely extracted from hospital medical records by 
specially trained registrars operating on behalf of the NCR.
Patients were included if they were diagnosed between 1999 and 2013 with 
an adenocarcinoma of the small intestine, according to the third version of the 
International Classification of Disease for Oncology (ICD-O) (topography code 
C17). Tumors with the following morphology codes were classified as adenocar-
cinomas: 8140, 8144, 8145, 8210, 8255, 8260, 8261, 8263, 8480, 8481, 8490, 8560, 
8570, 8574. Patients with adenocarcinomas arising from a Meckel’s divertic-
ulum, as well as patients with neuroendocrine tumors, gastrointestinal stromal 
tumors, lymphomas or undifferentiated tumors in the small intestine were 
excluded from analysis. 
 All adenocarcinomas were classified according to the Tumor Lymph Node 
Metastasis (TNM) classification and were staged following the recommenda-
tions of the International Union Against Cancer in the respective period. The 
tumors were categorized in two groups, either as locoregional (T1-4N0-2M0) or 
metastatic cancer (T1-4N0-2M1). 
 Vital status of patients was assessed at January 1, 2014 through linkage with 
civil municipal registries and the central bureau for genealogy, which collects 
data on all deceased Dutch inhabitants. Survival was computed based on 
all-cause mortality. 
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Statistical analyses 
Descriptive statistics were used to describe the patient and tumor character-
istics. Differences in certain tumor characteristics and treatment between 
the locoregional and metastatic group were compared and analyzed using a 
two-sided χ2-test. To evaluate trends in treatment and survival, patients were 
categorized by period of diagnosis  (1999-2003, 2004-2008 and 2009-2013), 
and subsequently, trends between the subgroups were analyzed by means of a 
Cochran-Armitage trend test.
Age-standardized incidence rates were calculated per 100,000 person-years 
using the European standardized population rate (ESR) for the respective study 
period. Estimated annual percentage changes (EAPCs) in incidence were estimated 
by Poisson regression models. The independent influence of relevant patient and 
tumor characteristics on the administration of chemotherapy for patients with 
locoregional and metastatic disease was analyzed by means of a multivariable 
logistic regression analysis, including the 95% confidence interval (CI).
Survival time was defined as the time from date of diagnosis to death. 
Patients who were lost to follow-up or still alive at 1 January 2014 were censored. 
Evaluation of significant differences of survival between the subgroups 
occurred by means of a log-rank test. Multivariable survival analyses, using the 
cox proportional hazards model, were carried out to identify independent prog-
nostic factors of overall survival. In order to investigate the effect of therapy on 
the hazard ratios (HR) of dying, two separate multivariable models were run 
with and without treatment variables (surgery yes vs. no and chemotherapy 
yes vs. no). Hazard ratios were presented with 95% confidence intervals.
The statistical package SAS Statistical software (version 9.4, SAS institute, Cary, 
NC, USA) was used to analyze the data. For all statistical tests, a two-sided 
p-value p < 0.05 was considered as statistically significant. 
Results
A total of 3,930 patients were diagnosed with a small bowel tumor between 
January 1, 1999 and December 31, 2013 in the Netherlands. The most common 
histological subtype was adenocarcinoma, accounting for 1,775 cases (45%), 
followed by neuroendocrine tumors (1,429 patients, 36%) and gastro-intestinal 
stromal tumors (529 patients, 13%). The 1,775 patients diagnosed with an adeno-
carcinoma were enrolled in this study. 
 73
Treatment and survival of patients with small bowel adenocarcinomas   4.1
The patients’ characteristics are summarized in table 1. We found an equal 
gender distribution, the median age at time of diagnosis was 69 (range 17-97). 
The tumors were mainly located in the duodenum (58%), and respectively 19% 
and 14% in the jejunum and the ileum. A comparison between patients diag-
nosed with tumors located in the duodenum versus patients with tumors 
located elsewhere in the small intestine showed that patients with tumors in 
the duodenum were often slightly older and more frequently had a tumor with 
a higher or unknown tumor stage. 
The age-standardized incidence of small bowel adenocarcinomas increased 
from 0.5 per 100,000 inhabitants in 1999 to 0.7 per 100,000 inhabitants in 2013 
with an estimated annual percentage change (EAPC) of 3.7% (p<0.001). The 
increased incidence of small bowel adenocarcinomas was mainly caused by a 
twofold increase of duodenal adenocarcinomas from 233 in 1999-2003 to 478 
cases in 2009-2013 (p= 0.013) (figure 1). 
 Thirty-three percent of the patients had metastatic disease. Over time the 
proportion of patients presenting with metastases increased from 27% in 1999-
2003 to 38% in 2009-2013 (p<0.0001). Moreover, the percentage of patients 
presenting with metastases in multiple organs increased as well from 8% in 
1999-2003 to 28% in 2009-2013 (p=0.0003). The most common metastatic site 
was the liver (46%), followed by the peritoneal cavity (29%) and extra regional 
lymph nodes (12%). Patients with metastatic disease arising from duodenal 
origin showed a different metastatic pattern compared to patients with primary 
tumors located elsewhere in the small intestine. The majority of patients with 
metastatic duodenal adenocarcinomas had metastases located in the liver (54%), 
whereas in patients with metastases from non-duodenal adenocarcinomas the 
peritoneal cavity was the most frequently affected site (44%). 
In the group of patients with locoregional disease, 73% underwent a surgical 
resection of the primary tumor in contrast to 30% of the patients with meta-
static disease (p<0.0001). The percentage of patients with locoregional disease 
undergoing a resection slightly increased from 71% in 1999-2003 to 77% in 2009-
2013, while the percentage of patients with metastatic disease undergoing a 
surgical resection of the primary tumor decreased from 38% to 25% (p=0.0031). 
Tumor location was an important predictive factor for surgery. In locore-
gional disease, 58% of the patients with duodenal carcinomas underwent a 
surgical intervention with curative intent compared to 95% of the patients 
with jejunal and ileal carcinomas (p<0.0001). The percentage of patients with 
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Table 1 Characteristics of patients diagnosed with a small bowel adeno-
carcinoma, in the Netherlands between 1999 and 2013 according 
to primary tumor localization (N=1,775)
Total
N (%)
Duodenum
N (%)
Non-Duodenum
N (%)
p-value
Sex
 Male 
 Female
909  (51.2)
866  (48.8)
541 (52.7)
485 (47.3)
368 (49.1)
381 (50.9)
0.1343
Age (years)
 < 50 
 50-59
 60-69
 70-79
 ≥ 80 
178 (10.0)
281 (15.8)
458 (25.8)
509 (28.7)
349 (19.7)
84 (8.2) 
155 (15.1)
257 (25.1)
307 (29.9)
223 (21.7)
94 (12.6)
126  (16.8) 
201  (26.8)
202 (27.0)
126  (16.8) 
0.0028
Location primary tumor
Duodenum
Jejunum
Ileum
Overlapping 
Unknown/NOS 
1026  (57.8)
336 (18.9)
257 (14.5)
42 (2.4)
114 (6.4)
1026 (100.0)
Not applicable 
Not applicable 
Not applicable 
Not applicable 
Not applicable 
336  (44.9)
257  (34.3)
42 (5.6)
114  (15.2)
n.a.
TNM stage group
I
II
III
IV
X
115 (6.5)
501 (28.2)
419 (23.6)
581 (32.7)
159 (9.0) 
66   (6.4)
219  (21.4)
257  (25.1) 
352  (34.3)
132  (12.9)  
49 (6.5)
282  (37.7)
162  (21.6)
229  (30.6)
27 (3.6)
< 0.0001
Number of metastatic sites
1
2
≥ 3 
447  (76.9)
97 (16.7) 
37 (6.4)
286 (81.3)
48 (13.6)
18 (5.1)
161  (70.3)
49 (21.4)
19 (8.3)
0.0092
Period of diagnosis
1999-2003
2004-2008
2009-2013
436  (24.6)
559 (31.5)
780  (43.9) 
233  (22.7)
315  (30.7)
478  (46.6)
203  (27.1)
244  (32.6)
302  (40.3) 
0.0207
 75
Treatment and survival of patients with small bowel adenocarcinomas   4.1
Total
N (%)
Duodenum
N (%)
Non-Duodenum
N (%)
p-value
Surgery
Yes
No
1045 (58.9)
730 (41.1)
418 (40.7)
608  (59.3)
627  (83.7)
122  (16.3)
< 0.0001
Chemotherapy
Yes
No
321 (18.1)
1454 (81.9)
165  (16.1)
861  (83.9)
156  (20.8)
593  (79.2)
0.0103
Total 1775 1026 749
NOS = not otherwise specified
Table 1 Continued
Figure 1 Primary tumor location within the small bowel for patients diag-
nosed with a small bowel adenocarcinoma between 1999 and 
2013 in the Netherlands according to period of diagnosis (N=1,775).
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duodenal adenocarcinomas undergoing surgery increased from 54% to 64% 
throughout the study period (p=0.0179). In metastatic disease, only 7% of 
the patients with duodenal adenocarcinomas underwent surgical resection 
of the primary tumor, in contrast to respectively 63% and 81% of the patients 
with jejunal and ileal tumors (p<0.0001). Other palliative interventions, such 
as a bilio-digestive or intestinal bypass, endoscopic stent placement or celiac 
plexus block, were performed in 24% of the patients with metastatic duodenal 
adenocarcinomas, and respectively in 5% and 6% of the patients with meta-
static jejunal and ileal tumors. In addition, 14% of the patients with locoregional 
duodenal adenocarcinomas received a palliative intervention.
Eleven percent of the patients with locoregional disease received chemo-
therapy, while 33% of the patients with metastatic disease did. The use of 
chemotherapy increased over time for patients with locoregional disease 
from 7% in 1999-2003 to 15% in 2009-2013 (p=0.0001). Of the 91 patients with 
locoregional disease, undergoing both surgical resection and chemotherapy, 
the majority received chemotherapy in the adjuvant setting. Multivariable 
logistic regression analyses showed that chemotherapy in patients with locore-
gional disease was more often offered to younger patients, patients with ileal 
tumors,  stage III tumors and patients who were diagnosed in the period 2009-
2013 (table 2). In patients with metastatic disease the prescription of palliative 
chemotherapy significantly increased from 19% in 1999-2003 to 37% in 2009-
2013 (p=0.001). In metastatic disease, younger patients and patients who were 
diagnosed after 2003 received chemotherapy more frequently. 
 The median overall survival of patients diagnosed with a small bowel adeno-
carcinoma remained stable around 13-14 months, with one and five year survival 
rates of 53% and 25% respectively. Patients with locoregional disease had a 
median overall survival of 25 months (one and five year survival rates 65% and 
36% respectively). The median overall survival of patients with locoregional 
disease increased from 19 months in the first period to 34 months in the last 
period (p=0.0006). Patients with locoregional disease who underwent a surgical 
resection with a curative intent, had a median overall survival of 48 months. 
Patients receiving (neo-)adjuvant chemotherapy in combination with surgery 
exhibited a significantly better median overall survival of 66 months (p=0.0338). 
The median overall survival of patients with metastatic disease remained 
stable around 4-5 months (one and five year survival rates 26% and 3% respec-
tively). A median overall survival of 10 months was found in patients with 
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Table 2 Crude percentages and adjusted odds for receiving chemotherapy 
among patients diagnosed with small bowel adenocarcinomas, 
in the Netherlands between 1999 and 2013 by extent of disease 
(N=1,775)
Locoregional disease (n = 1194) Metastatic disease (n = 581)
Crude 
percentage 
(%)
Odds ratios 
(95% CI)
Crude  
percentage 
(%)
Odds ratios
(95% CI)
Sex
 Male 
 Female
12.1
9.9
1.00 (reference)
0.85 (0.57-1.27)
31.0
34.0
1.00  (reference)
1.18  (0.80-1.73)
Age (years)
 < 50
 50-59
 60-69
 70-79
 ≥ 80 
25.9
18.9
16.0
5.6
0.0
2.16  (1.22-3.81)
1.54  (0.92-2.59)
1.00  (reference)
0.34  (0.19-0.61)
Not applicable
56.5
51.1
39.4
23.7
3.2
1.99  (1.08-3.67)
1.63  (0.95-2.78)
1.00  (reference)
0.48  (0.29-0.78)
0.05  (0.02-0.16)
Location primary tumor
 Duodenum
 Jejunum
 Ileum
 Overlapping
 Unknown/NOS
9.5
13.0
15.1
8.3
9.7
1.00  (reference)
1.61  (0.97-2.68)
2.00  (1.16-3.47)
1.03  (0.21-5.02)
1.28  (0.52-3.16
28.7
43.3
34.7
38.9
33.3
1.00  (reference)
1.49  (0.90-2.48)
1.16  (0.64-2.12)
1.11  (0.40-3.06)
1.33  (0.61-2.86)
TNM stage group
 I
 II
 III
 X
0.0
7.6
20.8
4.4
Not applicable
1.00  (reference)
3.45  (2.22-5.35)
1.89  (0.77-4.66)
Not 
included in 
the analysis
Period of diagnosis
 1999-2003
 2004-2008
 2009-2013
6.6
9.8
15.0
1.00  (reference)
1.74  (0.96-3.16)
3.10  (1.79-5.38)
18.6
34.7
36.9
1.00  (reference)
2.31  (1.27-4.19)
3.00  (1.72-5.26)
NOS = not otherwise specified
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metastatic disease who were treated with palliative chemotherapy, compared 
to a median overall survival of only 3 months in patients who did not receive 
palliative chemotherapy.
 Favorable prognostic factors in patients with locoregional disease, iden-
tified by a separate multivariable survival analysis,  were age < 60 years, low 
tumor stage (stage I, II) and diagnosis in the period 2009-2013 (table 3). Factors 
that were associated with poor survival included age ≥ 70 years, tumor localiza-
tion in the duodenum and an unknown tumor stage (stage X). Surgical treat-
ment and chemotherapy were added separately to the model to investigate its 
effect on the hazard ratio of death according to period of diagnosis and different 
patient and tumor characteristics. Surgical treatment and chemotherapy were 
both favorable prognostic factors. Remarkably, after adjustment for surgery 
only, having a tumor located in the duodenum was no longer a negative prog-
nostic factor and being diagnosed in the period 2004-2008 became a positive 
prognostic factor. Chemotherapy did not influence the effect of any character-
istic on the hazard ratio of death. 
In a multivariable survival analysis without adjustment for treatment 
including patients with metastatic disease, age < 50 years and a primary tumor 
located in the jejunum or ileum were positive prognostic factors (table 4). Age 
> 80 years was the only negative prognostic factor. No beneficial influence of 
time was seen. After adjustment for chemotherapy and surgery, both positive 
prognostic factors, a primary tumor located in the ileum became a negative 
prognostic factor. 
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Table 3 Crude median overall survival, crude 1-year survival rate, crude 
5-year survival rate, adjusted hazard ratios with and without 
adjustment for treatment in patients diagnosed with a locore-
gional small bowel adenocarcinoma in the Netherlands between 
1999 and 2013 (N=1,194)  
Crude median 
overall 
survival 
(months) 
Crude 
1-year 
survival 
(%) 
Crude 
5-year 
survival 
(%)
Multivariate 
HR (95% CI) 
Multivariate 
HR (95% CI) 
adjusted for 
treatment
Sex
 Male 
 Female
26.1
24.5
65.8
64.7
35.6
35.5
1.00 (reference)
0.87 (0.75-1.00)
1.00 (reference)
0.82 (0.71-0.95)
Age (years)
< 50
50-59
60-69
70-79
≥ 80
73.0
66.4
32.4
21.9
7.9
84.9
79.8
72.1
62.8
40.9
52.3
53.6
40.0
32.1
13.7
0.61  (0.44-0.83)
0.66  (0.51-0.86)
1.00  (reference)
1.34  (1.09-1.64)
2.18  (1.76-2.71)
0.66 (0.48-0.91)
0.68 (0.53-0.89)
1.00 (reference)
1.21 (0.98-1.48)
1.52 (1.21-1.90)
Location primary tumor
Duodenum
Jejunum
Ileum
Overlapping 
Unknown/NOS 
16.3
62.6
40.2
41.3
22.6
57.8
81.9
73.3
79.1
55.5
28.1
50.9
42.8
33.4
37.1
1.00  (reference)
0.62  (0.51-0.77)
0.79  (0.63-0.98)
0.76  (0.45-1.29)
0.75  (0.55-1.02)
1.00  (reference)
0.93  (0.74-1.16)
1.22  (0.97-1.54)
0.97  (0.58-1.65)
1.12  (0.82-1.54)
TNM stage group
I
II
III
X
77.2
42.7
20.5
4.7
84.8
73.4
65.0
26.4
60.3
44.7
29.3
5.7
0.39  (0.29-0.53)
0.65  (0.55-0.77)
1.00  (reference)
1.73  (1.39-2.17)
0.42  (0.31-0.56)
0.63  (0.53-0.75)
1.00 (reference)
0.85 (0.67-1.07)
Period of diagnosis
1999-2003
2004-2008
2009-2013 
18.5
23.1
34.1
61.3
63.7
69.4
27.7
37.3
40.8
1.00 (reference)
0.87 (0.73-1.03)
0.68 (0.56-0.81)
1.00  (reference)
0.84  (0.70-0.99)
0.74  (0.61-0.89)
Surgery
Yes
No
50.3
5.6
79.8
73.6
47.9
3.2
Not included in
the analysis
0.23  (0.18-0.28)
1.00  (reference)
Chemotherapy 
Yes
No
35.5
23.5
84.3
63.0
41.1
34.9
Not included in 
the analysis
0.55  (0.41-0.73)
1.00  (reference)
NOS = not otherwise specified
80
4    Epidemiology of small bowel adenocarcinoma
Table 4 Crude median overall survival, crude 1-year survival rate, crude 
5-year survival rate, adjusted hazard ratios with and without 
adjustment for treatment in patients diagnosed with a metastatic 
small bowel adenocarcinoma in the Netherlands between 1999 
and 2013 (N=581)  
Crude median 
overall 
survival 
(months) 
Crude 
1-year 
survival 
(%) 
Crude 
5-year 
survival 
(%)
Multivariate HR
(95% CI)  
Multivariate HR 
(95% CI) 
adjusted for 
treatment 
Sex
 Male 
 Female
4.5
5.1
21.2
30.5
1.4
3.9
1.00  (reference)
0.89  (0.75-1.06)
1.00 (reference)
0.90  (0.75-1.07)
Age (years)
 < 50 
 50-59
 60-69
 70-79
 ≥ 80 
8.3
5.7
5.2
4.7
2.4
38.7
31.0
28.9
23.1
12.2
12.8
1.5
1.9
1.0
1.9
0.69  (0.50-0.95)
0.97  (0.73-1.27)
1.00  (reference)
1.16  (0.93-1.46)
1.64  (1.26-2.15)
0.79  (0.57-1.08)
1.00  (0.76-1.32)
1.00  (reference)
1.02  (0.81-1.29)
1.21  (0.91-1.60)
Location primary tumor
 Duodenum
 Jejunum
 Ileum
 Overlapping 
 Unknown/NOS 
4.0
9.7
5.0
4.9
5.7
19.2
40.5
29.9
29.6
39.1
1.2
7.2
7.5
0.0
0.0
1.00  (reference)
0.54  (0.42-0.70)
0.74  (0.56-0.97)
0.83  (0.51-1.36)
0.79  (0.56-1.12)
1.00  (reference)
0.90  (0.68-1.18)
1.57  (1.13-2.17)
1.19  (0.72-1.97)
1.48  (1.03-2.15)
Period of diagnosis
 1999-2003
 2004-2008
 2009-2013 
4.5
4.8
5.2
27.1
27.7
23.9
3.8
2.9
1.7
1.00  (reference)
0.92  (0.72-1.17)
0.95  (0.76-1.20)
1.00  (reference)
1.10  (0.86-1.41)
1.12  (0.89-1.42)
Surgery
 Yes
 No
10.6
3.9
47.2
16.6
8.0
0.4
Not included 
inthe analysis
0.38  (0.30-0.50)
1.00  (reference)
Chemotherapy 
 Yes
 No
10.5
3.2
43.4
17.5
4.5
1.9
Not included 
inthe analysis
0.50  (0.40-0.61) 
1.00  (reference)
NOS = not otherwise specified, 
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Discussion
This population-based study examined the incidence, treatment and median 
overall survival over time in patients diagnosed with a small bowel adenocar-
cinoma in the Netherlands between 1999 and 2013. The study is one of  the 
largest conducted studies in the field of small bowel adenocarcinomas so far. 
Our study, showed that the incidence of small bowel adenocarcinomas is rising. 
Furthermore, we found that the resection rates in non-metastatic small bowel 
cancer increased and the median overall survival in patients with locoregional 
disease improved over time. The median overall survival of patients with meta-
static disease remained stable, despite increased treatment with palliative 
chemotherapy. 
The intestinal distribution pattern of small bowel adenocarcinomas that 
we found in our study was comparable with the distribution pattern found in 
previous studies.[3-5,7] It has been hypothesized that the duodenum might be 
more susceptible for carcinogenesis than the jejunum and ileum due to the 
metabolism or dilution of ingested carcinogens in transit through the small bowel 
or interactions of the carcinogens with the pancreaticobiliary secretions. [3,7,10,11] 
Based on our comparison between patients diagnosed with tumors located 
in the duodenum and patients diagnosed with tumors located elsewhere in the 
small intestine, it could be questioned whether these tumors should be considered 
as one entity. Patients with tumors located in the duodenum are often slightly 
older, have more advanced disease stages and have a different metastatic pattern.
A slight increase in the incidence of small bowel adenocarcinomas was seen 
between 1999 and 2013, which is mainly caused by the twofold increase of 
duodenal adenocarcinomas. The exact cause for the specific increase in duodenal 
adenocarcinomas is unknown. Partially it can be explained by improved diag-
nostics, resulting in a reduction of misclassification of duodenal adenocarci-
nomas as pancreatic tumors and adenocarcinoma of unknown primary (ACUP).
[10,12] The modified food consumption might have attributed to increased inci-
dence rates as well. Previous studies found sugar, refined carbohydrates, red 
meat and smoked food to be associated with the development of small bowel 
adenocarcinomas.[2,11]
The percentage of patients diagnosed with metastatic disease increased 
over time, which can be explained by stage migration caused by new and 
improved diagnostics, such as multidetector row computed tomography scans 
and magnetic resonance enteroclysis.[13] 
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Surgical resection is the only therapy for potential cure in small intestine adeno-
carcinoma.[2] In line with previous studies, 73% of the patients with locore-
gional disease underwent an intentionally curative resection.[5,7] Resection 
rates were higher in jejunal and ileal tumors compared to resection rates in 
duodenal tumors, since surgical resection of upper duodenal tumors requires a 
pancreaticoduodenectomy, which is specialized major surgery in comparison to 
the more simple segmental resections with removal of surrounding tissue for 
jejunal and ileal tumors.[5,7]
Over time the resection rates increased, especially due to an increased 
number of resections in patients with duodenal tumors. We hypothesize 
that may be due to the centralization of pancreaticoduodenectomies in the 
Netherlands.[14,15] The amount of surgical interventions in patients with meta-
static disease decreased drastically, which is probably the result of improved 
palliative interventions, such as endoscopically placed (bilio-)duodenal endo-
protheses, and the increased use of chemotherapy.[16] Palliative interventions 
in patients with non-metastatic small bowel cancer were mostly performed in 
patients with duodenal adenocarcinomas, which are more often irresectable 
compared to jejunal and ileal tumors.[7] 
 The proportion of patients receiving chemotherapy doubled during the study 
period, both for patients with locoregional and metastatic disease. Especially 
in patients with locoregional disease the twofold increase is remarkable, since 
non-observational studies addressing the beneficial effect of chemotherapy 
are lacking. Overman et al. found adjuvant chemotherapy to be associated 
with an improvement of disease free survival, but not with improvement of 
overall survival.[17] Recently, a population-based study conducted by Ecker et 
al. showed a survival benefit of 16 months (42 vs 26 months) for patients with 
stage III tumors treated with adjuvant chemotherapy.[18] We demonstrate that 
in patients with locoregional disease chemotherapy was more often offered to 
younger patients, patients with ileal or stage III tumors and patients who were 
diagnosed in the period 2009-2013. In metastatic disease however, the doubling 
of palliative chemotherapy is not surprising, since a survival benefit of several 
months has already been observed in multiple retrospective studies.[5,19-21] In 
patients with metastatic disease, only a younger age and diagnosis after 2003 
were positive predictive factors for receiving palliative chemotherapy. 
The median overall survival of patients with an adenocarcinoma of the small 
intestine did not improve over time and remained 13-14 months. Our results are 
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inferior to the reported overall survival of approximately 20 months in other 
population-based studies, but these studies were merely conducted before the 
millennium and might have included neuroendocrine tumors with a more indo-
lent behavior.[5,7,22,23]
The median overall survival of patients with locoregional disease improved 
from 19 months in 1999-2003 to 34 months in 2009-2013, which might be 
explained by stage migration, increased use of chemotherapy and the central-
ization of surgery. Moreover, we found that patients treated with adjuvant 
chemotherapy after surgical resection had a significantly better survival, 66 
months compared to 48 months for patients not treated with adjuvant chemo-
therapy. However, it should be noted that the amount of patients receiving 
both treatments were limited in our study. Furthermore, selection bias might 
have played a role. Fitter patients, those with a better survival beforehand, 
might have received chemotherapy more frequently. Other favorable prog-
nostic factors for prolonged survival in patients with locoregional disease, 
identified by multivariable analysis, were age < 60 years, tumor stage I and II, 
surgical treatment and chemotherapy. These findings are comparable to previ-
ously determined prognostic factors.[3,5,7,20,22,24] In addition, in patients with 
locoregional disease, duodenal tumors appeared to be an adverse prognostic 
factor in multivariable analysis without adjustment for treatment. However, 
after adjustment for surgery only, a duodenal tumor was not a negative prog-
nostic factor anymore, which implies that the poor prognosis of these tumors is 
the result of the relative lack of possibilities for surgical intervention. 
In metastatic disease the median overall survival remained stable around 4-5 
months despite doubling of the prescription of palliative chemotherapy from 
19% to 37% in the recent years. In patients with metastatic disease, favorable 
prognostic factors identified by multivariable analysis included age < 50 years, 
primary tumor located in the jejunum, surgical treatment and chemotherapy. 
These prognostic factors are consistent with previously published data.[3,7,22]
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Limitations
A limitation of our study is that detailed information on performance status, 
nutritional status, disease related symptoms, the specific tumor localization 
within the duodenum, type of chemotherapy and type of surgical and pallia-
tive interventions are lacking due to the population-based nature of our data. 
However, our results did not differ from the results of other studies.[3-5,7]
Conclusion
In conclusion, small bowel adenocarcinomas are rare tumors with an increasing 
incidence, mainly caused by the rise of duodenal adenocarcinomas. The median 
overall survival of patients with locoregional disease improved significantly 
over time, which might be due to the increasing use of chemotherapy and the 
implementation of centralizing pancreatic cancer surgery. However, the median 
overall survival of patients with metastatic disease remained stable, despite 
doubling the administration of palliative chemotherapy. Due to the rarity and 
poor prognosis of this disease, it is of importance to develop international 
studies to determine the optimal treatment for these patients. The differences 
found in characteristics and median overall survival between patients diag-
nosed with tumors located in the duodenum and tumors located elsewhere in 
the small bowel might suggest that in future research both should be consid-
ered as different entities. 
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Chapter 5.1
Ten weeks to live: A population-based study on 
treatment and survival of patients with metastatic 
pancreatic cancer in the south of the Netherlands
N Bernards, N. Haj Mohammad, G.J.M. Creemers,  I.H.J.T. de Hingh, H.W.M. 
van Laarhoven, V. E.P.P. Lemmens Acta Oncologica 2015 Mar;54(3):403-10
Abstract
Background: A large proportion of patients with pancreatic cancer present 
with metastatic disease. We conducted a population-based study to eval-
uate trends in treatment and survival of patients with metastatic pancre-
atic cancer.
Methods: We included all patients diagnosed with pancreatic cancer between 
1993 and 2010 in the South of the Netherlands (N=3,099). Multivariable 
logistic regression analysis was conducted to evaluate trends in treatment 
with chemotherapy. Crude overall survival according to period of diagnosis 
was analyzed, and independent risk factors for death were identified.
Results: Forty-eight percent of the patients (N=1,494) were diagnosed 
with metastatic disease. The percentage of patients being diagnosed with 
metastatic disease increased during the study period from 35% in 1993-
1996 to 59% in 2009-2010 (p<0.0001). Overall, 18% of these patients received 
chemotherapy. The prescription of palliative chemotherapy almost 
tripled from 10% to 27% (p<0.0001). Treatment largely depended on age, 
ranging from 38% among patients aged <50 years (compared to 60-69 yrs.: 
adjusted odds ratio (ORadj) 2.5, (95%CI=1.4-4.2)) to 1% among patients aged 
≥80 years ( ORadj 0.04,(95%CI=0.0-0.2)). Patients were more likely to receive 
chemotherapy if they had a high socioeconomic status (compared to low 
socioeconomic status ORadj 2.0, (95%CI=1.3-3.1)), and if diagnosis was patho-
logically verified (no verification vs. verification: ORadj 0.3, (95%CI=0.2-0.5)). 
The administration of chemotherapy varied widely between ten hospitals 
(5-34%, p<0.0001). The median overall survival of patients with metastatic 
pancreatic cancer remained 9-11 weeks. 
90
5    Epidemiology of pancreatic cancer 
Conclusion: A growing proportion of pancreatic cancer patients presented 
with metastatic disease. Usage of palliative chemotherapy increased over 
time, but median survival remained 9-11 weeks. In the near future, it 
should be evaluated if the recently introduced regimens have an impact 
on population-based survival
Introduction
Pancreatic cancer is a devastating disease, with a 1-year survival rate ranging 
from 12% to 28% in Europe.[1] It is characterized by an aggressive tumor biology 
with early metastases. As a result, 95% of the pancreatic cancer patients even-
tually die of the disease within 5 years. 
The only curative treatment modality for pancreatic cancer is surgery. In 
the last decades, the survival for patients with resectable pancreatic cancer 
increased due to technical advances in surgical treatment as well as advances in 
other surgery-related factors, such as the establishment of high volume centers 
and implementation of adjuvant chemotherapy.[2,3]
However, about 80% of the patients with pancreatic cancer is diagnosed 
with locally advanced or metastatic disease and does not qualify for surgical 
treatment. Furthermore, the majority of patients treated with pancreatic 
surgery eventually relapse and develop local recurrence or distant metastases.
[2,4] 
Population-based data on treatment and outcome of metastatic pancre-
atic cancer are scarce. Recently, data from the United States Surveillance, 
Epidemiology and End Result registry (SEER) showed a modest increase in 
median overall survival of patients with metastatic pancreatic cancer in the 
years 1988-2008.[5] 
We conducted a population based study to evaluate the shift over time in 
proportion of patients diagnosed with metastatic disease and in treatment 
patterns. Furthermore, we evaluated the effect of both shifts on median overall 
survival in the south of the Netherlands. 
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Methods
Data collection
For the present study we used data from the Eindhoven Cancer Registry (ECR), 
maintained by the Comprehensive Cancer Centre South. The ECR is a popula-
tion-based registry in the southern part of the Netherlands. The registry area 
comprises about 2.4 million inhabitants and encompasses ten community 
hospitals, two radiotherapy institutions and six pathology departments. The 
area does not contain university or specialized cancer hospitals. Information 
on patient, tumor and treatment characteristics was routinely extracted from 
medical records by trained registrars operating on behalf of the ECR. 
Our study included all patients who were diagnosed with a neoplasm of 
the pancreas (International classification of Disease for Oncology (ICD-O), second 
edition, topography code 157 and third edition, code C25) between 1 January 1993 
and 31 December 2010. We decided to restrict the morphology to adenocarci-
noma and excluded patients with neuroendocrine tumors, sarcomas or blas-
tomas of the pancreas. Tumors without histological confirmation were included.
The registrars classified all adenocarcinomas according to the Tumor Lymph 
Node Metastasis (TNM) classification and staged them following the recom-
mendations of the International Union Against Cancer in the respective period. 
The clinical Extent of Disease (cEOD) was used for staging if the tumor was not 
histologically confirmed. We categorized tumors as locoregional (confined to 
the pancreas, with or without extension to surrounding organs or locoregional 
lymph nodes) or metastatic pancreatic cancer. 
Vital status of patients was assessed at 1 January 2012 through linkage with 
civil municipal registries and the central bureau for genealogy. The latter is an 
institution that collects data on all deceased Dutch citizens. Survival was calcu-
lated based on all-cause mortality. 
Statistical analyses
We described proportions of patients who received chemotherapy according 
to gender, age, socioeconomic status, number of comorbid conditions, histo-
logic subtype, site of metastases, period of diagnosis and hospital of treatment 
(A to J). Differences in the administration of systemic chemotherapy between 
subgroups were tested by means of a χ2 test. Trends in treatment across the 
five periods (1993-1996, 1997-2000, 2001-2004, 2005-2008 and 2009-2010) 
were analyzed by means of a Cochran-Armitage trend test. Furthermore, the 
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independent influence of these variables on the administration of chemo-
therapy was evaluated by means of a logistic regression analysis. Missing values 
were included as separate dummies in the analyses in order not to loose statis-
tical power. 
Survival time was defined as the time from diagnosis to death or 1 January 
2012, for patients who were still alive. The significance of differences between 
survival curves were evaluated by means of a log rank test. Independent risk 
factors for death were discriminated by multivariable proportional hazard 
regression modelling. In order to investigate the effect of chemotherapy on 
the hazard ratios (HRs) of dying according to period of diagnosis and hospital 
of diagnosis, the model was run with and without treatment variable (chemo-
therapy yes versus no).
SAS Statistical software (version 9.3, SAS institute, Cary, NC, U.S.A.) was 
used to perform the statistical analyses. For all analyses, a two sided p-value 
<0.05 was considered statistically significant. 
Results
A total of 3,099 patients were diagnosed with pancreatic cancer between 
1 January 1993 and 31 December 2010. Forty-eight percent of the patients 
(N=1,494) were diagnosed with metastatic disease. This percentage increased 
over time, from 35% in 1993-1996 to 59% in 2009-2010 (p<0.01). 
General characteristics categorized by period are depicted in table 1. Fifty-five 
percent of our study population was male and 68% of the patients had a diag-
nosis confirmed by pathological examination. The median age at time of diag-
nosis was 68 years (range 32-99). Over time the proportion of elderly patients 
diagnosed with metastatic pancreatic cancer increased.
The liver (76%) and the peritoneal cavity (18%) were the most common 
metastatic sites. Twenty-four percent of the patients had metastases in two or 
more organs and this proportion increased over time. Patients with liver metas-
tases were more likely to have multiple organs affected compared to patients 
with non-liver metastases (p=0.03). 
The use of chemotherapy among patients with metastatic pancre-
atic cancer increased, from 10% in 1993-1996 to 27% in 2009-2010 (p<0.001) 
(figure 1). Several factors influenced the probability of receiving chemotherapy. 
Table 2 shows the crude proportions of patients treated with chemotherapy 
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according to relevant patient and tumor characteristics, and the adjusted odds 
of being treated with chemotherapy. Chemotherapy was administered more 
often to younger patients and patients with a high socioeconomic status 
(SES). In contrast, older patients and patients without pathological confirma-
tion received chemotherapy less frequently. Furthermore, there was a large 
inter-hospital variation in the prescription of chemotherapy (5 - 34%) and this 
variation was not related to the size of the hospital.  
The overall survival of patients with metastatic pancreatic cancer did not 
change in the course of time. The prognosis remained dismal, with 1-year survival 
rates between 4-7% and a median overall survival between 9-11 weeks (figure 
2). Patients treated with palliative chemotherapy exhibited a median overall 
survival of 25 weeks (1-year survival rate 17%), compared to 8 weeks in those not 
treated with chemotherapy (1-year survival rate 3%) (table 3). Other beneficial 
prognostic factors identified by multivariable survival analysis were female sex, 
single site metastases in extra regional lymph nodes, and dissemination limited 
to the lungs. Factors associated with poor survival included older age (70-79 yrs 
or 80+). Patients without microscopically verified pancreatic cancer carried the 
same dismal prognosis as patients with verified pancreatic cancer. 
Without adjustment for chemotherapy in the multivariable survival anal-
ysis, the risk of dying remained similar across the different study periods. After 
adjustment for chemotherapy the risk of dying increased significantly over 
time. Patients diagnosed in hospital B and G had a better survival, but after 
adjustment for chemotherapy this difference was not observed anymore. 
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Table 1 Characteristics of patients with metastatic pancreatic cancer, by 
period of diagnosis (N=1,494) 
Total
N   (%)
1993-1996
N    (%)
1997-2000
N   (%)
2001-2004
N (%)
2005-2008
N (%)
2009-2010
N  (%) p value
Sex
 Male 
 Female
829 (55.5)
665 (44.5)
119  (63.3)
69 (36.7)
135 (49.6)
137 (50.4)
171 (55.7)
136 (44.3)
250 (56.9)
189 (43.1)
154 (53.5)
134 (46.5)
0.46
Age (yrs)
 <50 
 50-59
 60-69
 70-79
 ≥80 
93 (6.2) 
241 (16.1)
512 (34.3)
469 (31.4)
179 (12.0)
22 (11.7) 
36 (19.1)
57 (30.3) 
53 (28.2)
20 (10.6)
15 (5.5)
54 (19.9)
92 (33.8)
87 (32.0)
24 (8.8)
20 (6.5)
50 (16.3)
110 (35.8)
91 (29.6)
36 (11.7)
26 (5.9)
67 (15.3)
151 (34.4)
140 (31.9)
55 (12.5)
10 (3.5)
34 (11.8)
102 (35.4)
98 (34.0)
44 (15.3)
0.03
Socioeconomic status (SES)
 Low 
 Intermediate
 High 
 Institutions 
 Unknown
372 (24.9)
584 (39.1)
424 (28.4)
72 (4.8)
42 (2.8)
42 (22.3)
59 (31.4)
57 (30.3)
14 (7.5)
16 (8.5)
85 (31.3)
99 (36.4)
70 (25.7)
16 (5.9)
2 (0.7)
75 (24.4)
118 (38.4)
97 (31.6)
13 (4.2)
4 (1.3)
102 (23.2)
187 (42.6)
127 (28.9)
13 (3.0)
10 (2.2)
68 (23.6)
121 (42.0)
73 (25.3)
16 (5.6)
10 (3.5)
<0.01
No. of comorbid conditions 
 0 
 1
 ≥2
 Unknown
712 (47.7)
469 (31.4)
179 (12.0)
134 (9.0)
105  (55.9)
34 (18.1)
14 (7.4)
35 (18.6)
151 (55.5)
70 (25.7)
22 (8.1)
29 (10.7)
141 (45.9)
100 (32.6)
30 (9.8)
36 (11.7)
198 (45.1)
155 (35.3)
60 (13.7)
26 (5.9)
117 (40.6)
110 (38.2)
53 (18.4)
8 (2.8)
<0.01
Histologic subtype
 Adenocarcinoma
 No histology
1023 (68.5)
471 (31.5)
134 (71.3)
54 (28.7)
175 (64.3)
97 (35.7)
197 (64.2)
110 (35.8)
303 (69.0)
136 (31.0)
214 (74.3)
74 (25.7)
0.12
Metastatic site
  Liver
  Peritoneal
  Lung
  Lymphnodes
  Other / unknown 
  2 organs 
  ≥3 organs 
840 (56.2)
124 (8.3)
47 (3.1)
45 (3.0)
78 (5.2)
270 (18.1)
90 (6.0)
114 (60.6)
16 (8.5)
7 (3.7)
4 (2.1)
22 (11.7)
18 (9.6)
7 (3.7)
165 (60.7)
31 (11.4)
6 (2.2)
12 (4.4)
15 (5.5)
40 (14.7)
3 (1.1)
192 (62.5)
15 (4.9)
9 (2.9)
9 (2.9)
17 (5.5)
43 (14.0)
22 (7.2)
232 (52.8)
32 (7.3)
10 (2.3)
14 (3.2)
18 (4.1)
108 (24.6)
25 (5.7)
137 (47.6)
30 (10.4)
15 (5.2)
6 (2.1)
6 (2.1)
61 (21.2)
33 (11.5)
<0.01
 95
Ten weeks to live: survival of patients with metastatic pancreatic cancer    5.1
Table 1 Characteristics of patients with metastatic pancreatic cancer, by 
period of diagnosis (N=1,494) 
Total
N   (%)
1993-1996
N    (%)
1997-2000
N   (%)
2001-2004
N (%)
2005-2008
N (%)
2009-2010
N  (%) p value
Sex
 Male 
 Female
829 (55.5)
665 (44.5)
119  (63.3)
69 (36.7)
135 (49.6)
137 (50.4)
171 (55.7)
136 (44.3)
250 (56.9)
189 (43.1)
154 (53.5)
134 (46.5)
0.46
Age (yrs)
 <50 
 50-59
 60-69
 70-79
 ≥80 
93 (6.2) 
241 (16.1)
512 (34.3)
469 (31.4)
179 (12.0)
22 (11.7) 
36 (19.1)
57 (30.3) 
53 (28.2)
20 (10.6)
15 (5.5)
54 (19.9)
92 (33.8)
87 (32.0)
24 (8.8)
20 (6.5)
50 (16.3)
110 (35.8)
91 (29.6)
36 (11.7)
26 (5.9)
67 (15.3)
151 (34.4)
140 (31.9)
55 (12.5)
10 (3.5)
34 (11.8)
102 (35.4)
98 (34.0)
44 (15.3)
0.03
Socioeconomic status (SES)
 Low 
 Intermediate
 High 
 Institutions 
 Unknown
372 (24.9)
584 (39.1)
424 (28.4)
72 (4.8)
42 (2.8)
42 (22.3)
59 (31.4)
57 (30.3)
14 (7.5)
16 (8.5)
85 (31.3)
99 (36.4)
70 (25.7)
16 (5.9)
2 (0.7)
75 (24.4)
118 (38.4)
97 (31.6)
13 (4.2)
4 (1.3)
102 (23.2)
187 (42.6)
127 (28.9)
13 (3.0)
10 (2.2)
68 (23.6)
121 (42.0)
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165 (60.7)
31 (11.4)
6 (2.2)
12 (4.4)
15 (5.5)
40 (14.7)
3 (1.1)
192 (62.5)
15 (4.9)
9 (2.9)
9 (2.9)
17 (5.5)
43 (14.0)
22 (7.2)
232 (52.8)
32 (7.3)
10 (2.3)
14 (3.2)
18 (4.1)
108 (24.6)
25 (5.7)
137 (47.6)
30 (10.4)
15 (5.2)
6 (2.1)
6 (2.1)
61 (21.2)
33 (11.5)
<0.01
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Total
N   (%)
1993-1996
N    (%)
1997-2000
N   (%)
2001-2004
N (%)
2005-2008
N (%)
2009-2010
N  (%) p value
Hospital of diagnosis
 Hospital A
 Hospital B
 Hospital C 
 Hospital D
 Hospital E 
 Hospital F
 Hospital G
 Hospital H
 Hospital I
 Hospital J
228 (15.3) 
85 (5.7)
154 (10.3) 
119 (8.0) 
72 (4.8)
217 (14.5)
236 (15.8)
131 (8.8)
107 (7.2)
145 (9.7)
21 (11.2)
16 (8.5)
13 (6.9)
14 (7.4)
11 (5.9)
23 (12.2)
33 (17.6)
17 (9.0)
21 (11.2)
19 (10.1)
46 (16.9)
11 (4.0)
26 (9.6)
25 (9.2)
12 (4.4)
38 (14.0)
35 (12.9)
23 (8.5)
24 (8.8)
32 (11.8)
41 (13.4)
26 (8.5)
29 (9.4)
26 (8.5)
18 (5.9)
38 (12.4)
43 (14.0)
37 (12.1)
17 (5.5)
32 (10.4)
69 (15.7)
13 (3.0)
45 (10.3)
36 (8.2)
19 (4.3)
76 (17.3)
77 (17.5)
32 (7.3)
29 (6.6)
43 (9.8)
51 (17.7)
19 (6.6)
41 (14.2)
18 (6.3)
12 (4.2)
42 (14.6)
48 (16.7)
22 (7.6)
16 (5.6)
19 (6.6)
0.01
Chemotherapy 
 Yes 
 No 
272 (18.2)
1222 (81.8)
18 (9.6)
170 (90.4)
26 (9.6)
246  (90.4)
60 (19.5)
247 (80.5)
90 (20.5)
349  (79.5)
78 (27.1) 
210 (72.9)
<0.01
Total 1494 188 (12.6) 272  (18.2) 307  (20.6) 439  (29.4) 288  (19.3)
Table 1 Continued
Figure 1 Administration of chemotherapy in patients diagnosed with met-
astatic pancreatic cancer in the southern Netherlands between 
1993 and 2010, according to period of diagnosis (N=1,494)
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Total
N   (%)
1993-1996
N    (%)
1997-2000
N   (%)
2001-2004
N (%)
2005-2008
N (%)
2009-2010
N  (%) p value
Hospital of diagnosis
 Hospital A
 Hospital B
 Hospital C 
 Hospital D
 Hospital E 
 Hospital F
 Hospital G
 Hospital H
 Hospital I
 Hospital J
228 (15.3) 
85 (5.7)
154 (10.3) 
119 (8.0) 
72 (4.8)
217 (14.5)
236 (15.8)
131 (8.8)
107 (7.2)
145 (9.7)
21 (11.2)
16 (8.5)
13 (6.9)
14 (7.4)
11 (5.9)
23 (12.2)
33 (17.6)
17 (9.0)
21 (11.2)
19 (10.1)
46 (16.9)
11 (4.0)
26 (9.6)
25 (9.2)
12 (4.4)
38 (14.0)
35 (12.9)
23 (8.5)
24 (8.8)
32 (11.8)
41 (13.4)
26 (8.5)
29 (9.4)
26 (8.5)
18 (5.9)
38 (12.4)
43 (14.0)
37 (12.1)
17 (5.5)
32 (10.4)
69 (15.7)
13 (3.0)
45 (10.3)
36 (8.2)
19 (4.3)
76 (17.3)
77 (17.5)
32 (7.3)
29 (6.6)
43 (9.8)
51 (17.7)
19 (6.6)
41 (14.2)
18 (6.3)
12 (4.2)
42 (14.6)
48 (16.7)
22 (7.6)
16 (5.6)
19 (6.6)
0.01
Chemotherapy 
 Yes 
 No 
272 (18.2)
1222 (81.8)
18 (9.6)
170 (90.4)
26 (9.6)
246  (90.4)
60 (19.5)
247 (80.5)
90 (20.5)
349  (79.5)
78 (27.1) 
210 (72.9)
<0.01
Total 1494 188 (12.6) 272  (18.2) 307  (20.6) 439  (29.4) 288  (19.3)
Figure 2 Overall survival of patients diagnosed with metastatic pancre-
atic cancer in the southern Netherlands between 1993 and 2010, 
according to period of diagnosis (N=1,494) 
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Table 2 Crude percentages, unadjusted and adjusted oddsa for receiving 
chemotherapy among patients diagnosed with metastatic pan-
creatic cancer in the southern Netherlands between 1993 and 
2010 (N=1,494) 
Crude
percentage 
% 
Univariate
Odds ratio 
(95% CI)
Multivariate 
Odds ratio 
(95% CI)
Sex
 Male 
 Female
19.7
16.4
1.00 (reference)
0.80 (0.61-1.05) 
1.00 (reference)
0.91 (0.67-1.24) 
Age (yrs)
 <50 
 50-59
 60-69
 70-79
 ≥80 
37.6
29.0
21.5
11.7
1.1
2.21 (1.38-3.53)
1.50 (1.06-2.12) 
1.00 (reference) 
0.49 (0.34-0.69)
0.04 (0.01-0.17) 
2.43 (1.41-4.18)
1.68 (1.13-2.49)
1.00 (reference)
0.49 (0.33-0.73)
0.04 (0.01-0.18)
Socioeconomic status (SES)
 Low 
 Intermediate
 High 
13.4
17.8
25.9
1.00 (reference)
1.40 (0.97-2.01) 
2.26 (1.56-3.26)
1.00 (reference)
1.18 (0.78-1.79)
2.05 (1.34-3.13)
Number of comorbid conditions
 0 
 1
 ≥2
21.5
17.3
14.0
1.00 (reference) 
0.76 (0.57-1.03)
0.59 (0.38-0.94)
1.00 (reference)
0.77 (0.54-1.09)
0.69 (0.41-1.16)
Histologic subtype
 Adenocarcinoma
 No histology
23.7
6.4
1.00 (reference) 
0.22 (0.15-0.33) 
1.00 (reference)
0.33 (0.21-0.51)
Site of metastases 
 Liver
 Peritoneal
 Lung
 Extraregional nodes
 Other
 2 organs 
 3+ organs 
18.6
17.7
12.8
15.6
12.8
18.9
22.2
1.00 (reference) 
0.95 (0.58-1.55) 
0.64 (0.27-1.54) 
0.81 (0.35-1.84)
0.65 (0.33-1.28) 
1.02 (0.72-1.45) 
1.25 (0.74-2.12) 
1.00 (reference) 
0.78 (0.45-1.37)
1.01 (0.38-2.68)
0.81 (0.32-2.03)
0.76 (0.35-1.63)
0.81 (0.54-1.22)
0.80 (0.44-1.48)
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Crude
percentage 
% 
Univariate
Odds ratio 
(95% CI)
Multivariate
Odds ratio 
(95% CI)
Period of diagnosis
 1993-1996 
 1997-2000
 2001-2004
 2005-2008
 2009-2010
9.6
9.6
19.5
20.5
27.1
1.00 (reference) 
1.00 (0.53-1.88) 
2.29 (1.31-4.02) 
2.44 (1.42-4.17)
3.51 (2.02-6.09)
1.00 (reference)
1.71 (0.85-3.46)
4.08 (2.15-7.73)
4.61 (2.48-8.58)
7.40  (3.87-14.15)
Hospital of diagnosis
 Hospital A
 Hospital B
 Hospital C 
 Hospital D
 Hospital E 
 Hospital F
 Hospital G
 Hospital H
 Hospital I
 Hospital J
14.9
29.4
18.2
5.0
13.9
11.1
34.3
15.3 
22.4
13.8
1.00 (reference) 
2.38 (1.32-4.30)
1.27 (0.73-2.19)
0.30 (0.12-0.74) 
0.92 (0.43-1.97)
0.71 (0.41-1.24)
2.98 (1.90-4.69)
1.03 (0.56-1.87)
1.65 (0.92-2.95)
0.91 (0.50-1.66) 
1.00 (reference) 
4.08 (2.05-8.14)
1.36 (0.74-2.50) 
0.39 (0.15-1.02)
1.07 (0.47-2.44) 
0.87 (0.48-1.58) 
5.27 (3.15-8.82)
1.22 (0.63-2.35)
1.86 (0.98-3.55) 
1.04 (0.55-1.98) 
a Adjusted for all variables listed. Included in the analysis but results not shown, SES institution-
alised, SES unknown and comorbidity unknown 
Table 2 Continued
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Table 3 Crude median overall survival, crude 1-year survival, unadjusted 
and adjusted hazard ratiosa for patients diagnosed with meta-
static pancreatic cancer in the southern Netherlands between 
1993 and 2010 (N=1,494) 
Crude median 
survival (weeks)
Crude 1-year 
survival (%)
Univariate
HR (95%)
Multivariable
HR (95% CI) 
Sex
 Male 
 Female
9.4
9.9
6.0
5.4
1.00 (reference)
0.97 (0.88-1.07)
1.00 (reference)
0.89 (0.80-0.99)
Age (yrs)
 <50 
 50-59
 60-69
 70-79
 ≥80 
14.3
12.0
11.1
7.9
5.1
8.6
7.1
7.6
3.2
3.4
0.85 (0.68-1.06)
0.92 (0.79-1.07)
1.00 (reference)
1.36 (1.20-1.54)
1.75 (1.48-2.08)
1.02 (0.81-1.28)
1.00 (0.86-1.18)
1.00 (reference)
1.20 (1.05-1.37)
1.38 (1.14-1.67)
Socioeconomic status (SES)
 Low 
 Intermediate
 High
8.7
9.4
10.9
3.8
4.8
8.7
1.00 (reference)
0.93 (0.82-1.06)
0.79 (0.68-0.91)
1.00 (reference)
0.97 (0.85-1.11)
0.87 (0.75-1.00)
Number of comorbid conditions
 0 
 1
 ≥2
10.0
9.0
9.0
6.6
4.7
2.8
1.00 (reference)
1.15 (1.02-1.29)
1.27 (1.07-1.49)
1.00 (reference) 
1.03 (0.91-1.17) 
1.05 (0.88-1.24)
Histologic subtype
 Adenocarcinoma
 No histology
10.4
7.6
6.5
4.0
1.00 (reference)
1.26 (1.13-1.40)
1.00 (reference)
1.02 (0.90-1.16) 
Site of metastases 
  Liver
  Peritoneal
  Lung
  Extra regional nodes
  Other
  2 organs 
  3 or more organs
9.7
8.2
17.9
21.6
10.6
7.1
5.6
5.6
5.7
6.4
20.0
6.4
4.1
3.3
1.00 (reference)
1.06 (0.88-1.28)
0.69 (0.52-0.93)
0.60 (0.44-0.81)
0.89 (0.71-1.12)
1.17 (1.02-1.35)
1.46 (1.17-1.81)
1.00 (reference) 
1.05 (0.86-1.27) 
0.56 (0.41-0.75) 
0.50 (0.37-0.69) 
0.84 (0.66-1.06) 
1.13 (0.99-1.31) 
1.65 (1.32-2.07) 
Period of diagnosis
 1993-1996
 1997-2000
 2001-2004 
 2005-2008
 2009-2010
10.9
8.7
9.7
9.7
9.0
3.7
5.9
7.2
5.0
6.3
1.00 (reference)
1.16 (0.96-1.39)
1.03 (0.86-1.23)
1.05 (0.89-1.25)
1.05 (0.87-1.26)
1.00 (reference) 
1.25 (1.03-1.52) 
1.19 (0.99-1.44)
1.21 (1.01-1.45) 
1.32 (1.08-1.61) 
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Discussion
This population-based study showed that an increasing proportion of pancre-
atic cancer patients presented with metastatic disease. The administration 
of palliative chemotherapy in these patients increased drastically, and large 
inter-hospital variations in the administration were noted. In the course of time, 
the population-based median overall survival remained dismal.
The increasing proportion of pancreatic cancer patients who present with 
metastatic disease is consistent with previous reports.[6,7] The improve-
ments in the accuracy of the current CT scans and the development of new 
diagnostic tools are major contributing factors. Once (metastatic) pancreatic 
cancer is suspected on imaging studies, pathologic confirmation is recom-
mended to establish the definitive diagnosis. In 68% of the patients with meta-
static pancreatic cancer the definitive diagnosis was verified by pathological 
examination. Low overall proportions of verification are common in pancreatic 
cancer. The EUROCARE-4 study, a study that gathered data from 93 European 
cancer registries between 1995 and 2002, found a verification rate of 63% (range 
30-91%) in all patients with pancreatic cancer.[8] Our data suggest that the rate 
Crude median 
survival (weeks)
Crude 1-year 
survival (%)
Univariate
HR (95%)
Multivariable
HR (95% CI) 
Hospital of diagnosis
   Hospital A
   Hospital B
   Hospital C 
   Hospital D
   Hospital E 
   Hospital F
   Hospital G
   Hospital H
   Hospital I
   Hospital J
10.4
12.6
9.4
7.1
9.3
8.9
10.2
8.1
9.1
10.1
5.3
7.1
7.1
4.2
6.9
3.7
5.9
3.8
9.4
6.2
1.00  (reference)
0.84  (0.66-1.08)
0.92  (0.75-1.12)
1.12  (0.90-1.40)
0.96  (0.74-1.26)
1.09  (0.91-1.32)
0.91  (0.76-1.10)
1.20  (0.96-1.48)
0.94  (0.75-1.19)
1.04  (0.85-1.28)
1.00  (reference) 
0.92  (0.71-1.20) 
0.86  (0.70-1.07) 
1.00  (0.79-1.25) 
0.86  (0.65-1.12) 
0.98  (0.81-1.19) 
1.01  (0.84-1.23) 
1.15  (0.92-1.43) 
1.02  (0.80-1.30) 
0.97  (0.78-1.20) 
Chemotherapy 
   No
   Yes 
7.6
25.3
3.1
17.3
1.00  (reference)
0.41  (0.36-0.47)
1.00  (reference)
0.39  (0.34-0.46)
a Adjusted for all variables listed. Included in the analysis but results not shown, SES unknown, 
comorbidity unknown, and tumor differentiation grade unknown.
Table 3 Continued
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is especially low in non-metastatic pancreatic cancer. Obtaining tissue in the 
absence of metastases can be difficult, since the pancreas is situated in the retro- 
peritoneum and the abundant presence of desmoplastic stroma in pancreatic 
tumors may hamper the identification of malignant tumor cells.[8,9] In case 
of metastatic disease, health care practitioners often refrain from diagnostic 
biopsies in patients who are considered unfit for systemic treatment. Although 
in several population-based studies, pathologically unverified tumors were not 
taken into account, we included these patients into our study, in order to obtain 
a true reflection of the outcome of daily clinical practice in pancreatic cancer 
care.[10,11] Since the overall survival of patients with histologically unverified 
pancreatic cancer was poor, the likelihood that these patients indeed suffered 
from pancreatic cancer is high. We believe it is of clinical relevance to report on 
the outcome of these patients, as they constitute a significant proportion of 
pancreatic cancer patients. 
Although no considerable progress has been made in the chemotherapeutic 
treatment of metastatic pancreatic cancer during the study period, the prescrip-
tion of chemotherapy increased from 10% 1993-1996 to 27% 2009-2010. Since 
1997, gemcitabine monotherapy has been the reference regimen for patients 
with metastatic pancreatic cancer. Although initial studies suggested a low 
response rate (6 to 11%), gemcitabine was approved for first-line treatment on 
the basis of significant improvement in ‘clinical benefit’ (pain relief, improved 
performance status, or both) and prolongation of survival (5.6 months in gemcit-
abine-treated patients versus 4.4 months in fluorouracil-treated patients).[12] In 
numerous trials over the past years, many different (drug) regimens have been 
tested. Until recently, none of these trials demonstrated a statistically significant 
survival benefit, except for gemcitabine plus erlotinib which was associated with 
a very modest and clinically irrelevant increase in overall survival of 2 weeks.[13] 
In the course of time, the prescription of palliative chemotherapy increased dras-
tically, possibly because physicians became more familiar with the use of chemo-
therapy in pancreatic cancer after the publication by Neoptolemos et al. in 2001 
of adjuvant gemcitabine chemotherapy in patients with resected pancreatic 
cancer.[14,15] A similar phenomenon has been observed in patients with metas-
tasized gastric cancer, after the introduction of perioperative chemotherapy.[16] 
In our study, the odds of receiving chemotherapy was influenced by several 
patient- and tumor-related factors. First, an inverse relationship between the 
administration of chemotherapy and age was found, which is consistent with 
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findings from previous reports.[17] Second, patients with a higher socioeco-
nomic status were more likely to receive chemotherapy.[6,7] This treatment 
selection according to SES has also been described by Krzyzanowska et. al. for 
elderly patients with advanced pancreatic cancer and by Chueng et al. for a 
cohort of patients living in the state of Florida. [17,18] Third, patients without 
microscopically verified pancreatic cancer had lower odds for receiving chemo-
therapy. This is not surprising, since most guidelines recommend “a positive 
biopsy” before systemic treatment is started, and a biopsy will only be omitted 
when patients are not fit for treatment. 
We observed a large hospital variation in prescription of palliative chemo-
therapy after adjusting for casemix. In the Netherlands, the treatment guidelines 
state that palliative chemotherapy should be considered in case of metastatic 
pancreatic cancer.[19] However, a recent study found that this consideration 
is strongly influenced by the physicians’ amount of experience and judgment 
about the benefit of treatment and performance status of the patient.[20] This 
could explain the large inter-hospital variation observed in our study.
In the present study, the median overall survival for patients who were treated 
with chemotherapy was 25 weeks compared to 8 weeks for untreated patients. 
In our multivariable proportional hazard analyses, chemotherapy was found to 
reduce the risk of death by 61%. This is high in comparison with the results from 
a meta-analysis of chemotherapy for locally advanced and metastatic pancreatic 
cancer. In this meta-analysis the risk of death was reduced by 36%.[21] 
The difference can be explained by the observational character of our study 
and underscores the influence of selection: fitter patients or patients with 
less advanced disease, i.e. those with a better overall survival beforehand, 
more often received chemotherapy. Unfortunately information on additional 
confounders such as performance status and disease related symptoms are 
lacking due to the population-based nature of our data. 
Although patients treated with systemic chemotherapy had a better overall 
survival, increased administration of chemotherapy did not improve popula-
tion-based overall survival. Perhaps, population-based improvement was not 
achieved because the proportion of metastatic pancreatic cancer patients treated 
with chemotherapy was too small, or the impact of the regimen on overall survival 
was too little to achieve population-based improvement. However, we found that 
the significantly worsened survival over time was no longer demonstrated after 
inclusion of chemotherapy in the multivariable survival analysis.  This might be 
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interpreted as  a beneficial effect of increased prescription rates of chemotherapy 
on an otherwise even increasingly detrimental prognosis of this patient group. 
Fortunately, treatment options for metastatic pancreatic cancer have 
increased with the introduction of new drugs and multidrug regimens. For 
instance FOLFIRINOX, introduced in 2011, was the first regimen to result in a 
median overall survival of almost 1 year in patients with metastatic pancre-
atic cancer.[22,23] However, the regimen is more toxic than gemcitabine and 
may therefore only be considered for young patients with a good performance 
status.[22] Recently, a new combination of nab-paclitaxel and gemcitabine was 
introduced by van Hoff et al. this regimen also showed a clinically meaningful 
improvement in overall survival of patients with metastatic pancreatic cancer 
and may be less toxic than FOLFIRINOX.[24] As mentioned before, the impact 
of a regimen on population-based overall survival depends on the proportion 
of patients eligible to receive the regimen and the efficacy of the regimen. 
Although FOLFIRINOX is currently the most effective treatment in metastatic 
pancreatic cancer, its use is restricted to a selected group of patients.[22] 
Nab-paclitaxel plus gemcitabine can be used more widely, but improved the 
median overall survival with only 1.8 months compared to gemcitabine alone.
[24] It is questionable if these regimens have enough impact to improve popu-
lation-based overall survival in the near future. 
 Considering these new treatment modalities the aforementioned large 
hospital variation in chemotherapy prescription rates might be of concern. The 
availability of new, more toxic, treatment regimens warrants more appropriate 
selection of patients, and possibly treatment by a medical oncologist with 
more experience with these regimens. It may be hypothesized that - similar to 
the centralization of surgical care for patients with resectable pancreatic cancer 
- patients eligible for chemotherapeutical treatment might also benefit from 
centralization. Local tumor boards might offer a solution until centralization is 
achieved.[2,25]  
Conclusion 
In conclusion, the median survival of patients with metastatic pancreatic cancer 
between 1993 and 2010 remained 10 weeks in spite of a significant increase in 
the proportion of patients being treated with palliative chemotherapy. In the 
near future, it should be evaluated if the recently introduced regimens have an 
impact on population-based survival. 
 105
Ten weeks to live: survival of patients with metastatic pancreatic cancer    5.1
References
[1] Moller H, Linklater KM, Robinson D. A vi-
sual summary of the EUROCARE-4 results: 
a UK perspective. British journal of cancer 
2009; 101 Suppl 2: S110-4.
[2] Lemmens VE, Bosscha K, van der Schell-
ing G, Brenninkmeijer S, Coebergh JW, de 
Hingh IH. Improving outcome for patients 
with pancreatic cancer through central-
ization. The British journal of surgery 2011; 
98: 1455-62.
[3] Seufferlein T, Bachet JB, Van Cutsem E, 
Rougier P. Pancreatic adenocarcinoma: 
ESMO-ESDO Clinical Practice Guidelines 
for diagnosis, treatment and follow-up. 
Ann Oncol 2012; 23 Suppl 7: vii33-40.
[4] Pancreatic cancer in the UK. Lancet 2011; 
378: 1050.
[5] Worni M, Guller U, White RR, Castleberry 
AW, Pietrobon R, Cerny T, et al. Modest 
improvement in overall survival for pa-
tients with metastatic pancreatic cancer: 
a trend analysis using the surveillance, ep-
idemiology, and end results registry from 
1988 to 2008. Pancreas 2013; 42: 1157-63.
[6] Baxter NN, Whitson BA, Tuttle TM. Trends 
in the treatment and outcome of pancre-
atic cancer in the United States. Annals of 
surgical oncology 2007; 14: 1320-6.
[7] Sharp L, Carsin AE, Cronin-Fenton DP, 
O'Driscoll D, Comber H. Is there un-
der-treatment of pancreatic cancer? Evi-
dence from a population-based study in 
Ireland. Eur J Cancer 2009; 45: 1450-9.
[8] De Angelis R, Francisci S, Baili P, Marchesi 
F, Roazzi P, Belot A, et al. The EUROCARE-4 
database on cancer survival in Europe: 
data standardisation, quality control and 
methods of statistical analysis. Eur J Can-
cer 2009; 45: 909-30.
[9] Bjerregaard JK, Mortensen MB, Schonne-
mann KR, Pfeiffer P. Characteristics, ther-
apy and outcome in an unselected and 
prospectively registered cohort of pan-
creatic cancer patients. Eur J Cancer 2013; 
49: 98-105.
[10] Boyd CA, Benarroch-Gampel J, Sheffield 
KM, Cooksley CD, Riall TS. 415 patients 
with adenosquamous carcinoma of the 
pancreas: a population-based analysis of 
prognosis and survival. The Journal of sur-
gical research 2012; 174: 12-9.
[11] Cress RD, Yin D, Clarke L, Bold R, Holly 
EA. Survival among patients with ade-
nocarcinoma of the pancreas: a popula-
tion-based study (United States). Cancer 
Causes Control 2006; 17: 403-9.
[12] Burris HA, 3rd, Moore MJ, Andersen J, 
Green MR, Rothenberg ML, Modiano MR, 
et al. Improvements in survival and clini-
cal benefit with gemcitabine as first-line 
therapy for patients with advanced pan-
creas cancer: a randomized trial. J Clin On-
col 1997; 15: 2403-13.
[13] Moore MJ, Goldstein D, Hamm J, Figer A, 
Hecht JR, Gallinger S, et al. Erlotinib plus 
gemcitabine compared with gemcitabine 
alone in patients with advanced pancre-
atic cancer: a phase III trial of the National 
Cancer Institute of Canada Clinical Trials 
Group. J Clin Oncol 2007; 25: 1960-6.
106
5    Epidemiology of pancreatic cancer 
[14] Neoptolemos JP, Dunn JA, Stocken DD, 
Almond J, Link K, Beger H, et al. Adjuvant 
chemoradiotherapy and chemotherapy 
in resectable pancreatic cancer: a ran-
domised controlled trial. Lancet 2001; 358: 
1576-85.
[15] Oettle H, Post S, Neuhaus P, Gellert K, 
Langrehr J, Ridwelski K, et al. Adjuvant 
chemotherapy with gemcitabine vs ob-
servation in patients undergoing cura-
tive-intent resection of pancreatic cancer: 
a randomized controlled trial. Jama 2007; 
297: 267-77.
[16] Bernards N, Creemers GJ, Nieuwenhui-
jzen GA, Bosscha K, Pruijt JF, Lemmens VE. 
No improvement in median survival for 
patients with metastatic gastric cancer 
despite increased use of chemotherapy. 
Ann Oncol 2013.
[17] Krzyzanowska MK, Weeks JC, Earle CC. 
Treatment of locally advanced pancre-
atic cancer in the real world: popula-
tion-based practices and effectiveness. J 
Clin Oncol 2003; 21: 3409-14.
[18] Cheung MC, Yang R, Byrne MM, Solorzano 
CC, Nakeeb A, Koniaris LG. Are patients of 
low socioeconomic status receiving sub-
optimal management for pancreatic ade-
nocarcinoma? Cancer 2010; 116: 723-33.
[19] National Working Group on Gastroin-
testinal Cancers. Guideline: Pancreatic 
cancer The Netharlands: Comprehensive 
Cancer Centre 2011.
[20] Schildmann J, Tan J, Salloch S, Vollmann 
J. "Well, I think there is great variation...": 
a qualitative study of oncologists' expe-
riences and views regarding medical cri-
teria and other factors relevant to treat-
ment decisions in advanced cancer. The 
oncologist 2013; 18: 90-6.
[21] Sultana A, Smith CT, Cunningham D, Star-
ling N, Neoptolemos JP, Ghaneh P. Me-
ta-analyses of chemotherapy for locally 
advanced and metastatic pancreatic can-
cer. J Clin Oncol 2007; 25: 2607-15.
[22] Conroy T, Desseigne F, Ychou M, Bouche 
O, Guimbaud R, Becouarn Y, et al. FOLFIRI-
NOX versus gemcitabine for metastatic 
pancreatic cancer. The New England jour-
nal of medicine 2011; 364: 1817-25.
[23] Ko AH. FOLFIRINOX: a small step or a great 
leap forward? J Clin Oncol 29: 3727-9.
[24] Von Hoff DD, Ervin T, Arena FP, Chiorean 
EG, Infante J, Moore M, et al. Increased 
survival in pancreatic cancer with nab-pa-
clitaxel plus gemcitabine. The New En-
gland journal of medicine 2013; 369: 1691-
703.
[25] de Wilde RF, Besselink MG, van der Tweel 
I, de Hingh IH, van Eijck CH, Dejong CH, et 
al. Impact of nationwide centralization of 
pancreaticoduodenectomy on hospital 
mortality. The British journal of surgery 
2011; 99: 404-10.
 107
Abstract
Background: This population-based study assessed which factors were 
associated with pathological verification of pancreatic cancer. 
Methods: All patients diagnosed with a malignancy of the pancreas 
between 1993 and 2010 in the South of the Netherlands (N=3,321) were 
included. 
Results: Pancreatic cancer was pathologically verified in 59% of the 
patients. The proportion of verification increased over time from 56% in 
1993-1996 to 69% in 2009-2010 (p<0.0001). High rates of verification were 
found among young patients (<50 years vs. 60-69 yrs: adjusted odds ratio 
(ORadj) 3.2, (95%CI:1.9-5.4)), patients with a high socioeconomic status (high 
vs. low: ORadj 1.3 (95%CI:1.1-1.7)), patients with metastatic disease (metastatic 
vs locoregional: ORadj 3.2, (95%CI:2.7-3.8)) and patients treated with chemo-
therapy (yes vs. no: ORadj 2.4, (95%CI:1.8-3.2)). The most favorable prognosis 
was found in patients with verified locoregional disease (median overall 
survival (mOS) 7.6 months, 95%CI:7.1-8.6). Patients with unverified meta-
static disease carried the worst prognosis (mOS 1.7 months, 95%CI:1.4-2.0). 
Conclusion: Pathological verification remains preferable and desirable 
whenever possible. However, the median survival rate exhibited by patients 
without verification suggests that the vast majority of patients suffered 
from true invasive pancreatic cancer. This may justify treatment decisions 
even in the absence of pathologic verification in selected patients. 
Chapter 5.2
The relevance of pathological verification in 
suspected pancreatic cancer
N. Bernards, G.J. Creemers, C.J. Huysentruyt, I.H.J.T. de Hingh, G.P. van der 
Schelling, A.P.  de Bruïne, V.E.P.P. Lemmens Cancer Epidemiology 2015 
Apr;39(2):250-5
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Introduction
According to the current guidelines, suspected malignancies of the pancreas 
should be pathologically confirmed whenever possible. For patients with a 
resectable pancreatic tumor a preoperative biopsy is not always necessary as 
pathological verification will automatically follow after resection. For patients 
with locally advanced or metastatic pancreatic cancer, the guidelines recom-
mend fine needle aspiration.[1,2] 
Obtaining tissue to establish the diagnosis can be notoriously difficult in 
patients with suspected pancreatic cancer. It often requires invasive investiga-
tions, such as ultrasound guided punctures. These procedures are more compli-
cated in patients with a poor performance status. A German survey revealed 
that not all physicians treated their patients according to the international 
recommendations. Of the respondents only 61% agreed with the guideline 
and stated that pathological verification is mandatory. In addition, for 37% of 
the respondents an elevation of the tumor marker CA19-9 plus a tumor in the 
pancreas on imaging was sufficient for the diagnosis.[3]
In the EUROCARE-4 study, a study that collected data from 93 European 
cancer registries between 1995 and 2002 a microscopic verification rate of 63% 
(range 30-91%) was found for pancreatic cancer.[4]
Although patients without pathological verification constitute a significant 
proportion of the patients with pancreatic cancer, no previous studies described 
this group of patients in detail. Therefore we assessed the clinical relevance and 
associated factors of pathological verification. 
Methods
Data collection
For the present study we used data from the Eindhoven Cancer Registry (ECR), 
maintained by the Comprehensive Cancer Centre Netherlands. The registry 
collects data on all patients newly diagnosed with cancer in the southern part 
of the Netherlands. The area comprises about 2.4 million inhabitants (~15% of 
the Dutch population) and encompasses ten community hospitals, two radio-
therapy institutions and six pathology departments. 
In case of histological or cytological verification of a tumor the ECR is noti-
fied by the national automated pathological archive (PALGA). If this verification 
is lacking, notification occurs by additional sources as the national registry of 
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hospital discharge (LMR), multidisciplinary team reports and diagnosis-therapy 
combinations (specific codes used for reimbursement purposes). Completeness 
of the data was estimated to be at least 95%.[5]
Our study included all patients who were diagnosed with a neoplasm of 
the pancreas (International classification of Disease for Oncology (ICD-O), second 
edition, topography code 157 and third edition, code C25), between 1 January 
1993 and 31 December 2010. Trained registrars, operating on behalf of the ECR, 
extracted patient characteristics such as gender, date of birth, comorbidity and 
socioeconomic status, as well as tumor characteristics, such as date of diag-
nosis, anatomic location, histology, stage, and primary treatment from the 
medical records.
Tumors were categorized as verified whenever there was histological or 
cytological verification from the primary tumor or one of the metastatic sites. 
There was no additional information on the timing of verification. 
Carcinomas were classified according to the Tumor Lymph Node Metastasis 
(TNM) classification and staged following the recommendations of the 
International Union against Cancer in the respective period. For staging of 
other neoplasms especially those without pathological verification the clinical 
extent of disease (cEOD) was used. From a practical perspective we classified 
the tumors as locoregional (confined to the pancreas with or without extension 
to the surrounding organs) or metastatic disease.
Vital status of all patients on January 1, 2014 was assessed through linkage 
with civil municipal registries and the Central bureau for genealogy, which 
collects data on all citizens who die. 
Statistical analyses 
We performed all statistical analyses using SAS statistical software (version 
9.3, SAS institute, Cary, NC, U.S.A.). The percentage of cases for which the diag-
nosis was based upon pathological verification was described for different 
subgroups. Differences between those groups were tested by means of a χ2 
test and trends across the five periods (1993-1996, 1997-2000, 2001-2004, 2005-
2008 and 2009-2010) were analyzed by means of a Cochran-Armitage trend 
test. Independent influences on the rate of pathological verification were eval-
uated by means of a logistic regression analysis. 
Survival time was defined as the time from diagnosis to death or January 1, 
2014, for patients who were still alive. The median follow-up time (from initial 
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diagnosis to January 1, 2014) of patients alive (N=134) was 64 months (range 
37-250 months). The crude survival was calculated with the life test and differ-
ences between survival curves were evaluated by means of a log rank test. The 
independent prognostic effect of pathological verification was estimated using 
Cox regression analyses, the hazard rates for death were adjusted for gender, 
age, socioeconomic status, comorbidity, extend of disease and period of diag-
nosis. Chemotherapy and resection were added separately to the model to 
investigate the effect of treatment on the hazard ratio of death. 
Patients with an overall survival of more than 2 years (24 months) were 
defined as long-term survivors. 
Results
Between January 1, 1993 and December 31, 2010, a total of 3,321 patients 
were diagnosed with a neoplasm of the pancreas in the southern part of 
the Netherlands. The median age at diagnosis was 70 years (range 29-100). 
Fifty-two percent of the patients were male and 49% of the patients presented 
with metastatic disease. Table 1 displays the general characteristics by the pres-
ence of pathological verification and disease extension (locoregional or meta-
static disease). 
In 1,960 patients (59%) the diagnosis was confirmed by pathological exam-
ination. In 83% of the cases pathological verification was achieved by histo-
pathology, in the remaining patients cytological sampling was used. The 
percentage of verification increased over time from 56% in 1993-1996 to 69% 
in 2009-2010 (p<0.0001). Figure 1 shows that pathological verification was 
obtained more often in patients with metastatic disease compared to patients 
with non-metastatic disease. In patients with non-metastatic disease the veri-
fication rate increased significantly over time, from 45% in the first period to 
57% in the last period (p<0.0001) and in patients with metastatic pancreatic 
cancer the verification rate remained stable between 74% and 77% (p=0.10). 
The results of the logistic regression analysis are shown in table 2. Younger 
patients and patients with a higher socioeconomic status were more likely 
to have their diagnosis confirmed by cytology or histology. After adding the 
treatment variables surgery and chemotherapy to the model these differences 
persisted. The differences between periods of diagnosis disappeared entirely 
after adding the treatment variables. During the study period the resection 
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rate in patients with non-metastatic pancreatic cancer increased from 11% in 
1993-1996 to 24% in 2009-2010 (p<0.0001). The prescription of chemotherapy 
increased from 6% to 27% (p<0.0001). In patients with non-metastatic disease, 
tumors located in the tail were more often pathologically verified (tail 71%, 
head 45%) . In metastatic disease, high verification rates were found, especially 
if metastases were limited to the peritoneum (90%) or to extra regional lymph 
nodes (85%). Low rates of verification were found in patients with pulmonary 
metastases only (50%). In 73% of the patients with histologically verified meta-
static disease, tissue was obtained from one of the metastatic sites. In the 
remaining patients tissue was sampled from the primary tumor. 
Adenocarcinoma was the histological subtype found in 90% of the patho-
logically verified cases, another 3% was represented by large cell carcinomas. 
Tumors of neuroendocrine origin accounted for 4% of the verified cases. 
The median overall survival for all patients was 3.5 months with a 2-year 
survival rate of 7%. Figure 2 shows the crude survival curves for patients with 
and without pathologically verified pancreatic cancer, stratified according to 
disease extension (locoregional or metastatic disease). Patients with patho-
logically verified locoregional disease had the most favorable prognosis with 
a median survival of 7.6 months and a 2-year survival rate of 18%. Patients 
without pathologically verified locoregional disease had a median survival of 
4.4 months and a 2-year survival of 5%. In patients with metastatic disease with 
or without pathological verification the median survival was 2.5 months and 1.7 
months respectively and the 2-year survival was 3% and 2%. 
Table 3 shows a multivariable proportional hazard regression analysis 
modeling the risk of death for patients with a neoplasm of the pancreas. 
Younger patients, patients with a higher socioeconomic status and those diag-
nosed in more recent periods had a more favorable prognosis. In contrast, 
survival was worse for older patients and patients with comorbidity. Almost all 
differences between subgroups and between periods of diagnosis disappeared 
after adding treatment, chemotherapy and surgery, into the model. 
Ten percent of the patients with pathologically verified pancreatic cancer and 
only 4% of the patients without verification survived for more than 2 years. 
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Table 1 General characteristics of patients diagnosed with a neoplasm of 
the pancreas in the South of the Netherlands, between 1993 and 
2010, stratified according to pathological verification and disease 
extension (non-metastatic or metastatic disease) (N=3,321) 
Total 
N  (%)
Locoregional
Verified 
N (%)
Locoregional
Unverified 
N (%)
Metastatic 
Verified 
N (%)
Metastatic 
Unverified
N (%)
P-value
Sex
 Male 
 Female
1734 (52.2)
1587 (47.8)
403 (50.1)
402 (49.9) 
421 (47.3) 
469 (52.7) 
676 (58.5) 
479 (41.5) 
234 (49.7)
237 (50.3) 
< 0.0001
Age (yrs)
 <50 
 50-59
 60-69
 70-79
 ≥80 
187 (5.6)
480 (14.5)
988 (29.8)
1141 (34.4)
525 (15.8)
61 (7.6)
151 (18.8)
260 (32.3)
264 (32.8)
69 (8.6)
11 (1.2)
56 (6.3)
175 (19.7)
378 (42.5)
270 (30.3)
106 (9.2)
239 (20.7)
426 (36.9)
310 (26.8)
74 (6.4)
9 (1.9)
34 (7.2)
127 (27.0)
189 (40.1)
112 (23.8) 
< 0.0001
Socioeconomic status 
 Low
 Intermediate 
 High 
 Institutions 
 Missing 
925 (27.9)
1242 (37.4)
864 (26.0)
191 (5.7)
99 (3.0)
215 (26.7)
294 (36.5)
242 (30.1)
26 (3.2)
28 (3.5)
304 (34.2)
313 (35.2)
161 (18.1)
86 (9.7)
26 (2.9)
270 (23.4)
466 (40.3)
346 (30.0)
36 (3.1)
37 (3.2)
136 (28.9)
169 (35.9)
115 (24.4)
43 (9.1)
8 (1.7)
<0.0001
Number of comorbid conditions
 0
 1
 ≥2 
 Unknown
1518 (45.7)
1042 (31.4)
430 (12.9)
331 (10.0)
374 (46.5) 
249 (30.9)
95 (11.8)
87 (10.8)
362 (40.7)
284 (31.9)
141 (15.8)
103 (11.6)
583 (50.5)
355 (30.7) 
128 (11.1)
89 (7.7)
199 (42.3)
154 (32.7)
66 (14.0)
52 (11.0)
0.0002
Histologic subtype*
 Adeno-
 carcinoma 
 Neuro-
 endocrine 
 Other 
1755 (89.5)
85 (4.3)
120 (6.1)
736 (91.4)
33 (4.1)
36 (4.5)
n.a.
n.a.
n.a.
1019 (88.2)
52 (4.5)
84 (7.3)
n.a.
n.a.
n.a.
0.0334
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Total 
N  (%)
Locoregional
Verified 
N (%)
Locoregional
Unverified 
N (%)
Metastatic 
Verified 
N (%)
Metastatic 
Unverified
N (%)
P-value
Location primary tumor
 Head
 Body
 Tail 
 Overlapping 
 Unknown/
 NOS 
2204 (66.4)
275 (8.3)
392 (11.8)
232 (7.0)
218 (6.6)
605 (75.2)
52 (6.5)
62 (7.7)
41 (5.1)
45 (5.6)
745 (83.7)
43 (4.8)
26 (2.9)
30 (3.4) 
46 (5.2)
572 (49.5)
133 (11.5)
234 (20.3)
128 (11.1)
88 (7.6)
282  (59.9)
47 (10.0)
70 (14.9)
33 (7.0)
39 (8.3)
< 0.0001 
Location of metastases **
 Liver
 Peritoneum
 Lung 
 Lymphnodes
 Other 
 2 
 3 or more 
912 (56.1)
131 (8.1)
52 (3.2) 
53 (3.3)
83 (5.1)
292 (18.0)
103 (6.3)
n.a. 
n.a. 
n.a. 
n.a.
n.a.
n.a.
n.a. 
n.a. 
n.a. 
n.a. 
n.a.
n.a.
n.a.
n.a. 
601 (52.0)
118 (10.2) 
26 (2.3) 
45 (3.9)
63 (5.5) 
214 (18.5) 
88 (7.6) 
311 (66.0)
13 (2.8) 
26 (5.5)
8 (1.7) 
20 (4.3) 
78 (16.6) 
15 (3.2) 
< 0.0001
Period of diagnosis
 1993-1996
 1997-2000
 2001-2004
 2005-2008
 2009-2010 
566 (17.0) 
697 (21.0) 
642 (19.3) 
876 (26.4)
540 (16.3)
162 (20.1)
162 (20.1)
127 (15.8) 
228 (28.3) 
126 (15.7) 
195 (21.9)
243 (27.3) 
192 (21.6) 
165 (18.5) 
95 (10.7) 
155 (13.4) 
195 (16.9) 
213 (18.4) 
347 (30.0) 
245 (21.2) 
54 (11.5) 
97 (20.6) 
110  (23.4) 
136  (28.9) 
74 (15.7)
< 0.0001
Surgery
 Yes
 No
296 (8.9)
3025 (91.1) 
282 (35.0) 
523 (65.0)
1 (0.1)
889 (99.9)
13 (1.1) 
1142 (98.9)
0 (0.0)
471 (100.0)
< 0.0001
Chemotherapy 
 Yes
 No
485 (14.6)
2836 (85.4) 
143 (17.8)
662 (82.2)
37 (4.2) 
853 (95.8)
275 (23.8)
880 (76.2)
30 (6.4) 
441 (93.6)
< 0.0001
Total 3321 805 890 1155 471
* Histological subtype available in 1960  patients (59.0%)
** Metastatic subsite available in 1626  patients (49.0%)
Table 1 Continued
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Table 2 Crude percentages and oddsa of pathological verification in 
patients diagnosed with a neoplasm of the pancreas, in the south-
ern Netherlands between 1993 and 2010 (N=3,321) 
Crude % Verification Odds ratio (95% CI)
Sex
 Male 
 Female
62.2
55.5
1.00 (reference)
0.97 (0.82-1.14) 
Age (yrs.)
 <50 
 50-59
 60-69
 70-79
 ≥80 
89.3
81.3
69.4
50.3
27.2
3.20 (1.91-5.35)
1.70 (1.27-2.27)
1.00 (reference)
0.55 (0.45-0.67)
0.27 (0.21-0.36)
Socioeconomic status
 Low 
 Intermediate
 High
 Institutions 
52.4
61.2
68.1
32.4
1.00 (reference)
1.10 (0.90-1.35)
1.32 (1.06-1.66)
0.63 (0.43-0.91)
Number of comorbid conditions
 0 
 1
 ≥2
63.0
58.0
51.9
1.00 (reference)
1.05 (0.87-1.27)
1.00 (0.77-1.29)
Extent of disease
 Locoregional
 Metastatic 
47.5
71.0
1.00 (reference)
3.19 (2.70-3.77)
Period of diagnosis
 1993-1996 
 1997-2000
 2001-2004
 2005-2008
 2009-2010
56.0
51.2
53.0
65.6
68.7
1.00 (reference)
0.71 (0.55-0.93)
0.68 (0.52-0.89)
1.13 (0.87-1.47)
1.26 (0.93-1.70)
Surgery 
 No
 Yes
55.0
99.7
1.00 (reference)
329.5 (46.0-999.999)
Chemotherapy 
 No
 Yes 
54.4
86.2
1.00 (reference) 
2.40 (1.78-3.24)
a Adjusted for all variables listed. Included in the analysis but results not shown for  
SES unknown, comorbidity unknown. 
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Table 3 Crude median overall survival in months, crude 1-year survival 
and risk of dying (hazard ratios) in patients diagnosed with a neo-
plasm of the pancreas, in the southern Netherlands between 1993 
and 2010 (N=3,321)
 Crude median 
overall survival 
(Months) 
Crude 2-year 
survival (%) 
Multivariate HR 
(95%CI) a 
Multivariate HR 
(95%CI) adjusted 
for treatment a
Sex
 Male 
 Female
3.4
3.7
7.2
7.0
1.00 (reference)
0.97 (0.90-1.04)
1.00 (reference) 
0.96 (0.89-1.03)
Age (yrs.)
 <50 
 50-59
 60-69
 70-79
 ≥80 
5.6
5.2
4.1
3.3
2.2
12.3
10.8
8.2
5.7
2.9
0.84 (0.71-0.98)
0.89 (0.79-0.99)
1.00 (reference) 
1.27 (1.16-1.39)
1.68 (1.49-1.89)
0.92 (0.78-1.08)
0.93 (0.83-1.04)
1.00 (reference)
1.17 (1.07-1.28)
1.43 (1.27-1.61)
Socioeconomic status (SES) 
 Low 
 Intermediate
 High
 Institutions 
3.3
3.6
3.9
2.7
6.0
6.7
8.2
4.7
1.00 (reference) 
0.98 (0.90-1.07)
0.89 (0.81-0.98)
1.01 (0.86-1.18)
1.00 (reference)
0.96 (0.88-1.05)
0.92 (0.84-1.01)
1.02 (0.87-1.20)
Number of comorbid conditions
 0 
 1
 ≥2
3.8
3.3
3.0
7.3
6.6
4.4
1.00 (reference)
1.11 (1.02-1.20)
1.17 (1.05-1.31)
1.00 (reference)
1.08 (0.99-1.17)
1.12 (1.00-1.25)
Extent of disease/ pathological verification
 Locoregional, verified
 Locoregional, unverified
 Metastatic verified 
 Metastatic unverified
7.6
4.4
2.5
1.7
18.3
4.8
3.3
1.7
1.00 (reference) 
1.34 (1.20-1.48)
2.46 (2.23-2.70)
2.87 (2.54-3.24)
1.00 (reference)
0.98 (0.87-1.09)
1.94 (1.75-2.16)
2.12 (1.87-2.41)
Period of diagnosis
 1993-1996 
 1997-2000
 2001-2004
 2005-2008
 2009-2010
3.8
2.9
3.5
3.6
3.9
5.3
5.0
6.2
8.8
10.0
1.00 (reference)
1.05 (0.94-1.18)
0.90 (0.80-1.01)
0.84 (0.76-0.94)
0.73 (0.65-0.83)
1.00 (reference)
1.10 (0.98-1.23)
0.99 (0.89-1.12)
0.94 (0.84-1.05)
0.88 (0.77-1.00) 
Surgery
 No 
 Yes 
3.2
15.4
4.1
38.2
Not included in
the analysis
1.00 (reference) 
0.44 (0.38-0.51)
Chemotherapy
 No
 Yes
3.0
8.3
6.1
12.8
Not included in 
the analysis
1.00 (reference) 
0.54 (0.48-0.60) 
a Adjusted for all variables listed. Included in the analysis but results not shown for SES unknown, 
comorbidity unknown
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Figure 1 Crude percentage of verification according to disease extension 
and period of diagnosis, in patients diagnosed with a neoplasm of 
the pancreas, in the southern Netherlands, between 1993 and 2010 
(N=3,321)   
Figure 2 Overall survival according to pathological verification and dis-
ease extension, in patients diagnosed with a neoplasm of the 
pancreas, in the southern Netherlands, between 1993 and 2010 
(N=3,321)  
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Discussion 
In our study we found that in 59% of the patients with suspected pancreatic 
cancer, pathological verification was obtained. The rate of pathological verifi-
cation in our study seems in line with other population-based studies. In the 
EUROCARE 4 study a comparable overall verification rate of 63% (range 30-91%) 
was found. The verification rate was established as one of the quality indica-
tors for participating registries.[4] In the United states pancreatic cancer cases 
without microscopic verification represent one fourth of the total number of 
pancreatic cancer cases.[6,7] The validity of diagnostic information from regis-
tries with low rates of verification is obviously questionable. However, high 
rates of pathological verification do not simply mean that the validity of the 
data is excellent. Instead, exceptionally high proportions of verification might 
suggests over-reliance on the pathology laboratory as source of information, 
and failure to find cases without pathological verification.[7] However, the wide 
range of verification worldwide, may hamper the comparability across studies, 
countries and contents. 
The rate of pathological verification was higher in patients with metastatic 
disease compared to patients with non-metastatic disease. However, in this 
latter group of patients the rate of verification increased significantly over time 
from 45% to 57%. This can be partially explained by the increased resection rate 
after the introduction of high-volume centers in the southern Netherlands.
[8,9] Furthermore, the diagnostic advances that have been made in pancre-
atic cancer played an important role, especially the introduction of endoscopic 
ultrasonography (EUS) in the early nineties. EUS rapidly evolved to a diagnostic 
imaging modality by which fine needle biopsies could be guided into small or 
encased pancreatic lesions. Eventually, endoscopic ultrasound combined with 
fine needle aspiration became the primary modality for tissue verification with 
a sensitivity of 85% and a specificity of 98%.[10]
In this study, the highest rate of verification was found in pancreatic tail 
tumors (70%). Due to a lack of symptoms, tumors at this location are usually 
larger at the time of diagnosis making them more accessible for diagnostic 
procedures.[11] In addition, given anatomical circumstances localized pancreatic 
tail tumors are more often resected as compared to tumors located in the head 
of the pancreas in spite of a larger tumor size.[12]
In 75% of the patients with metastatic pancreatic cancer, the diagnosis 
was microscopically verified. High rates of verification were especially found in 
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patients with metastases limited to the peritoneum or to extra regional lymph 
nodes. One reason for the high verification rate found in patients with peri-
toneal dissemination might be the inability to detect small volume peritoneal 
implants on imaging studies.[13,14] These small volume peritoneal implants 
might be identified by coincidence during surgery with an initially curative 
intent. In patients who are not eligible for surgery there must be an under-
estimation of the peritoneal disease burden.[14] The identified large volume 
implants or moderate to high-volumes of ascites are easily accessible for diag-
nostic procedures. For patients with suspected extra regional lymph node 
involvement, it can be hypothesized that the high verification rate is a result of 
the major therapeutic implications which extra regional nodal involvement has 
on the treatment choice. 
Patient characteristics such as age and socioeconomic status influenced the 
rate of verification as well. Although younger patients and those with a higher 
socioeconomic status more often underwent resection or received chemo-
therapy with upfront verification, this effect was not only treatment-related. 
Possibly, younger patients and patients with a higher socioeconomic status 
are more eager to have their diagnosis established.[9] Not only patient char-
acteristics differed between patients with and without pathological verifica-
tion, previous population-based studies showed an association with etiological 
factors as well, such as cigarette smoking and body mass index.[6,15,16] 
Our finding that 90% of the patients with a tissue diagnosis had an adeno-
carcinoma is in agreement with the already published literature.[17] The not 
otherwise specified large cell carcinomas of the pancreas could have been 
adenocarcinomas as well, poorly or undifferentiated. The proportion of neuro-
endocrine tumors that we found is slightly higher compared to the proportion 
found in several more dated studies.[18,19] A possible explanation might be the 
growing interest in neuroendocrine malignancies.[20]
Median overall survival in all patients with pancreatic cancer is dismal (3,5 
months). Crude survival curves showed that patients with pathologically veri-
fied pancreatic cancer carried a more favorable prognosis, regardless of the 
extent of disease, with the best prognosis found in patients with verified 
locoregional disease. These patients had a median overall survival of 7.6 months 
which is comparable to the median overall survival found in a large popula-
tion-based study using data from the SEER registry.[21] The prognosis of patients 
with pathologically unverified locoregional disease was only 4.4 months. The 
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difference in overall survival between these subgroups was mainly explained 
by treatment, in particular surgical resection. After adjusting for the effect of 
treatment in a multivariable model, the risk of death between subgroups was 
comparable. Moreover, 5% percent of the patients with unverified locoregional 
disease had an overall survival exceeding two years. Since long-term survival 
in patients with pancreatic cancer is extremely rare, especially if the primary 
tumor has not been resected, it is likely that these patients suffered from a 
more indolent tumor of the pancreas or even a benign disease. It could be infor-
mative to collect additional data in long-term survivors to investigate whether 
the initial diagnosis has been revised by the treating physician. Even in long-
term survivors with pathologically verified disease re-evaluation showed false 
diagnosis.[22]
For patients with metastatic disease, those with verified cancer had a median 
overall survival of 2.5 months compared to 1.7 months in patients without 
pathologically verified metastatic disease. These differences in survival seem at 
least partly a result of selection bias and treatment-related differences as well, 
especially the prescription of chemotherapy. Patient with verified cancer were 
more frequently treated with chemotherapy since the guidelines recommend 
upfront pathological confirmation. And biopsies might be omitted in patients 
who are not candidates for palliative treatment, the patients that have a worse 
overall survival in advance.
In selected patients, an elevated level of the serum marker CA 19-9 in combi-
nation with a pancreatic mass on imaging studies might be enough to estab-
lish the diagnosis pancreatic cancer. Previous research found significantly 
higher concentrations of CA 19-9 in patients with a pancreatic adenocarcinoma 
compared to patients without a malignancy and those with a tumor of neuroen-
docrine origin. The sensitivity and specificity of elevated serum 19-9 concentra-
tions in symptomatic patients were respectively between 79-81% and 82-90%.
[23] However, the predictive value of CA 19-9 was especially high in patients 
with a pancreatic mass on imaging studies. The combination of a suspected 
mass, weight loss, elevated bilirubin levels and elevated serum concentrations 
of CA 19-9 provided an almost 100% specificity and positive predictive value for 
pancreatic cancer.[23,24] 
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Limitations
We would like to acknowledge the limitations inherent to this population-based 
nature of our study. First and foremost, the proportion of patients without veri-
fied pancreatic cancer found in our study seems to be an underestimation. 
However, the completeness of our registry is estimated to be at least 95%.[5] 
Second, detailed information on serum CA 19-9 levels, imaging studies or diag-
nostic procedures are lacking. 
Conclusion
In conclusion, both patients with and without pathologic verification of 
a pancreatic mass have a dismal prognosis. The survival data as obtained in 
the current study suggest that all patients, including those without verifica-
tion, suffered from true invasive pancreatic cancer. Before starting palliative 
treatment including chemotherapy and radiotherapy pathological verification 
remains preferable and desirable. However, in selected patients, a high clinical 
suspicion of pancreatic cancer, may justify treatment even in the absence of 
pathological verification. 
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Abstract
Background: We conducted a population-based study to investigate long-
term survival in patients diagnosed with a (suspected) pancreatic adeno-
carcinoma.
Methods: All patients diagnosed with a pancreatic adenocarcinoma or 
with a pathologically unverified tumor of the pancreas between 1993 and 
2008 in the south of the Netherlands were selected from the Netherlands 
Cancer Registry (NCR). Medical charts of patients who were alive five years 
or longer after diagnosis were reviewed.
Results: A total of 2,564 patients were included, of whom 1,365 had a pancre-
atic adenocarcinoma and 1,199 had a pathologically unverified pancreatic 
tumor. The five-year survival rate of patients with pathologically verified 
adenocarcinomas was 1.7% (24 of 1,365 patients). Twenty-one of these 24 
long-term survivors were among the 207 cases that underwent surgical 
resection as initial treatment; five-year survival rate after resection thus 
being 10.1%. Half of the long-term survivors who underwent surgical 
resection eventually died of recurrent disease. The five-year survival rate 
among patients with clinically suspected but microscopically unverified 
pancreatic tumors was 1.3% (16 of 1,199 patients). In 15 of these 16 long-term 
survivors the initial clinical diagnosis was revised: 14 had benign disease 
and one a premalignant tumor.
Conclusion: Long-term survival among patients with pancreatic adeno-
carcinoma is extremely rare. As long-term survival in clinically suspected 
but pathologically unverified cancer is very unlikely, repeated fine needle 
Chapter 5.3
Does long-term survival exist in pancreatic 
adenocarcinoma?
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aspiration or, preferably, histological biopsy is recommended in order to 
establish an alternative diagnosis in patients who survive longer than 
expected (more than 6–12 months).
Introduction
Survival after a diagnosis of pancreatic cancer is often short, with a five-year 
survival rate reported as low as 7% in Europe.[1] The only potentially curative 
treatment is radical surgery, which is, together with adjuvant chemotherapy 
standard of care in patients with a resectable pancreatic adenocarcinoma.[2] 
Nevertheless, the majority of patients is diagnosed with inoperable locally 
advanced or metastatic disease, therapeutic options in these stages are limited. 
 In Europe, the overall microscopic verification rate for pancreatic tumors is 
63%.[3]The major histological type of pancreatic tumors is ductal adenocarci-
noma, which represents about 85% of all pancreatic neoplasms and is associated 
with poor survival rates. Other types of pancreatic cancer, such as neuroendo-
crine tumors, may exhibit a less aggressive behavior. A recent population-based 
Dutch study showed a poor prognosis in patients with pancreatic tumors both 
with and without pathological verification, suggesting that virtually all patients, 
including those without verification, suffered from true pancreatic adeno-
carcinoma.[4] Only a small proportion of the patients had an overall survival 
exceeding two years. Considering these results, one might question if long-term 
survival exists in pancreatic cancer. We conducted a population-based study in 
order to investigate long-term survival in all patients diagnosed with pancre-
atic cancer in the south of the Netherlands in the years 1993–2008. Long-term 
survival was defined as an overall survival exceeding five years.
Methods
Data collection 
We used data from the Netherlands Cancer Registry (NCR), maintained by the 
Comprehensive Cancer Centre Netherlands. The registry collects data on all 
patients with newly diagnosed cancer in the Netherlands. We limited our study 
to the area of the previous Eindhoven Cancer Registry (ECR), in order to be able 
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to perform a medical chart review. This area hosts 2.4 million inhabitants (~15% 
of the Dutch Population) and is served by 10 general hospitals, two large radio-
therapy institutes and six pathology laboratories. The pathology laboratories 
all participate in the nationwide automated pathology archive (PALGA) which 
notifies the cancer registry. Additional sources responsible for notification are 
the national registry of hospital discharge (LMR), multidisciplinary team reports 
and diagnosis-therapy combinations (specific codes used for reimbursement 
purposes). The completeness of the registry exceeds 95%. After notification, 
information on patient characteristics, tumor characteristics and initial treat-
ment is routinely extracted from medical records by trained administrators 
within 6–9 months after diagnosis. For the present study we selected patients 
with a malignancy of the pancreas diagnosed between 1 January 1993 and 
31 December 2008. We decided to restrict our inclusion to adenocarcinomas 
(ICD-O morphology codes 8140, 8141, 8260, 8440, 8453, 8470, 8471, 8480, 8481, 
8490, 8500) and pancreatic neoplasms without pathological verification (ICD-O 
morphology code 8000). 
 Vital status of patients was assessed at 1 January 2014 through linkage with 
civil municipal registries and the central bureau for genealogy. The latter is an 
institution that collects data on all deceased Dutch citizens. The survival was 
calculated based on all-cause mortality. We defined patients with an overall 
survival of more than five years as long-term survivors. Additional data were 
retrospectively extracted from the medical records of long-term survivors 
by two experienced researchers with the approval and under supervision of 
the treating physicians. The additional data concerned letters and pathology 
reports to investigate if the initial clinical or pathological diagnosis had been 
re-evaluated. 
Statistical analyses 
We performed all statistical analyses using SAS statistical software (version 9.3, 
SAS institute, Cary, NC, USA). Survival time was defined as the time from diag-
nosis to death or 1 January 2014, for patients who were still alive. The crude 
survival was calculated with the life test, a log rank test was carried out to 
compare survival curves between different subgroups.
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Results
Between 1 January 1993 and 31 December 2008 a total of 2,796 patients were 
diagnosed with a neoplasm of the pancreas of whom 1,365 (48.8%) patients had 
an adenocarcinoma, and 1,199 (42.9%) patients had a pathologically unverified 
tumor of the pancreas. Two hundred and thirty-two patients were excluded 
from further analyses: 68 (2.4%) patients with a neuroendocrine tumor and 164 
(5.9%) patients with other types of pancreatic malignancies (figure 1). 
 General characteristics of the remaining 2,564 patients are depicted in table 
1. Fifty-two percent of our study population was male and the median age 
at time of diagnosis was 70 years (range 32–100) and 45.1% had metastases 
at time of diagnosis. The proportion of patients presenting with metastatic 
disease increased from 34.7% in 1993–1996 to 52.8% in 2005–2008 (p<0.0001).
Eight percent (N=207) of the total study population was eligible for surgery 
with a curative intent. The resection rate did not change over time (p=0.08). 
However, an increasing proportion (p<0.0001) of the surgically treated patients 
received adjuvant chemotherapy. In 2008, 50.0% of the surgically treated 
patients received adjuvant chemotherapy. 
 Forty-seven percent of the patients (N=1,201) had non-metastatic unre-
sected pancreatic cancer, of whom 32.8% had their diagnosis pathologically 
confirmed. Eight percent (N=100) of these patients received treatment within 
six months after diagnosis. The treatment rate was higher in patients with a 
microscopically verified pancreatic adenocarcinoma compared to patients with 
a non-microscopically verified pancreatic tumor (16.5% vs. 4.3%, p<0.0001). 
Fifty-nine patients (59.0%) received palliative chemotherapy and 24 patients 
(24.0%) were treated with chemoradiotherapy. 
The remaining 45.1% of the patients (N=1,156) had metastases at time of diag-
nosis, the verification rate in these patients was 66.1%. Sixteen percent of 
the patients with metastatic pancreatic cancer received chemotherapy, the 
prescription of chemotherapy increased significantly over time (8.8% in 1993–
1996 to 20.4% in 2005–2008, p<0.0001) and was significantly higher in patients 
with microscopically verified disease (20.9% vs. 6.1%, p<0.0001).
 The median overall survival of surgically treated patients was 13.7 months 
(95% CI 11.3–16.1) with a one-year survival rate of 55.8% (figure 2). The outcome 
of these patients significantly improved over time from a median survival of 
7.1 months (95% CI 4.7–13.8) in 1993–1996 to 17.4 months (95% CI 13.6–25.0) in 
2005–2008 (log rank for these periods p=0.004). The outcome of patients with 
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Table 1 General characteristics of patients diagnosed with a neoplasm 
of the pancreas, in the southern Netherlands between 1993 and 
2008 (N=2,564)
N  %
Sex
 Male
 Female 
1,327
1,237
51.8
48.2
Age (yrs) 
 < 50 
 50-59 
 60-69 
 70-79 
 ≥ 80
140
353
751
904
416
5.5
13.8
29.3
35.3
16.2
Socioeconomic status (SES) 
 Low 
 Intermediate
 High 
 Institutionalised 
 Unknown
737
964
667
156
40
28.7
37.6
26.0
6.1
1.6
Number of comorbid conditions
 0 
 1
 ≥2
 Unknown 
1,210
767
301
286
47.2
29.9
11.7
11.2
Histologic subtype 
 Adenocarcinoma 
 Unknown 
1,365
1,199
53.2
46.8
Extent of disease 
 Resected 
 Unresected locoregional 
 Metastatic 
207
1,201
1,156
8.1
46.8
45.1
Period of diagnosis 
 1993-1996 
 1997-2000
 2001-2004
 2005-2008 
522
653
601
788
20.4
25.5
23.4
30.7
Chemotherapy 
 Adjuvant 
 Palliative 
 No 
23
245
2,296
0.9
9.6
89.5
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Figure 1 Study flow chart 
Adenocarcinoma 
or non-microscopic verified neoplasm
 N = 2,564
Excluded N = 68 
Neuroendocrine tumor 
Excluded N = 164 
Other malignancy
Verified 
N = 207 (100%)
Long-term survivors 
N = 21 (10.1%)
Lost to follow up
N = 1
Long-term 
survivors 
N = 2 (0.5%)
Long-term 
survivors 
N = 1 (0.1%)
Long-term 
survivors
N = 15 (1.9%)
Long-term 
survivors 
N = 1 (0.3%)
Resected 
N = 207  (8.1%) 
Unresected Locoregional
N = 1201 (46.8%) 
Metastatic 
N = 1156 (45.1%) 
Eindhoven Cancer Registry 1993-2008
Diagnosed with a neoplasm 
of the pancreas
N = 2,796
Verified
N = 394 
(32.8%)
Unverified
N = 807 
(67.2%)
Verified
N = 764 
(66.1%)
Unverified
N = 392 
(33.9%) 
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unresected and metastatic pancreatic cancer remained unchanged over time. 
The median survival for patients with unresected localized pancreatic cancer 
was 4.6 months (95% CI 4.2–5.0) with a one-year survival rate of 15.4%. Patients 
with metastatic pancreatic cancer carried the poorest prognosis of only 2.2 
months (95% CI 2.1–2.4) with a one-year survival rate of 5.2%. There were small 
but significant differences in survival between patients with metastatic micro-
scopically verified pancreatic cancer and patients with non-verified metastatic 
disease.
 Only 40 patients (1.6%) of our total study population had an overall survival 
exceeding five years. Of the long-term survivors, 21 patients underwent surgical 
resection as initial treatment which represented 10.1% of the total of 207 surgi-
cally resected patients. The general characteristics of this group of patients 
are depicted in Table 2. Additional data collection of this group of 21 long-term 
survivors showed that despite surgery, three patients developed locoregional 
recurrence or metastases within five years, and seven patients more than five 
years after initial diagnosis. Nine of these 10 patients with recurrent disease 
died between five and 10 years after initial diagnosis. 
Figure 2 Overall survival of patients diagnosed with pancreatic cancer in 
the southern Netherlands between 1993 and 2008, according to 
extent of disease (N=2,564)
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Table 2 General characteristics of 21 long-term survivors with surgically 
resected pancreatic cancer, diagnosed in the southern Nether-
lands between 1993 and 2008 
N
Sex
 Male
 Female 
12
9
Age (yrs) 
 < 50 
 50-59 
 60-69 
 70-79 
 ≥ 80
2
3
11
5
0
Socioeconomic status (SES) 
 Low 
 Intermediate
 High 
 Institutionalised 
 Unknown
6
6
7
1
1
Number of comorbid conditions
 0 
 1
 ≥2
 Unknown 
13
4
2
2
 Tumour grade
 Good/moderate
 Poor/undifferentiated
 Unknown 
14
2
5
N
T stage 
 1 
 2
 3
 4
 X
7
5
6
1
2
N stage
 0
 1
 X
8
7
6
TNM Stage
 1
 2
 3
 X
9
6
4
2
Period of diagnosis 
 1993-1996 
 1997-2000
 2001-2004
 2005-2008 
1
7
4
9 
Adjuvant chemotherapy 
 Yes 
 No 
6
15
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Seventeen long-term survivors had non-metastatic unresected cancer, of 
whom 15 patients had non-microscopically verified disease at time of diagnosis. 
In 14 of these 15 patients the diagnosis was revised by the treating physician. 
The majority of these patients had a pancreatitis (focal or auto-immune), one 
patient had an intraductal papillary mucinous neoplasm (IPMN), one patient 
had a cystic adenoma, and one patient sclerosing cholangitis. The patient 
without revision of the diagnosis died 5.1 years after the initial diagnosis. 
 Two long-term survivors with unresected disease had a histologically veri-
fied adenocarcinoma at time of diagnosis. One of these patients only received 
a palliative bypass, the other patient was treated with palliative chemotherapy. 
Both tumors showed a remarkable indolent disease course.
 Two long-term survivors had metastatic disease at time of diagnosis. One of 
them had a pathologically verified metastatic adenocarcinoma of the pancreas 
and was treated with palliative chemotherapy as well. The other one had meta-
static disease without microscopic verification. In this patient the diagnosis was 
revised. Additional biopsies revealed a Wegener’s granulomatosis/ANCA asso-
ciated vasculitis and after correct immunosuppressive treatment the imaging 
studies normalized within a couple of months.
Discussion
In this population-based study including all patients with pathologically veri-
fied (adenocarcinoma) pancreatic cancer or clinically suspected pancreatic 
cancer in the period 1993 until 2008 we found that only 40 of 2,564 patients 
(1.6%) survived for more than five years.
The recently published Eurocare-5 data, reported a remarkably high five-year 
survival rate of 7% for patients diagnosed between 2000 and 2007 throughout 
Europe with any type of pancreatic tumor.[1] The authors suggest that difficul-
ties with ascertainment of vital status in some countries might have biased 
their long-term survival estimates. More in line with our results are the five-
year survival rates reported in population-based studies in Norway (1965–2007), 
Finland (1990–1996) and Australia (2002–2003) of <3%, 1.8% and 2.6%, respec-
tively, in patients with pancreatic cancer. The Norwegian cohort included all 
registered pancreatic cancer patients, both pathologically verified and unver-
ified. At five years of diagnosis, relative survival was 5.3% in men and 2.6%. in 
women. Five-year survival rate in patients with pancreatic cancer diagnosed 
in 1990–2006 was less than 3%.[5] In the Finnish study, all types of pancreatic 
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cancer were included. Re-evaluation of histological specimens of the long-term 
survivors initially recorded as having histologically proven pancreatic adenocar-
cinoma, confirmed pancreatic adenocarcinoma in only 10 of 26 patients, repre-
senting 11.2% of all long-term survivors (10 of 89 patients).[6] In the Australian 
study, neuroendocrine and ampullary tumors were excluded and, similar to our 
results, half of the long-term survivors had undergone surgical resection. As 
the other half of the long-term survivors had no pathologically confirmed diag-
nosis, true pancreatic cancer in these patients may be doubted because long-
term survival in patients with pancreatic cancer, especially if the primary tumor 
has not been resected, is extremely rare and a more indolent or benign disease 
seems a more likely cause.[7]
In our study the five-year survival among patients with clinically suspected 
but microscopically unverified pancreatic cancer was 1.3% (16 of 1,199 patients). 
However, in 15 of the 16 long-term survivors without initial pathological veri-
fication, the diagnosis was revised: 14 patients had a benign disease and one 
a premalignant tumor. As data collection by the registry occurred within 6–9 
months after initial diagnosis, revision of the primary diagnosis had taken place 
after this period of time. None of the long-term survivors with pathologically 
unverified metastatic or unresected pancreatic cancer were diagnosed with 
pancreatic malignancies that exhibited a more indolent clinical course, such 
as neuroendocrine tumors. Several explanations could be proposed for this 
finding. First of all, pancreatic neuroendocrine tumors are rare, representing 
only 1–3% of all pancreatic tumors.[8,9] Second, computed tomography tech-
nology, the imaging modality that is most commonly used to investigate 
known or suspected pancreatic tumors, has improved. As a result, we succeed 
to differentiate better between pancreatic neuroendocrine tumors and other 
malignancies of the pancreas. Detection rate of neuroendocrine tumors with 
CT scan exceeds 80%.[10] Finally, although overall survival for patients with 
pancreatic neuroendocrine tumors is more favorable than for patients with 
pancreatic adenocarcinomas, the median overall survival in metastatic disease 
does not exceed 2-5.8.[11,12]
The five-year survival of patients with pathologically verified pancre-
atic cancer in our study was 1.7% (24 of 1,365 patients). The majority of these 
long-term survivors with a verified adenocarcinoma had undergone surgical 
resection (21 of 24 patients), comprising 10.1% of all surgically treated patients 
(N=207). The five-year survival rate of surgically treated patients in our study 
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is comparable with the five-year survival rate of 12.2%, found in a recently 
published large cohort study, including 11,081 patients with surgically resected 
invasive pancreatic adenocarcinoma.[13] By contrast, our results seem inferior to 
the results found in the phase III CONKO-001 trial, in which patients who under-
went surgical resection had a five-year survival of 15.0%.[14] However, this trial 
was performed in a selected group of patients. Another explanation for the 
lower five-year survival of surgically treated patients in our study might be that 
adjuvant chemotherapy was not part of standard care during the first period of 
this study. Significant survival differences were found in the CONKO-001 trial 
between patients treated with surgery alone and those who received adjuvant 
chemotherapy, five-year survival rates were, respectively, 9.1% and 20.7%.[14]
In our study, we tried to identify prognostic factors predicting long-term 
survival, however, the small number of five-year survivors among the surgi-
cally treated patients was not suitable for testing in a multivariate model. In 
a recently published large cohort study, Paniccia et al. identified pathologic T 
stage, lymph node ratio and administration of adjuvant chemotherapy as vari-
ables associated with long-term survival in surgically treated pancreatic adeno-
carcinomas.[13] In our study, the surgically treated long-term survivors had very 
different tumor characteristics. It is noteworthy that approximately half of 
surgically treated long-term survivors (9 of 21 patients) eventually died from 
metastatic or locoregional recurrence, further emphasizing the largely pallia-
tive nature of surgery in pancreatic cancer.
Several studies have shown that surgical resection is performed in 8–15% 
of all pancreatic carcinomas.[7,14-16] In the present study, 8.1% of the patients 
underwent surgical resection. Whilst the resection rate did not change over time, 
some important surgery-related improvements were made, including the imple-
mentation of centralization of pancreatic cancer surgery from 2005 onwards 
and the standard use of adjuvant chemotherapy, improving disease-free and 
overall survival through the administration of adjuvant gemcitabine during six 
months.[17-19] Our population-based data showed an increase in median overall 
survival of surgically treated patients from seven months in the early period to 17 
months in the period 2005–2008, which is consistent with median survival rates 
demonstrated in several other population-based studies.[16,20,21] 
In contrast to the surgically treated patients, the median overall survival 
of patients with unresected and metastatic pancreatic cancer remained 
unchanged over time. Whilst the proportion of patients presenting with 
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metastatic disease increased due to improved and more accurate diagnostic 
imaging techniques, no beneficial effect on survival as a result of stage migra-
tion could be observed. Unfortunately, in this population-based study we have 
no information as to why surgical resection could not be performed in patients 
referred to as having irresectable non-metastatic pancreatic cancer. Among 
unresected patients (locally advanced unresected + metastatic disease), 10.3% 
received chemotherapy. During the course of the study, no substantial prog-
ress had been made in chemotherapeutic treatment of advanced pancreatic 
cancer. However, the prescription of chemotherapy in metastatic disease had 
more than doubled, from 8.8% in 1993–1996 to 20.4% in 2005–2008, possibly 
because physicians gained more experience with the use of chemotherapy in 
the adjuvant setting. Since 2011, new treatment options for metastatic pancre-
atic cancer have emerged, demonstrating an overall survival benefit by using 
combination chemotherapy.[22,23] The FOLFIRINOX regimen is currently the 
most effective treatment in metastatic disease, but due to toxicity, its use is 
restricted to a select group of patients.
Conclusion 
In conclusion, long-term survival in patients suffering from pancreatic cancer is 
extremely rare. We found that only 1.6% of all patients survived for more than 
five years. Of the patients who were eligible for surgical resection, 10.1% survived 
for at least five years. Perhaps the number of long-term survivors may further 
increase in the future, by optimizing centralization, more extensive surgery, and 
increased use of possibly better (neo) adjuvant strategies. However, unresect-
able and metastatic disease at presentation remains a key problem, stressing 
the need for better understanding of the disease and better systemic treat-
ment options. Survival in patients with pathologically verified (adenocarci-
noma) pancreatic cancer and clinically suspected but microscopically unverified 
pancreatic cancer was very similar, demonstrating the reliability of the clinical 
and radiological judgement. However, if a patient with pathologically unveri-
fied pancreatic cancer survives longer than expected (more than 6–12 months 
depending on the extent of the disease at the time of primary diagnosis), we 
recommend to perform fine needle aspiration or, preferably, histological biopsy 
in order to obtain pathological confirmation of the diagnosis.
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Abstract
Background: In pancreatic cancer surgery, a relationship between surgical 
volume and postoperative mortality and overall survival has been estab-
lished. As a result, high-volume centers report significantly better survival 
rates. In this population-based study, we aimed to explore the influence of 
incidence and treatment volume on the outcome of patients with meta-
static pancreatic cancer diagnosed in the Netherlands.
Methods: All patients diagnosed with metastatic pancreatic cancer in 
the Netherlands between 2007 and 2011 were included. We defined three 
types of high-volume centers: high volume incidence center based on 
the number of patients diagnosed with metastatic disease, high-volume 
treatment center based on number of patients diagnosed with metastatic 
disease and started on palliative chemotherapy and high volume surgical 
center based on the number of resections with a curative intent performed 
in patients with non-metastatic pancreatic cancer. 
Independent predictors of administration of palliative chemotherapy 
were evaluated by means of logistic regression analysis. The multivari-
able Cox proportional hazard model was used to assess the impact of being 
diagnosed or treated in a high-volume centers on survival.
Results: 5,385 patients presented with metastatic pancreatic cancer of 
which 24% received palliative chemotherapy. Being treated with chemo-
therapy in a high-volume treatment center was associated with improved 
survival (HR 0.76 95% CI 0.67-0.87). Also, in patients with metastatic 
Chapter 5.4
Volume matters in the systemic treatment of meta-
static pancreatic cancer: a population-based study 
in the Netherlands
N. Haj Mohammad, N. Bernards, M.G.H. Besselink, O.R. Busch, J.W. 
Wilmink, G.J.M. Creemers, I.H.J.T. De Hingh, V.E.P.P. Lemmens, H.W.M. van 
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pancreatic cancer, being diagnosed in a high-volume surgical center was 
associated with improved survival (HR 0.74 95% CI 0.66-0.83).
Conclusion: Being treated with chemotherapy in a high volume treat-
ment center was associated with an improved overall survival compared 
to being treated in a non-high volume treatment center. This suggests 
that a volume-outcome relationship, as previously described in resectable 
pancreatic cancer, might also be present in systemically treated patients 
with metastatic disease. 
 
Introduction
The incidence of pancreatic cancer is rising in developed countries. In 2012, 
pancreatic cancer was the fifth leading cause of cancer related-mortality in 
Europe.[1] By 2030, pancreatic cancer is expected to become the second leading 
cause of cancer-related death.[2] 
The only potential curative treatment for pancreatic cancer is surgical 
resection. Unfortunately, only 20% of the pancreatic cancer patients present 
with resectable disease. Patients not fit enough to undergo surgery or those 
with irresectable or metastatic tumors have a poor prognosis with a median 
overall survival of approximately three months.[3] In 1997, gemcitabine mono-
therapy became the first-line palliative treatment for this subgroup of patients. 
In numerous trials over the years, different drug regimens have been tested. 
None of these trials demonstrated a statistically significant survival benefit, 
except for gemcitabine plus erlotinib which was associated with a very modest 
survival benefit of only 2 weeks.[4] Fortunately, two encouraging trials have 
been published recently showing a significant survival benefit for patients 
treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX in comparison 
with gemcitabine monotherapy.[5-7]
Limited treatment options in pancreatic cancer might have led to reserved 
prescription and heterogeneity in administration of palliative chemotherapy. A 
recently published population-based study investigating the use of palliative 
chemotherapy in patients with metastatic pancreatic cancer showed a large 
variation in prescription rate between ten community hospitals, varying from 
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5-34%.[8] Reasons for not offering palliative chemotherapy were age and socio-
economic status of the patient.[9,10] However, preference and experience of 
the treating physician might have played an important role as well.[11] 
In pancreatic cancer surgery, a relationship between the number of surgi-
cally treated patients in a hospital and postoperative outcome has been estab-
lished, with a lower postoperative mortality in high-volume treatment centers.
[12-15] Interestingly, the number of resections per hospital had a greater impact 
on the post operative mortality than the surgeons caseload, indicating the 
importance of a specialized medical infrastructure for this specific group of 
patients.[16] It might be hypothesized that the outcome of systemically treated 
patients is positively influenced by the experience of a medical oncologist, 
defined by the number of treated patients. Moreover, the combined experience 
of the multidisciplinary team providing pancreatic cancer care may be a rele-
vant factor determining patient outcome as well. 
In 245 patients with resectable pancreatic cancer, a superior survival was 
found for patients treated with adjuvant chemotherapy in a high-volume treat-
ment hospital compared to patients treated in a low-volume hospital.[17] These 
data were presented at ASCO Gastrointestinal Cancers Symposium 2016 and 
underline that further elaboration is necessary on differences in patterns of 
care and their impact on survival.
To our knowledge, no information is available on the relationship between 
volume and outcome of patients with metastatic pancreatic cancer. Therefore, 
we conducted a nationwide population-based study in patients with meta-
static pancreatic cancer and assessed whether volume influenced the prescrip-
tion of palliative chemotherapy and impacted the median overall survival. 
Methods
Data collection
Data were obtained from the Netherlands Cancer Registry (NCR). This is a 
population-based database which collects information on all patients newly 
diagnosed with a malignancy in the Netherlands. The registry area includes 
about 16.7 million inhabitants and encompasses 91 hospitals, of which 8 
academic centers. The NCR is notified by the national automated patholog-
ical archive (PALGA), if the newly diagnosed cancer is microscopically verified. 
In the absence of verification, notification occurs by additional sources, such as 
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the national registry of hospital discharge, multidisciplinary team reports and 
diagnosis therapy combinations (specific codes for reimbursement purposes). 
Within 6-9 months after notification, trained registration clerks operating 
on behalf of the NCR extract patient and tumor characteristics from medical 
records. Data are coded according to a national manual and cancer topography 
and morphology are classified according to the International Classification of 
Disease for Oncology (ICD-O) second or third edition.
Our inclusion was limited to patients diagnosed with an adenocarcinoma, a 
not otherwise specified carcinoma (ICD-O morphology codes 8010, 8012, 8020, 
8140,8141, 8260, 8310, 8440, 8470, 8480, 8481, 8490, 8500, 8560) or a non-micro-
scopic verified neoplasm of the pancreas between January 2007 and December 
2011. Other morphology codes were excluded or did not occur during the study 
period. Patients diagnosed at autopsy were excluded. Carcinomas were classi-
fied according to the Tumor Lymph Node Metastases classification and staged 
according to the recommendations of the international Union against Cancer 
(UICC) TNM classification in the respective period. For staging of neoplasms 
without microscopic verification the clinical Extent of Disease (cEOD) was used. 
To assess the influence of hospital volume on outcome, we defined high-
volume centers based on the upper quartile (Q3/75th percentile). Each volume 
threshold dichotomized the data and created two categories for comparison: 
hospitals with volume greater or equal to the cutoff value and hospitals with 
volume less than the cut-off value. We defined three different types of high-
volume centers. 
1)  High-volume incidence center: a hospital volume that refers to the number 
of patients diagnosed with metastatic pancreatic cancer. This may be 
regarded the most straightforward hospital volume. ≥101 patients diag-
nosed in 5 years (range 14 -183) However, as pancreatic cancer treatment 
may be an important determinant of outcome of pancreatic cancer patients 
and a high volume incidence center does not necessarily treat a high volume 
of patients, we also identified high volume treatment center. 
2)  High-volume treatment center: a hospital volume that refers to the number 
of metastatic pancreatic cancer patients treated with chemotherapy. This 
may be regarded as a proxy for the experience of a hospital to deliver care 
to this patient population that may develop specific complications in this 
disease stage. ≥28 patients treated in 5 years (range 1-116);
3)  High-volume surgical center: a hospital volume which refers to the number 
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of surgical procedures in pancreatic cancer, which may be regarded as a 
proxy for the presence of a well-developed infrastructure to deliver complex 
care to pancreatic cancer patients; ≥ 68 resections with curative intent 
treated in 5 years (range 1-123). 
Vital status of all patients on 1st of January 2014 was assessed through linkage 
with civil municipal registries and the Central bureau for genealogy, which 
collects data on all citizens who die. 
Figure 1 Flow diagram of included patients 
* NNO not otherwise specified 
N= 5385  patients diagnosed with metastatic pancreatic adenocarcinoma in 
the Netherlands between January 2007 and December 2011
Exclusion:  N= 30 incomplete registration 
N= 93 diagnosed at autopsy 
N= 287 other morphology than adenocarcinoma or NNO
Exclusion: N= 4596 non-metastatic pancreatic  adenocarcinoma 
N= 9981 patients diagnosed with pancreatic adenocarcinoma in the 
Netherlands between January 2007 and December 2011
N=10391  patients diagnosed with pancreatic cancer in the Netherlands 
between January 2007 and December 2011
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Statistical analysis
We performed all statistical analyses using SAS statistical software (version 
9.4, SAS institute, Cary, NC, U.S.A.). Two sided p-values of <0.05 were consid-
ered statistically significant. 
The proportion of patients treated with chemotherapy was described for 
different subgroups and high-volume centers. Differences between subgroups 
were tested by means of a χ2 test and trends over time were analyzed by means of 
a Cochran-Armitage trend test. Independent influences on prescription of palli-
ative chemotherapy were evaluated by means of a logistic regression analysis. 
The different types of high-volume centers were added separately to the model. 
Survival time was defined as the time from diagnosis to death or 1 January 2014, 
for patients who were still alive. The crude survival was calculated with the life 
test and differences between survival curves were evaluated by means of a log 
rank test. The independent prognostic effect of being diagnosed or treated in a 
high-volume center was estimated using Cox regression analyses; 
The hazard ratios for death were adjusted for gender, age, extent of disease 
and period of diagnosis. The influence of being diagnosed in a high-volume 
treatment center was investigated in patients treated with chemotherapy 
only; untreated patients were excluded from this analysis. In the other models 
chemotherapy was added separately to investigate the effect of treatment on 
the hazard ratio of death. 
Results
Between 1 January 2007 and 31 December 2011 9,981 patients were diagnosed 
with pancreatic cancer in the Netherlands, of whom 5,385 (54%) patients 
presented with metastatic disease. The patient selection is shown in figure 1. 
Fifty-two percent of the patients with metastatic disease were male, the 
median age at time of diagnosis was 69 years (range 21-100) and in 68% of the 
cases the diagnosis was microscopically confirmed. The general characteristics 
of patients treated in high-volume centers are shown in table 1. 
We defined high-volume centers, based on three different volume thresh-
olds. In total, 17 hospitals were classified as a high-volume center. Thirteen 
hospitals were classified as high-volume incidence center, seven hospitals as 
high-volume treatment center and four hospitals as high-volume surgical center. 
Only one hospital qualified for all three high-volume definitions. Another four 
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Table 1 General characteristics of patients diagnosed with a neoplasm of 
the pancreas in the Netherlands between 2007 and 2011, strati-
fied according to high volume center (N=5,385) 
Total 
N (%)
High-volume 
incidence center
N (%)
High-volume 
treatment center 
N (%)
High-volume 
surgical center 
N (%)
Sex
 Male 
 Female
2796 (52)
2589 (48) 
825 (54)
707 (46)
455 (55)
380 (46)
215 (59)
148 (41)
Age (yrs)
 <50 
 50-59
 60-69
 70-79
 ≥80 
239 (4)
817 (15)
1671 (31)
1731 (32)
927 (17) 
68 (4) 
228 (15)
505 (33)
471 (31) 
260 (17) 
47 (6) 
140 (17) 
302 (36) 
250 (30) 
96 (12) 
29 (8) 
83 (23) 
131 (36) 
97 (27) 
23 (6)
Histologic subtype 
 Adenocarcinoma 
 Non-microscopic 
 verified
3640 (68)
1745 (32)
1082 (71) 
450 (29)
659 (79)
176 (21) 
312 (86) 
51 (14)
Location of metastase
 Liver
 Peritoneum
 Lung 
 Extra regional 
 lymphnodes
 Other 
 2 organs
 3 or more organs
2770 (51)
425 (8) 
244 (5) 
179 (3) 
100 (2)
1190 (22)
431 (8) 
775 (51)
110 (7) 
66 (4)
61 (4)
25 (2)
340 (22)
131 (9)
407 (49)
54 (7) 
36 (4) 
38 (5) 
 
18 (2) 
199 (24) 
73 (9)
168 (46)
36 (10)
14 (4)
27 (7)
7 (2)
84 (23)
23 (6)
Chemotherapy 
 Yes
 No
1274 (24) 
4111 (76) 
400 (26)
1132 (74)
329 (39) 
506 (61) 
100 (28)
263 (73)
Total 5385 (100) 1532 (28) 835 (16) 363 (7)
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high-volume incidence centers were high-volume treatment centers as well. 
Twenty-four percent (N=1,274) of the patients with metastatic pancreatic 
cancer received palliative chemotherapy. Table 2 shows the crude proportions of 
patients treated with chemotherapy in the different high-volume centers. The 
odds of receiving palliative chemotherapy were higher in high-volume treat-
ment centers. Whereas palliative chemotherapy was not administered more 
frequently in high-volume incidence centers or high-volume surgical centers. 
Other predictive factors for prescription of chemotherapy were younger age at 
time of diagnosis, the presence of microscopic verification (OR 3.13 (2.63-3.85), 
two sites of metastases (OR 0.73 (0.57-0.94) and a more recent year of diag-
nosis. (OR for 2011, 2007 reference 1.55 (1.24-1.94))
We found that patients diagnosed in the hospital that qualified for all three 
high-volume definitions had pathological verification more often compared 
to patients who were diagnosed in a hospital that was only one type of high 
Table 2 Crude percentages and adjusted odds for receiving chemotherapy 
among patients diagnosed with metastatic pancreatic cancer in 
the Netherlands between 2007 and 2011 (N=5,385)
Crude
percentage % 
Multivariate Odds ratio 
(95% CI)
Diagnosed in high-volume 
incidence center *
 Yes 
 No 
26
23
1.14 (0.98-1.32)
1.00 (reference) 
Treated in high-volume
treatment center *
 Yes 
 No 
39
21
2.20 (1.85-2.61)
1.00 (reference)
Diagnosed in high-volume
surgical center *
 Yes 
 No 
28
23
0.82 (0.64-1.07) 
1.00 (reference) 
* Different types of high volume centers were added separately to the model adjusted for tumor 
and patient characteristics 
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Table 3 Crude median overall survival, crude 1-year survival and adjusted 
hazard ratios for patients diagnosed with metastatic pancreatic 
cancer between 2007 and 2011 in the Netherlands (N=5,385)
Crude Median 
survival  (weeks)
Crude 1-year 
survival (%)
Multivariable
HR (95% CI) 
Diagnosed in high-volume 
incidence center *
 Yes 
 No 
9.9
9.4
6.7
5.5 
0.86 (0.94-1.06)
1.00 (reference) 
Treated in high-volume
treatment center * ** 
 Yes 
 No 
28.4
22.9
21.3
11.6
0.76 (0.67-0.87) 
1.00 (reference) 
Diagnosed in high-volume
surgical center *
 Yes 
 No 
14.7
9.3
11.9
5.4 
0.74 (0.66-0.83)
1.00 (reference) 
* Different types of high volume centers were added separately to the model adjusted for all the 
above listed variables. 
** Only patients treated with palliative chemotherapy were included in the analysis (N = 1,274)
volume center. However, patients in that specific hospital were not treated 
with palliative chemotherapy more frequently compared to other high-volume 
hospitals.
The median overall survival of patients with metastatic pancreatic cancer 
was 9.6 weeks (1-year survival rate 6%). Table 3 shows the results of a multi-
variable proportional hazards regression analysis modeling the risk of death for 
patients with metastatic pancreatic cancer. Factors that were associated with 
poor survival were older age (≥80 years), absence of microscopic verification 
and metastases in multiple organs. Beneficial prognostic factors were metas-
tases limited to the lungs or limited to extra-regional lymph nodes, treatment 
with palliative chemotherapy and treatment in a high-volume surgical center. By 
excluding treatment with chemotherapy from the model (result not shown) the 
beneficial effect of younger age was statistically significant. 
The median overall survival in patients treated with palliative chemotherapy 
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was 24 weeks (1-year survival rate 14%). Multivariable hazard regression analysis 
in patients treated with palliative chemotherapy revealed that being treated 
in a high-volume treatment center was associated with improved survival (HR 
0.76, 95CI 0,67-0,87). 
Discussion
To our best knowledge, this is the first study showing a positive association 
between hospital volume and overall survival in patients with metastatic 
pancreatic cancer. This population-based study demonstrated that being diag-
nosed in a high-volume surgical center and being treated with palliative chemo-
therapy in a high-volume treatment center was associated with an improved 
overall survival. 
The presence of microscopic verification as well as younger age are well-
known and established predictors for starting palliative chemotherapy.[10] In 
this study, we did not find any relationship between the volume of incidence 
and the prescription of palliative chemotherapy in a multivariate regression 
analysis. Being diagnosed in a high volume incidence center neither seemed to 
influence the survival of patients with metastatic pancreatic cancer. Remarkably, 
being treated with palliative chemotherapy in a high-volume treatment center 
positively influenced the survival of patients with metastatic pancreatic cancer. 
This may be explained by the experience of physicians in high-volume treat-
ment centers with the specific patient population and adverse events of 
prescribed chemotherapeutic agents. As early as 1979, Luft et al. described an 
inverse relation between surgical volume and mortality in patients with resec-
table pancreatic cancer.[18] High-volume surgical centers reported significantly 
better survival rates.[14,19,20] 
In metastatic disease, the medical oncologist has to weigh patients' prog-
nosis, treatment toxicity and the possible positive impact on quality or quantity 
of life. Together with the patient, the physician has to decide to start palliative 
chemotherapy or to provide supportive care only. Given the often poor clin-
ical condition of pancreatic cancer patients which may deteriorate rapidly, this 
decision making process is complex. Moreover, when starting palliative chemo-
therapy, toxicity has to be managed adequately. This includes appropriate reduc-
tions in chemotherapy dosage, and deciding when to stop or to continue therapy. 
Therefore, experience with the treatment of this specific patient population, 
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gained by treating a relatively high number of patients, may be of paramount 
importance for the outcome of these patients. Furthermore, we hypothesize 
that not only the expertise of an individual medical oncologist, but also the 
complete infrastructure of the hospital may relate to patient outcome.[21] The 
specific tumor and treatment-related complications such as pain management, 
nutritional care and biliary drainage, request comprehensive care. For example, 
cholangitis due to compression of the bile ducts and duodenal obstruction by a 
primary tumor in the head of the pancreas is common in patients with meta-
static pancreatic cancer. Decompression has shown to improve the quality of 
life of these patients and may improve survival.[22,23] A yearly volume of ≥50 
endoscopic retrograde cholangiopancreatographies per endoscopist was asso-
ciated with a lower risk of procedural failure.[24] Our finding that patients being 
diagnosed with metastatic pancreatic cancer in a high-volume surgical center 
exhibited an improved survival, suggests that an experienced multidisciplinary 
team and an adequate infrastructure of a hospital may contribute to improved 
survival as well. 
The prognosis of patients with pancreatic cancer remains poor with a 
median overall survival of 9.6 weeks. It is difficult to compare our results with 
the outcome of randomized controlled trials, which show higher survival 
rates due to inclusion of relatively young patients with a good performance 
status. However, we found that the median overall survival was comparable 
to the median overall survival found in other population-based studies.[25-27] 
In contrast to other population-based studies we also included patients with 
pathologically unverified neoplasms of the pancreas. We found that a signif-
icant proportion of pancreatic cancer patients did not have their diagnosis 
confirmed by pathological examination. Possibly, because these patients were 
considered unfit for palliative chemotherapy and pathological confirmation 
would not have had therapeutic consequences. The overall survival of these 
patients was only 7 weeks and, so the likelihood that these patients suffered 
from pancreatic cancer as well is high. 
In our series, 24% of the patients with metastatic pancreatic cancer was 
treated with palliative chemotherapy. The reported percentage in previous 
population-based studies including patients with metastatic pancreatic cancer 
was highly variable. Moreover, the presented specific subsets of patients 
treated with palliative chemotherapy were inconsistent. David et al. found 
that 30% of the patients with advanced pancreatic cancer received palliative 
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chemotherapy after palliative surgery, in patients who did not undergo resec-
tion the percentage was only 17%.[28] Sharp et al. found a similar percentage 
in patients with locally advanced and metastatic pancreatic cancer.[29] In an 
Australian cohort study including patients with locally advanced and meta-
static pancreatic cancer, 43% of the patients received palliative chemotherapy, 
however this was a smaller study with 1863 patients and selection bias may 
have occurred.[30] A second Australian study by Jefford et al. reported 54% 
chemotherapy prescriptions, but analyzed both resectable and irresectable 
tumors.[31] A recent study by Oberstein et al. seems to report a considerably 
higher percentage of patients treated with palliative chemotherapy (54%). 
However, patients who died within 30 days (22%) were excluded from the anal-
ysis.[32] Median survival in patients treated with palliative chemotherapy was 
24 weeks. This corresponds well with previously published data from the south 
of the Netherlands.[8] Similar to previous studies, we found that younger age 
and limited metastases were related to better survival.[25,33] 
It should be noted that this analysis was conducted in the era before 
FOLFIRINOX and nab-paclitaxel with gemcitabine. With the introduction of 
these new regimens, experience of the medical oncologist might become even 
more important. The combination therapies have different efficacies, different 
side effects, and different routes of administration.[6,7,34] As there are no direct 
data comparing FOLFIRINOX with the combination nab-paclitaxel and gemcit-
abine, experience with all known palliative treatment options is of utmost 
importance to select the appropriate treatment for each individual patient. 
Because of the higher toxicity of these therapies, less patients will be consid-
ered fit enough and as a consequence the experience per center with a specific 
regimen might decrease. Thus, concentration of medical oncological care for 
patients with metastatic pancreatic cancer may become even more important.
It should be acknowledged that even with very careful analysis of popula-
tion-based data it cannot be excluded that part of our results are explained by 
selection bias. Patients treated in high-volume surgical centers may be a selec-
tion of fit patients with limited metastatic tumor load. Part of these patients 
may initially have been considered resectable while explorative laparotomy 
revealed irresectable disease, for instance due to small peritoneal metastases. 
Furthermore, it may be argued that younger, fitter patients select high-volume 
hospitals. To minimize the confounding effect of palliative chemotherapy itself, 
only patients were analyzed that were treated with palliative chemotherapy. 
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Yet, other confounders related with usage of palliative chemotherapy cannot 
be ruled out. However, after adjustment for patient and tumor characteris-
tics, we showed that survival was better in high-volume treatment centers. 
Unfortunately, we did not have information on performance status available in 
our dataset.[35] This lack of information on performance status is a significant 
limitation to our study. Furthermore, the hospital volumes that we defined in 
our study need validation and from these data no definite conclusions can be 
drawn on whether a specific type of high-volume center should be the norm for 
best clinical practice. 
Conclusion
In conclusion, in this nationwide database, hospital volume of palliative 
chemotherapy was associated with improved survival demonstrating that a 
volume-outcome relationship, as described for pancreatic surgery, may also 
exist for pancreatic medical oncology. 
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Summary and General Discussion
This thesis revealed trends in absolute incidence, treatment and overall 
survival of patients diagnosed with metastatic upper gastrointestinal 
cancers in the Netherlands. 
Summary
Among patients with esophageal cancer the proportional incidence of meta-
static disease increased from 22% in 1994-1998 to 32% in 2009-2013. In chapter 
2.1, we investigated the use of external beam radiotherapy, chemoradiotherapy, 
brachytherapy and chemotherapy in these metastatic esophageal cancer 
patients in the South of the Netherlands, diagnosed between 1 January 1994 
and 31 December 2013 (N=1,020). Major changes in treatment strategies took 
place. We demonstrated that patients were increasingly treated with one or 
more of the above mentioned modalities. Seventy percent of the patients diag-
nosed between 2009 and 2013 received treatment, compared to 56% between 
1994 and 1998. The prescription rates of chemoradiotherapy and chemo-
therapy increased drastically, whereas the use of external beam radiotherapy 
and brachytherapy decreased. These altered treatment strategies, together 
with a more appropriate patient selection and stage migration, ultimately led 
to an improvement of overall survival from 18 weeks in 1994-1998 to 25 weeks 
in 2009-2013. 
In gastric cancer, the proportional incidence of metastatic disease increased as 
well, presumably as a result of stage migration (chapter 3.1). Again we noticed 
a marked increase in the prescription rate of palliative chemotherapy, from 5% 
in 1990 to 36% in 2011. After adjustment for patient and tumor characteristics, 
a large inter-hospital variation was observed in the prescription rates of pallia-
tive chemotherapy. Unfortunately, the substantial increase in the prescription 
rate of palliative chemotherapy did not impact the median overall survival of 
patients with metastatic gastric cancer, which remained poor between 15 and 
17 weeks. 
The most common metastatic site in gastric cancer was the perito-
neal cavity, in chapter 3.2 we focused on this subgroup of patients with 
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peritoneal carcinomatosis. Although the efficacy of palliative chemotherapy in 
this subgroup has not been proven in terms of overall survival benefit, prescrip-
tion rates increased drastically. Once more, no improvement in median overall 
survival was observed. 
In chapter 4, we showed the results of one of the largest population-based 
studies in adenocarcinomas of the small bowel conducted so far. The study 
confirmed previously published data on the rising incidence, which is mainly 
caused by a twofold increase in the incidence of duodenal adenocarcinomas. 
During the study period, the proportional incidence of metastatic disease 
increased from 27% in 1999-2003 to 38% in 2009-2013. The most common 
metastatic sites were the liver (46%) and the peritoneal cavity (29%). The loca-
tion of the primary tumor was associated with the metastatic site. A part of our 
study focused on patients with locoregional disease. One of the most notable 
findings was the use of chemotherapy in 15% of these patients. A significant 
increase in median overall survival was found in the subset of patients treated 
with adjuvant chemotherapy. The prescription rate of palliative chemotherapy 
increased from 19% to 37% in patients with metastatic small bowel adenocar-
cinomas. Although patients treated with palliative chemotherapy exhibited an 
improved median overall survival compared to patients receiving supportive 
care only, the increased prescription rate did not influence the median overall 
survival of the total population with metastatic disease, which remained 
between 4-5 months. 
This thesis had a special focus on pancreatic malignancies, one of the leading 
causes of cancer-related deaths worldwide. The disease is often detected in an 
advanced stage: in chapter 5.1 we investigated trends in treatment and overall 
survival in patients with metastatic pancreatic cancer. Although gemcit-
abine monotherapy has been the reference regimen since 1995, the prescrip-
tion rate of palliative chemotherapy increased almost threefold from 10% in 
1993-1996 to 27% in 2009-2010. As in metastatic gastric cancer, large inter-hos-
pital variations were observed in the prescription of palliative chemotherapy. 
Unfortunately, increased use of palliative chemotherapy did not impact the 
median overall survival of patients with metastatic pancreatic cancer which 
remained 10 weeks, with a 1-year survival rate of only 6%. In this study we also 
noticed that a significant proportion of the patients diagnosed with a malig-
nancy of the pancreas did not have a pathologically verified tumor. 
Therefore, in chapter 5.2 we investigated the relevance of pathological 
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verification in suspected pancreatic cancer. Although obtaining tissue to 
establish the diagnosis can be notoriously difficult in patients with suspected 
pancreatic cancer, the current guidelines strongly recommend pathological veri-
fication, especially in patients with locally advanced or metastatic disease prior 
to treatment. Our data showed that the prognosis of patients without patho-
logical verification was comparable to the prognosis of patients with patholog-
ically verified malignancies of the pancreas. This suggests that they suffered 
from true pancreatic cancer. Therefore, in our opinion verification still remains 
desirable in patients with suspected locally advanced or metastatic pancreatic 
cancer. However, if a biopsy cannot be obtained, a high clinical suspicion should 
justify treatment even in the absence of pathological verification.
The very poor prognosis associated with locoregional and metastatic 
pancreatic cancer led to the research question “does long-term survival exist 
in pancreatic cancer?” (Chapter 5.3). In a population-based study including 
2,564 patients with adenocarcinomas or microscopic unverified cancers of the 
pancreas, we found that only 40 patients (1.6%) survived for more than five-
years. Twenty-one long-term survivors had received a curative resection of the 
primary tumor, with a five year survival rate of 10%. Additional data collection 
in these 21 long-term survivors revealed that locoregional or distant recurrence 
had occurred in 10 patients, so the disease-free survival after curative resection 
after five years was only 5%. Of the remaining 19 long-term survivors, 16 had a 
non-microscopically verified neoplasm at time of diagnosis. The diagnosis was 
revised to a more benign one in 15 patients, the majority of these patients were 
later diagnosed with a focal or auto-immune pancreatitis. 
In an attempt to improve the poor prognosis of patients with resectable 
pancreatic cancer, surgical care has been centralized. Morbidity and mortality 
were significantly lower in these high volume surgery centers. In chapter 5.4 
we investigated whether there was a volume-outcome relationship in meta-
static pancreatic cancer as well. We defined three types of high-volume centers, 
high-volume incidence center, a volume which refers to the number of patients 
diagnosed with metastatic pancreatic cancer. High-volume treatment center 
refers to the number of metastatic pancreatic cancer patients receiving pallia-
tive chemotherapy and a high-volume surgical center refers to the number of 
curative surgical procedures in a hospital. In total, 17 hospitals of the 91 were 
classified as high-volume centers. Of the 9,981 included patients 24% received 
palliative chemotherapy. The results of a multivariable regression analysis 
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showed that chemotherapy was not administered more frequently in high 
volume incidence centers. The median overall survival found in this nationwide 
study was comparable to the survival found in chapter 5.2. Palliative chemo-
therapy was associated with a better overall survival in comparison to patients 
receiving supportive care only. Surprisingly, being treated in a high-volume 
treatment center was associated with an improved overall survival compared 
to being treated in a non high-volume treatment center, respectively 28 weeks 
and 23 weeks. Being diagnosed in a high-volume surgical center positively 
impacted overall survival as well, which might suggest that the infrastructure 
in these hospitals is better suited to treat this complex disease. 
General discussion
This thesis reported trends in incidence, treatment and survival of patients 
diagnosed with metastatic malignancies of the esophagus, stomach, small 
bowel and pancreas. In this chapter the results observed in this thesis will be 
discussed in a broader context.
Trends in incidence of metastatic upper gastrointestinal 
cancer 
The absolute number of new patients with esophageal adenocarcinoma, small 
bowel adenocarcinoma and pancreatic cancer increased. In contrast, there has 
been a decrease in the absolute number of patients presenting with gastric 
cancer.[1]
Throughout the studies in this thesis an increase in the proportional inci-
dence of metastatic disease was observed. The most notable increase, from 
35% in 1993-1996 to 59% in 2009-2010 was seen in patients diagnosed with 
pancreatic cancer. The increases seem to reflect stage migration. Evolution 
of diagnostic imaging techniques, such as the improvement of computed 
tomography scans, introduction of FDG positron emission tomography and 
endoscopic ultrasonography, have led to detection of small metastases that 
previously remained unidentified.[2] 
Besides the improved diagnostic accuracy, altered tumor biology might 
have played a role as well, especially in esophageal and gastric cancer. In esoph-
ageal cancer the histologic distribution changed drastically. During the last 
two decades adenocarcinomas became the predominant histologic subtype in 
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most developed countries.[3,4] Patients diagnosed with adenocarcinomas of 
the esophagus more frequently had metastases at time of diagnosis in compar-
ison to patients with squamous cell cancers of the esophagus, respectively 34% 
and 24%. Therefore the altered histologic distribution in esophageal cancer 
might have attributed to the increase in proportional incidence of metastatic 
disease. In gastric cancer an altered histologic distribution might have played a 
role as well. Gastric cancer can be classified according to the Lauren classifica-
tion, which distinguishes intestinal type gastric cancer and diffuse type gastric 
cancer. In intestinal gastric cancer the glandular appearance of the stomach 
remains preserved, whereas in diffuse type gastric cancer the glandular archi-
tecture is lost completely and tumor cells diffusely infiltrate the stomach.[5,6] 
Multiple population-based studies showed that the incidence of intestinal type 
gastric cancer decreased more sharply compared to the more aggressive diffuse 
type.[7,8] This change in histologic distribution could be an explanation for the 
increase in proportional incidence of metastatic gastric cancer. In small bowel 
adenocarcinomas and pancreatic cancer there is no evidence for an altered, 
more aggressive tumor biology. 
Trends in systemic treatment of metastatic upper 
gastrointestinal cancer 
In patients diagnosed with metastatic esophageal cancer, gastric cancer, small 
bowel cancer and pancreatic cancer prescription rates of palliative chemo-
therapy increased significantly. 
In metastatic gastroesophageal cancer, chemotherapy has proven to be 
superior to ‘best supportive care’.[9,10] Several agents have shown to be active 
in gastroesophageal cancer, for instance fluoropyrimidines, platinum-deri-
vates, taxanes, anthracyclines and irinotecan. A meta-analysis by Wagner et 
al. showed that combination regimens were more effective than single-agents, 
survival increased from 6.7 months to 8.3 months.[10] 
Initial regimens were based on infusional fluorouracil and an anthracycline 
(e.g. epirubicin), later cisplatin was added. For years, this combination was the 
first line treatment in patients with a good clinical condition. One of the major 
disadvantages of this regimen was the need for a central venous access and 
an ambulatory infusion pump to administer the fluorouracil. Furthermore, the 
highly nephrotoxic cisplatin needed a long intravenous hydration scheme and 
required an overnight hospital admission. 
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The REAL2 trial evaluated whether infusional fluorouracil and cisplatin, 
could be replaced by capecitabine and oxaliplatin, respectively. They randomly 
assigned 1002 patients with untreated locally advanced or metastatic gastro-
esophageal cancer to four different triplet therapies: epirubicin and cisplatin 
plus fluorouracil (ECF) or capecitabin (ECX) or epirubicin and oxaliplatin plus 
either fluorouracil (EOF) or capecitabine (EOX). Results showed that capecit-
abine and oxaliplatin were at least as effective as fluorouracil and cisplatin. 
The fluoropyrimidine-related adverse events were similar in the capecitabine 
groups and the fluorouracil groups and oxaliplatin showed a more favourable 
toxicity profile in comparison to cisplatin, with lower incidence of grade 3 and 4 
neutropenia and renal toxicity.[11] More important, capecitabine and oxaliplatin 
were more patient convenient, a central venous access and a long intravenous 
hydration scheme were no longer needed. The introduction of these agents 
might have led to increased prescription of palliative chemotherapy in patients 
with metastatic gastroesophageal cancer. 
Due to the rarity of small bowel adenocarcinoma, no randomized controlled 
trials have addressed the role of palliative chemotherapy. Some small retro-
spective studies showed that chemotherapy improved survival compared 
to best supportive care. Most of the studied regimens were based on fluor- 
ouracil combined with a platinum-based derivative. The largest study, including 
80 patients with metastatic small bowel adenocarcinoma, found that pla- 
tinum-based regimens were superior to non-platinum based regimens in 
terms of response rates and overall survival.[12] This might suggest that plati-
num-based regimens should be the standard of care in metastatic small bowel 
adenocarcinoma, however larger prospective studies are needed. Although 
these studies are currently lacking, the prescription rate of palliative chemo-
therapy in patients with metastatic small bowel adenocarcinomas increased 
from 19% in 1999-2003 to 37% in 2009-2013. 
In metastatic pancreatic cancer, gemcitabine monotherapy has been the 
reference regimen for two decades. Guidelines were based on a publication of 
Burris et al. in 1995. The study, including 126 patients with advanced pancreatic 
cancer, compared the effectiveness of gemcitabine and fluorouracil in advanced 
pancreatic cancer. Patients were randomly assigned to treatment with gemcit-
abine 1,000 mg/m2 weekly during 7 weeks followed by 1 week of rest, after 
which gemcitabine was administered weekly during three weeks followed by 1 
week of rest, or to fluorouracil 600 mg/m2 once weekly. The primary outcome 
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was clinical benefit, which was measured in terms of pain, performance score 
and weight. In 24% of the patients treated with gemcitabine there was an 
improvement of clinical condition compared to 4.8% of the patients treated 
with fluorouracil. The median overall survival improved from 4.4 months to 5.7 
months (p = 0.0022).[13] Until 2011, gemcitabine monotherapy remained the 
reference regimen, since all studies conducted in advanced pancreatic cancer 
yielded disappointing results. The majority of these studies compared gemcit-
abine with a gemcitabine based combination. None of them, demonstrated a 
statistically significant survival benefit, except for gemcitabine plus erlotinib, 
which improved the median overall survival with two weeks.[14] Although no 
progress has been made for the treatment of  pancreatic cancer during the 
studied periods, the prescription rate of palliative chemotherapy almost tripled 
from 10% in 1993-1996 to 27% 2009-2010. 
The marked increases in the prescription rates of palliative chemotherapy 
are probably not only the result of the ongoing introduction of new cyto-
toxic agents. The fact that phycisians became more familiar with the use of 
certain agents might be a contributory factor as well. More experience with for 
instance epirubicin, cisplatin and fluorouracil (ECF) in the treatment of  gastro-
esophageal cancer was gained after publication of the MAGIC trial in 2006. This 
trial showed that perioperative ECF in patients with resectable gastroesopha-
geal cancer reduced tumor size, tumor stage and improved the overall survival.
[15] The trial drastically changed the treatment of resectable gastric cancer, but 
might also have influenced the prescription rates in metastatic gastroesopha-
geal cancer. Increases in prescription rates of palliative chemotherapy in meta-
static pancreatic cancer were observed after introduction of gemcitabine in the 
adjuvant setting. In 2007, Oettle et al. presented the first results of the CONKO-
001 trial which showed that gemcitabine was well tolerated and significantly 
delayed the development of recurrent disease.[16] Final results of this study 
presented one year later at the 44th ASCO annual meeting, showed that adju-
vant treatment with gemcitabine also improved median overall survival. [17,18]
Furthermore reduced skepticism towards systemic therapies could have 
played a role as well. Great improvements in the palliative systemic treatment 
of for instance metastatic colorectal cancer might have reduced the skepticism 
and increased expectations among physicians and patients towards systemic 
therapies for other indications. Multiple studies have shown that patients 
nowadays would choose chemotherapy, even for small gains. They value the 
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small benefits greatly and believe that toxicity is of minor importance.[19] 
Another contributing factor might be the improved management of treat-
ment-related toxicity. More effective agents became available to prevent 
chemotherapy-induced nausea, such as selective 5-HT3 antagonists, neuro-
kinin-1 antagonists and corticosteroids. The majority of patients experience 
complete protection with these agents.[20] The incidence of treatment-related 
neutropenic fever has also been reduced after the introduction of granulocyte 
colony-stimulating factors (GCSF). Administration of granulocyte colony-stimu-
lating factors is recommended when the anticipated incidence of neutropenic 
fever is 20% or after neutropenic fever has occurred in one of the prior cycles.[21] 
Some end of life studies suggest that we continue palliative systemic treat-
ment too long. An increasing number of new regimens are initiated in the last 
weeks of life, despite the fact that it seems to negatively impact the quality 
of life.[22-24] In light of this, there are serious concerns about the financial 
consequences of these (palliative) systemic treatments, with rapidly esca-
lating health care costs. The cancer-drug industry has become major, hundreds 
of biotech companies try to develop new drugs based on molecular targets.
[25] The newly introduced agents are often costly, with prices exceeding 4,000 
euro a month.[26] Between 2003 and 2011 the annual direct costs for cancer 
care in the Netherlands doubled from 2.4 billion euro to 4.8 billion euro.[27] This 
trend is no longer sustainable. We must find ways to reduce the costs. Smith et 
al. suggest to limit second-line and third-line treatments to sequential mono-
therapies. This might reduce the prescription of palliative chemotherapy and 
toxicity related hospitalizations.[26]
Hospital variation in the prescription of palliative 
chemotherapy 
Among patients with metastatic gastric and pancreatic cancer this thesis showed 
inter-hospital variation in the prescription of palliative chemotherapy. Large 
differences in prescription rates between community hospitals existed, varying 
from 9% to 27% in patients with metastatic gastric cancer and from 5% to 34% 
in patients with metastatic pancreatic cancer. These differences persisted after 
adjustment for case-mix in multivariable logistic regression analysis. 
A partial explanation for the large inter-hospital variation in patients with 
metastatic malignancies, might be the vague and unclear national guidelines 
which state that “palliative chemotherapy should be considered in patients 
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with a good clinical condition”. The definition of “good clinical condition” is 
a sum of many subjective variables. In an attempt for a more objective defi-
nition, two rating scales have been developed around the 1950s: the Eastern 
Cooperative Oncology Group Performance status (ECOG) and the Karnofsky 
Performance status scales (KPS). Both scales are based on a patients ability to 
perform daily activities and have shown to correlate with survival and treat-
ment-related toxicity. However, these simple and useful scales are subject to 
bias.[28] Different studies have shown that inter-observer agreement rates 
using this scales were very low.[28,29] Since the 1950s, no new tools have been 
adapted in clinical practice. A great need remains for a more objective tool to 
select patients eligible for treatment more accurately. Introduction of such 
a tool might reduce inter-hospital variation in the prescription of palliative 
chemotherapy. 
Furthermore, we hypothesize that there are other patient, physician or insti-
tutional related factors that influenced prescription of palliative chemotherapy. 
Due to the population-based nature of our data, we were unable to capture 
these factors. Patient-related factors that might have influenced the prescrip-
tion rates besides performance status were nutritional status and disease-re-
lated symptoms. However, one could assume that these patient factors were 
roughly comparable between the community hospitals included in our studies. 
Probably physician-related factors and institutional related factors might have 
played a role too. A population-based study in elderly women diagnosed with 
breast cancer, showed that the administration of chemotherapy was influ-
enced by practice settings. Chemotherapy was prescribed more frequently in 
private practices compared to non-private practices. In addition, physician-re-
lated factors such as graduation year and sex of the physician influenced the 
odds of receiving chemotherapy. Physicians graduated after 1975 prescribed 
chemotherapy more frequently compared to physicians graduated before 1975 
and male physicians were more likely to prescribe chemotherapy compared to 
female physicians.[30] Besides these factors, we hypothesize that experience, 
clinical traditions, presence of a dedicated multidisciplinary team, involvement 
of medical specialists in scientific research and teaching status of a hospital 
also play a role.[31] 
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Survival of patients with metastatic upper gastrointestinal 
cancer 
The increased prescription rates of palliative chemotherapy in upper gastroin-
testinal cancers only impacted median overall survival of patients with meta-
static esophageal cancer, which increased from 18 to 25 weeks.[4] To assess if 
this was a true effect of treatment, we first developed a multivariable hazard 
regression model without a treatment variable and later added the variable 
separately. After adjusting for treatment, the hazard ratio of dying according to 
period of diagnosis attenuated, which suggests that altered treatment strate-
gies contributed to the reduced mortality over time.[32] Other population-based 
studies hypothesized that stage migration played a role as well.[2] Although the 
effect of stage migration might be expected in patients with metastatic gastric 
cancer, small bowel cancer, and pancreatic cancer, the median overall survival in 
these patients remained stable last two decades.[33-35] 
Although the increased prescription rates of palliative chemotherapy did 
not impact overall survival of the entire group of patients presenting with 
metastatic upper gastrointestinal malignancies, this does not imply that these 
patients should not be treated with palliative chemotherapy. Individual patients 
might benefit from systemic treatment. In all studies, patients treated with 
chemotherapy had a significantly better overall survival compared to patients 
treated with supportive care only.[4,33-35] Partially, the better overall survival 
observed in treated patients is very likely to be explained by the observational 
character of our studies. The observational character might have led to selec-
tion bias: fitter patients, those with a better overall survival beforehand, had 
higher odds receiving chemotherapy. Unfortunately, it has been impossible to 
adjust fully for selection bias, since important confounders such as the previ-
ously mentioned performance status, nutritional status and disease-related 
symptoms were lacking in our database at the time of studies. Furthermore, 
it is very likely that the gains achieved with systemic treatments in the treated 
patients are too little to impact the overall survival of the entire population 
with metastatic upper gastrointestinal cancer. Hopefully, future regimens that 
will be discussed later, will be able to achieve this.  
Volume-outcome and centralization 
Volume-outcome effects have been widely studied for surgical procedures. In 
this thesis, we were the first to describe a non-surgical volume-outcome effect. 
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We found that patients with metastatic pancreatic cancer treated in a high-
volume center, based on the number of patients receiving palliative chemo-
therapy, had a better overall survival compared to patients treated in a non 
high-volume center.[36] This could be explained by a better ability of physicians 
in high-volume treatment centers to manage treatment related toxicity. 
Although this was the first study to show a volume-outcome relation, some 
systemic treatments are already centralized in the Netherlands. One example is 
the systemic treatment with ipilimumab, a monoclonal antibody that induces 
an antitumor response in metastatic melanomas. Ipilimumab can cause some 
serious side effects, for which early recognition is of utmost importance. Therefore 
treatment with this targeted agent is performed in specialized centers only.[37] 
Second, patients with metastatic testicular cancer seem to benefit from 
centralization. Verhoeven et al. showed that centralization in patients with 
metastatic testicular cancer positively impacted the overall survival. After 
centralization the overall survival increased from 73% to 88% in patients with 
metastatic seminomas and from 79% to 85% in patients with metastatic 
non-seminomas.[38] 
It is unclear whether systemic treatments of other metastatic malignancies 
such as pancreatic cancer should be centralized. Advantages of centralization 
are more experience with the prescribed chemotherapeutic and targeted ther-
apies in high volume centers. This might lead to earlier recognition of treat-
ment-related toxicity. Furthermore, centralization will boost the participation 
of patients in clinical research, which is of utmost importance for the treat-
ment of  metastatic upper gastrointestinal cancer. Disadvantages of centraliza-
tion might be, that referral to expertise centers, increases the travelling time for 
patients with a limited life expectancy. In addition, specialized centers might 
not necessarily be better equipped for the treatment of elderly patients with 
comorbidity than community hospitals. 
If we decide to centralize care for patients with metastatic malignancies, an 
unresolved question is where to set the bar. In future studies different volume 
thresholds should be investigated, to establish acceptable minimum volume 
standards. 
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Future perspectives 
Last decades, new insights in the molecular basis of malignancies led to the 
introduction of targeted therapies. These therapies are directed against specific 
target molecules in or on cancer cells. Despite promising results in preclinical 
trials, the majority of investigated targeted agents in upper gastrointestinal 
cancers failed in clinical trials. 
Currently, there are two targeted therapies approved for the treatment of 
advanced gastroesophageal cancer: trastuzumab, a monoclonal antibody 
directed against the human epidermal growth factor receptor 2 (HER2), and 
ramucirumab, a vascular endothelial growth factor receptor-2 (VEGF-2) inhib-
itor. Trastuzumab was approved after the publication of the ToGA trial in 2010, 
which demonstrated that trastuzumab in combination with chemotherapy 
improved the median overall survival of patients with advanced HER-2 posi-
tive gastroesophageal cancers.[39] Approximately 10-15% of esophagogastric 
adenocarcinomas overexpress HER-2.[39] Novel approaches to target HER2 posi-
tive disease are studied, such as pertuzumab, a monoclonal antibody directed 
against the extracellulair domain of HER2.[40]
Ramucirumab was approved in 2014 after publication of the REGARD trial. 
In this trial, ramucirumab exhibited a small but significant survival benefit, as 
single agent in patients with advanced gastroesophageal cancer progressing 
after first-line chemotherapy.[41] The RAINBOW trial showed a survival benefit 
as well, comparing weekly paclitaxel plus ramucirumab with weekly paclitaxel 
plus placebo.[42] Based on these studies, the recently introduced Dutch guide-
line states that second-line treatment with paclitaxel and ramucirumab should 
be considered in patients with advanced gastroesophageal cancer. Another 
promising targeted agent directed against the vascular endothelial growth 
factor receptor might be the tyrosine kinase inhibitor (TKI) apatinib. In a large 
Chinese phase III trial where apatinib was administered in third line, the median 
overall survival of patients with advanced or metastatic gastroesophageal 
cancer improved with 1.8 months. However, there is no clinical experience with 
this agent outside of China, and it is not clear whether these results are appli-
cable to a global population.[43] 
Immunotherapeutic approaches like antibodies directed against pro-
grammed cell death 1 (PD-1) have demonstrated efficacy in a variety of solid 
tumors. This programmed death 1 protein is a key immune checkpoint receptor 
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expressed by activated T cells. Binding of PD-1 to its ligand, leads to immuno-
suppression and prevents rejection by the immune system. In a phase IB trial 
in advanced gastric cancer, antibodies directed against PD1 showed promising 
results, with a manageable toxicity profile and promising antitumor activity, 
warranting further research in phase II and phase III trials.[44]
For the treatment of metastatic pancreatic cancer, major improvement came 
with the introduction of triplet chemotherapy including fluorouracil, oxali-
platin and irinotecan (FOLFIRINOX). This combination has proven to be supe-
rior to gemcitabine monotherapy. However, significantly more adverse events 
were observed in the FOLFIRINOX group, therefore this combination should be 
preserved for the selected group of patients with a good performance status 
(ECOG 0-1).[14] In patients with a lower performance status (ECOG 2), treatment 
with the nab-paclitaxel plus gemcitabine could be considered especially if they 
have a heavy tumor load. [45] Recently, the results of the NAPOLI-1 trial were 
published which investigated the efficacy of adding nanoliposomal irinotecan 
to fluorouracil plus folinic acid in gemcitabine pretreated patients with adeno-
carcinoma of the pancreas. The authors concluded that nanoliposomal irino-
tecan represents a new treatment option for patients with pancreatic cancer, it 
improved survival and had a manageable toxicity profile.[46]
Despite numerous attempts, most targeted therapies have failed to demon-
strate a significant improvement in overall survival. The only exception was 
gemcitabine plus erlotinib, which has demonstrated a statistically significant 
but clinically modest benefit.[47,48] A problem in treating pancreatic cancer is 
its genetic diversity. Until now, the targetable mutations have been targeted 
in an unselected patient population.[49] Possibly results of targeted agents 
will improve if patient selection is refined based on the molecular phenotype 
of the tumor. 
Pancreatic cancer is characterized by a dense desmoplastic stroma, 
surrounding the tumor cells. It has been hypothesized that this microenvi-
ronment represents a barrier that prevents effective penetration of chemo-
therapeutic and targeted agents to reach cancer cells. Currently, therapeutic 
agents targeting this tumor-associated stroma are subject of great interest.
[50] Moreover, researchers found that the immune system also plays an 
important role in shaping the tumor microenvironment. Most cancers exploit 
multiple mechanisms in order to escape immune cell recognition and anti-
tumor effector functions. In pancreatic cancer chemokine pathways are found 
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to recruit myeloid cells to the tumor microenvironment, which modulate it in 
such a way that it promotes tumor growth. Different types of immunotherapy 
are currently tested in patients with advanced pancreatic cancers.[50,51]
Hopefully the advances in the systemic treatments of upper gastrointes-
tinal cancer will be able to impact the overall survival of these subgroups of 
patients in the future. However, it should be noted that most treatments will 
be for highly selected patients, which will be the minority of the population. 
Furthermore, the impact of the introduced agents on median overall survival of 
the individual patients might be too little to impact the overall survival of the 
entire population.[34] However, population-based studies presenting real-word 
data remain of importance to monitor the effect of the introduction of new 
treatment regimens on the outcome of cancer.
Strengths and limitations of register-based studies 
The studies included in this thesis were based on data from the Netherlands 
Cancer Registry (NCR). Trained datamanagers operating on behalf of this 
registry routinely collected patient, tumor and treatment characteristics from 
medical records 6-9 months after initial diagnosis. 
Register-based observational studies as included in this thesis have several 
strengths. First of all they often have large sample sizes and great statistical 
power.[52] This makes it possible to study rare diseases such as small bowel 
adenocarcinomas. Second, the registry covers virtually all cases. If a tumor is 
pathologically verified, the Dutch cancer registry is notified by the national 
automated pathological archive PALGA. If this pathological verification is 
lacking, notification occurs by additional sources as the national registry of 
hospital discharge (LMR), multidisciplinary team reports and diagnosis-therapy 
combinations (specific codes used for reimbursement purposes). The complete-
ness of the Dutch cancer registry is estimated to be at least 95%. Other forms of 
research such as surveys and/or clinical studies might be influenced by subop-
timal participation rates. 
However, register-based observational studies also have limitations. The data 
are collected independent of the research question, as a result important 
information might be lacking.[52] In the dataset used, for instance, additional 
information on performance status, nutritional status, disease related symp-
toms, number and size of the metastases, used chemotherapeutic agents 
and treatment-related toxicity was lacking. Therefore differences in baseline 
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characteristics between patients treated with chemotherapy and patients 
receiving supportive care only cannot be ruled out. This might have led to 
selection-bias, patients in a good clinical condition with limited disease related 
symptoms, those with a better overall survival beforehand, presumably had 
higher odds receiving chemotherapy. 
Concluding remarks 
The studies included in this thesis investigated trends in treatment and overall 
survival of patients diagnosed with metastatic upper gastrointestinal malig-
nancies. Over time, increasing proportions of patients were treated with palli-
ative chemotherapy. Only in patients with metastatic esophageal cancer the 
increased prescription rate led to an increase in median overall survival. The 
median overall survival of patients with metastatic gastric cancer, small bowel 
adenocarcinomas and pancreatic cancer remained unchanged. However, this 
does not alter the fact that individual patients might benefit from palliative 
treatment. Adequate patient selection is of utmost importance. The large 
inter-hospital variation in prescription rates suggests that there is still room for 
improvement.
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Nederlandse samenvatting 
Door vergrijzing van de bevolking neemt het aantal nieuwe kankerpa-
tiënten in Nederland toe. Een aanzienlijk deel hiervan heeft een tumor 
gelokaliseerd in het maag-darmkanaal. Darmkanker is momenteel de 
meest voorkomende soort kanker in Nederland. Ook maagkanker is een 
groot probleem, wereldwijd is het de vierde meest voorkomende vorm 
van kanker en het is de tweede belangrijkste oorzaak van sterfte door 
kanker. In Nederland is de incidentie van maagkanker de afgelopen 
twee decennia gelukkig gedaald. Deze afname is vooral toe te schrijven 
aan de verkleinde kans op besmetting met de Helicobacter pylori-bac-
terie, een bacterie die in het zure milieu van de maag kan overleven en in 
verband wordt gebracht met het ontstaan van een maagslijmvliesontste-
king en maagkanker. Slokdarmkanker is de achtste meest voorkomende 
kanker wereldwijd. In tegenstelling tot de incidentie van maagkanker is 
de incidentie van slokdarmkanker de laatste jaren toegenomen. Dit lijkt 
met name toe te schrijven aan de toename van het adenocarcinoom, een 
vorm van slokdarmkanker die ontstaat als een gevolg van overgewicht 
en reflux, oftewel het terugvloeien van maagzuur in de slokdarm. Kanker 
van de alvleesklier is de tiende meest voorkomende vorm van kanker in 
Nederland. Ondanks dat het niet een van de meest voorkomende kanker-
soorten is, is het wel de vierde meest voorkomende oorzaak van kankerge-
relateerde sterfte in de Westerse wereld. De meerderheid van de patiënten 
met een alvleeskliertumor heeft dan ook al uitzaaiingen op het moment 
van diagnose, maar liefst 55%. Deze percentages zijn lager voor patiënten 
met darm- (23%), slokdarm- en maagkanker (37%). 
Patiënten met uitgezaaide vormen van kanker zijn veelal niet meer te genezen, 
om het leven te verlengen kunnen patiënten palliatief behandeld worden. 
Veelal bestaat deze behandeling uit chemotherapie al dan niet in combinatie 
met doelgerichte therapie. De medicatie gebruikt bij chemotherapie noemt 
men ook wel cytostatica, dit zijn medicamenten die cellen doden of de celde-
ling remmen. Sinds de introductie van de eerste cytostatica kort na de Tweede 
Wereldoorlog is er veel veranderd. Er zijn tal van nieuwe middelen bijgekomen. 
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Bovendien zijn we vaker combinaties van cytostatica gaan gebruiken. Aan het 
begin van de 21ste eeuw stagneerde de ontwikkeling van deze vorm van medi-
catie. Echter, met de komst van doelgerichte therapieën (targeted therapy) lijkt 
er een heel nieuw tijdperk aangebroken. Deze therapieën grijpen aan op speci-
fieke eigenschappen van kankercellen of hun omgeving en brengen daardoor 
meestal minder schade toe aan de gezonde cellen dan chemotherapie. Deze 
ontwikkelingen tezamen hebben geleid tot een verviervoudiging van het aantal 
voorgeschreven systemische therapieën. Voor patiënten met niet uitgezaaide 
tumoren uitgaande van het bovenste maag-darmkanaal hebben de toege-
nomen voorschriften van chemotherapie in combinatie met centralisatie van 
de zorg in gespecialiseerde centra geleid tot een verbetering van de overleving. 
In dit proefschrift hebben we ons gericht op de subgroep van patiënten 
met uitzaaiingen van tumoren die hun oorsprong vinden in het bovenste 
maag-darmkanaal. Tot het bovenste maag-darmkanaal rekenen wij de slok-
darm, de maag, de alvleesklier en de dunne darm. We bestudeerden trends in 
de behandeling en overleving van patiënten die lijden aan een van deze vormen 
van kanker. We hebben gekeken of de voorschriften van chemotherapie toege-
nomen zijn over de tijd, en of dit van invloed is geweest op de overleving. 
Daarnaast hebben we aandacht besteed aan twee veelbesproken onder-
werpen binnen de gezondheidszorg. In het kader van de gewenste transpa-
rantie in de gezondheidszorg, hebben wij onderzocht of er een verschil was 
in het voorschrijven van chemotherapie tussen tien perifere ziekenhuizen in 
Noord-Brabant en Noord-Limburg. Verder hebben wij ons in het kader van de 
huidige normeringsdiscussie, afgevraagd of er ook in het geval van uitgezaaide 
kanker van de alvleesklier een relatie bestaat tussen het aantal met chemothe-
rapie behandelde patiënten en de overleving van deze patiënten. Om de boven-
genoemde onderzoeksvragen te kunnen beantwoorden hebben wij gebruik 
gemaakt van de data van de kankerregistratie van het Integraal Kankercentrum 
Nederland (IKNL). 
De studie beschreven in hoofdstuk 2.1 geeft inzicht in de behandeling en 
overleving van patiënten met een uitgezaaide vorm van slokdarmkanker 
(oesophagus carcinoom). Uit deze studie blijkt dat 30% van de patiënten 
met slokdarmkanker uitzaaiingen heeft op het moment dat de diagnose 
gesteld wordt. Dit percentage is sterk toegenomen van 22% in 1994-1998 tot 
32% in 2009-2010. De meest waarschijnlijke verklaring voor deze toename 
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is stadiummigratie. Door verbetering van onder andere de kwaliteit van de 
CT-scan en door de introductie van nieuwe beeldvormende technieken zoals 
de PET-scan en de endo-echografie worden uitzaaiingen veelal in een eerder 
stadium opgespoord. Voor patiënten met uitzaaiingen van slokdarmkanker 
zijn er tal van palliatieve behandelingsmogelijkheden. Uitwendige bestraling, 
brachytherapie (inwendige bestraling van de slokdarm) en chemoradiother-
apie (chemotherapie gecombineerd met uitwendige bestraling van de slok-
darm) zijn met name gericht zijn op het verlichten van klachten veroorzaakt 
door de tumor in de slokdarm zelf. Chemotherapie, daarentegen, heeft als doel 
de uitzaaiingen aan te pakken en tijdelijk te verkleinen. In onze studie werden 
1,020 patiënten met een uitgezaaide vorm van slokdarmkanker geïncludeerd. 
Hiervan ontving 62% tenminste één van de eerder genoemde behandelingen. 
Het percentage behandelde patiënten nam toe over de tijd van 56% in 1994-
1998 tot 70% in 2009-2013, waarbij opvallende veranderingen in het gebruik van 
de verschillende modaliteiten hebben plaatsgevonden. Zo is het gebruik van 
uitwendige bestraling en brachytherapie (inwendige bestraling) sterk vermin-
derd. De voorschriften van chemoradiotherapie en chemotherapie daaren-
tegen toonden juist een sterke toename van respectievelijk 3% in 1994 tot 19% 
in 2013 en van 14% in 1994 tot 31% in 2013. Deze veranderde voorschriften over 
de tijd lijken tezamen met stadiummigratie en een adequate patiëntselectie 
een gunstig effect te hebben gehad op de overleving. De mediane overleving 
van patiënten met een uitgezaaide vorm van slokdarmkanker nam namelijk toe 
van 18 weken in 1994-1998 naar 25 weken in 2009-2013. 
Ook patiënten met maagkanker presenteerde zich veelal met uitzaaiingen, in 
2011 was dit percentage 44% (hoofdstuk 3.1). Deze uitzaaiingen bevonden zich 
met name ter hoogte van het buikvlies, 44% van de patiënten had zogeheten 
peritoneale metastasering, ook een aanzienlijk percentage had uitzaaiingen ter 
hoogte van de lever (40%). Voor deze patiënten is genezing niet meer mogelijk, 
wel kan gepoogd worden met chemotherapie het leven te verlengen. In 1990 
ontving slechts 5% van de patiënten met uitgezaaide maagkanker palliatieve 
chemotherapie. Gedurende de studieperiode is dit percentage echter gestegen 
tot 36% in 2011. Oudere patiënten lijken minder vaak behandeld te worden 
met chemotherapie. Hetzelfde geldt voor patiënten met comorbiditeiten en 
patiënten met uitzaaiingen in meerdere organen. Jongere patiënten evenals 
patiënten met een hoge sociaaleconomische status ontvangen juist vaker 
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chemotherapie. Rekening houdend met deze factoren is de meest opvallende 
bevinding de sterke variatie in het voorschrijven van chemotherapie tussen 10 
verschillende ziekenhuizen in Noord-Brabant en Noord-Limburg. Zo werd in het 
ene ziekenhuis 9% van de patiënten behandeld terwijl dit percentage in een 
ander ziekenhuis ruim 27% was. Helaas heeft het toegenomen voorschrijven 
van chemotherapie niet kunnen leiden tot een betere overleving op populat-
ieniveau, deze bleef voor patiënten met uitgezaaide maagkanker tussen de 15 
en 17 weken. Wel was het zo dat patiënten die behandeld werden met chemo-
therapie een betere overleving hadden dan niet behandelde patiënten, 32-37 
weken versus 9-16 weken. Hierbij moet de kanttekening worden gemaakt dat 
er in onze studie waarschijnlijk sprake was van selectiebias. Patiënten in een 
betere algemene toestand ontvingen vaker chemotherapie, terwijl de oudste 
en meest fragiele patiënten zeer waarschijnlijk niet behandeld werden. Door 
ontbrekende variabelen in onze dataset, zoals algemene fysieke conditie, voed-
ingstoestand, en symptomatologie gerelateerd aan de ziekte was het onmo-
gelijk om hier op een juiste manier onderzoek naar te doen. 
In hoofdstuk 3.2 hebben we aandacht besteed aan de grote groep maag-
kankerpatiënten met uitzaaiingen ter hoogte van het buikvlies (peritonitis carci-
nomatosa). Ondanks dat er gedacht wordt dat chemotherapie minder effectief 
is in deze subgroep van patiënten nam ook hier het percentage met chemother-
apie behandelde patiënten sterk toe. Zo werd in de periode 1995-1998 slechts 
11% van de patiënten met peritonitis carcinomatosa behandeld, in vergelijking 
met ruim 42% in 2007-2011. Helaas werd er ook in deze subgroep van patiënten 
geen verbetering van de mediane overleving gezien, deze bleef 4 maanden. Er 
wordt gedacht dat patiënten met peritonitis carcinomatosa uitgaande van de 
maag, evenals patiënten met peritonitis carcinomatosa van colorectale origine 
baat zouden kunnen hebben bij chemotherapie die direct wordt toegediend in 
de buikholte (intraperitoneale chemotherapie). 
Een van de zeldzaamste tumoren van het maag-darmkanaal is het adenocarci-
noom van de dunne darm. In hoofdstuk 4.1 bespreken we de resultaten van één 
van de grootste tot nu toe gepubliceerde studies op populatieniveau naar de 
incidentie, behandeling en overleving van deze tumor.
De incidentie van het adenocarcinoom van de dunne darm neemt langzaam 
toe van 0.5 tot 0.7 nieuwe gevallen per 100.000 personen per jaar, in respecti-
evelijk 1999 en 2013. Het grootste deel van deze tumoren lijkt voor te komen 
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in de twaalfvingerige darm oftewel het duodenum. In totaal had 30% van de 
door ons geïncludeerde populatie (N=3,930) uitzaaiingen op het moment van 
diagnose. Net als bij slokdarm- en maagkanker nam dit percentage toe over de 
tijd. Opvallend was dat de locatie van de primaire tumor bepalend leek voor het 
metastaseringspatroon, zo zaaiden tumoren gelokaliseerd in het duodenum 
veelal uit naar de lever, terwijl tumoren gelokaliseerd elders in de dunne darm 
meestal uitzaaiden naar het peritoneum. 
De enige curatieve behandeling voor patiënten zonder uitzaaiingen was een 
curatieve resectie van de primaire tumor. In onze studie vonden we dat de locatie 
van de tumor van invloed was op het al dan niet ondergaan van een resectie. Zo 
werden tumoren gelokaliseerd in het duodenum beduidend minder vaak geoper-
eerd (58%) dan tumoren elders in de dunne darm (95%). Dit kan worden toeges-
chreven aan de complexiteit van de betreffende chirurgische ingrepen. Hoewel 
er geen studies waren over de effectiviteit van chemotherapie rondom de oper-
atie, werd het in toenemende mate voorgeschreven. Het percentage steeg van 
7% in 1999-2003 tot 15% in 2009-2013. Ook voor patiënten met een gemetasta-
seerde tumor van de dunne darm was het bewijs voor palliatieve chemother-
apie gering. Er waren slechts enkele retrospectieve op populaties gebaseerde 
studies die een gunstig effect van palliatieve chemotherapie op de overleving 
aan konden tonen. Toch nam ook hier het voorschrijven van palliatieve chemo-
therapie sterk toe van 19 % in 1999-2003 tot 37% in 2009-2013. 
In onze studie was de mediane overleving van patiënten met een adenocar-
cinoom van de dunne darm 13 tot 14 maanden. Patiënten zonder uitzaaiingen 
hadden een mediane overleving van 25 maanden, deze nam significant toe in de 
loop der jarenvan 19 maanden in 1999-2003 tot 34 maanden in 2009-2013. Er zijn 
verschillende mogelijke verklaringen voor deze verbetering zoals het centraliseren 
van patiënten of de toename in het gebruik van chemotherapie. Patiënten met 
uitzaaiingen van dunne darmkanker hadden een gemiddelde overleving van 4 tot 
5 maanden. Deze bleef onveranderd tijdens de studieperiode. 
Alvleesklierkanker (pancreas carcinoom) is een van de meest agressieve vormen 
van kanker. Het merendeel van de patiënten heeft helaas al uitzaaiingen op 
het moment van diagnose (hoofdstuk 5.1). Opnieuw zien we in onze studie dat 
verbeterde diagnostische technieken hebben geleid tot een toename van het 
aantal patiënten dat zich presenteerde met uitzaaiingen, van 35% in 1993-1996 
tot maar liefst 59% in 2009-2010. Achttien procent van de totale studiepopulatie 
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werd behandeld met palliatieve chemotherapie, in de onderzochte periode verd-
rievoudigden de voorschriften van 10% naar 27%. Opvallend was dat het voorschri-
jfgedrag niet alleen beïnvloed werd door de leeftijd van de patiënt, maar dat ook 
zijn sociaal economische status en eventuele pathologische bevestiging van de 
tumor de kans op het ontvangen van chemotherapie beïnvloedden. Rekening 
houdend met de kenmerken van de patiënt die zich presenteerde in het zieken-
huis werd wederom een sterke variatie in voorschrijfgedrag tussen de verschil-
lende ziekenhuizen waargenomen. Waar in het ene ziekenhuis slechts 5% van 
de patiënten chemotherapie ontving, bleek dit in een ander ziekenhuis wel 34%. 
Helaas heeft ook hier het toegenomen gebruik van chemotherapie niet geleid 
tot een verbetering van de zeer korte overleving, deze bleef mediaan 10 
weken. Hopelijk zullen recent geïntroduceerde behandelingen hier in de nabije 
toekomst verandering in brengen. 
Tijdens het bestuderen van alvleesklierkanker is ons opgevallen dat een 
aanzienlijk deel van de patiënten geen pathologische bevestiging had van de 
diagnose. Daarom hebben we in hoofdstuk 5.2 onderzoek gedaan naar de rele-
vantie van deze pathologische bevestiging in patiënten met een voor alvlees-
klierkanker verdachte afwijking. In de studie werden 3,321 patiënten geïncludeerd 
die tussen 1993 en 2010 werden gediagnosticeerd met een pathologisch beves-
tigde tumor van de alvleesklier of een voor alvleesklierkanker verdachte afwij-
king. We zagen dat in 59% van de patiënten de tumor pathologisch bevestigd 
was, dit percentage nam toe over de tijd van 56% in 1993-1996 tot 69% in 2009-
2010. Jongere patiënten en patiënten met een hoge sociaaleconomische status 
hadden vaker een pathologisch bevestigde tumor. Verder lijkt het er op dat 
het verkrijgen van materiaal voor het stellen van een diagnose makkelijker is 
wanneer patiënten uitzaaiingen hebben. De positie van de alvleesklier in het 
lichaam en de reactie van het alvleesklierweefsel op de tumor bemoeilijken 
namelijk het verkrijgen van geschikt materiaal voor pathologisch onderzoek. 
Een biopsie van een uitzaaiing, waarmee men de diagnose ook kan bevestigen, 
is in sommige gevallen dan gemakkelijker. 
Volgens de huidige richtlijnen heeft de meerderheid (85%) van de patiënten 
voorafgaand aan een behandeling met chemotherapie of chemoradiotherapie 
een pathologisch bevestigde diagnose. Wij vroegen ons af of deze bevestiging 
eigenlijk wel noodzakelijk was of dat een sterke verdenking op CT-scan in combi-
natie met een verhoging van tumormarkers niet voldoende zou kunnen zijn. 
Uit onze dataset blijkt dat de patiënten waarbij de diagnose is gesteld op basis 
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van beeldvormend onderzoek net zo’n slechte overleving hebben als patiënten 
waarbij de diagnose is gesteld op basis van pathologisch onderzoek. Derhalve 
stellen wij dat het verkrijgen van materiaal voor pathologisch onderzoek nog 
steeds zeer wenselijk is. Echter, indien dit onmogelijk blijkt, dient patiënten niet 
ten koste van alles behandeling te worden onthouden. 
Uit de voorgaande studies is gebleken dat zowel patiënten met een uitge-
zaaide vorm van alvleesklierkanker als patiënten met een niet uitgezaaide 
vorm van alvleesklierkanker een slechte prognose hebben. We hebben ons in 
hoofdstuk 5.3 afgevraagd of langetermijns overleving wel bestaat bij patiënten 
met alvleesklierkanker. We vonden dat 40 van de 2,564 patiënten (1.6%) geïn-
cludeerd in deze studie vijf jaar na het stellen van de diagnose nog in leven 
waren. Eenentwintig van deze overlevenden waren geopereerd aan een niet 
uitgezaaide vorm van alvleesklierkanker. Van het totaal aantal geopereerde 
patiënten (N=207) blijkt dus slechts 10% vijf jaar na het stellen van de diagnose 
nog in leven te zijn. Na gedetailleerd onderzoek van de betreffende patiën-
tendossiers zagen we dat er zich bij 3 patiënten alsnog een lokaal recidief had 
voorgedaan. 7 anderen hadden uitzaaiingen ontwikkeld in andere organen. Dit 
houdt in dat de ziektevrije overleving na 5 jaar slechts 5% bedroeg. Wel dienen 
we er rekening mee te houden dat deze resultaten dateren uit een periode voor 
de centralisatie van alvleesklierchirurgie. 
Zeventien overlevenden hadden een niet uitgezaaide en niet geopereerde 
vorm van alvleesklierkanker. Slechts bij 2 patiënten bleek de tumor ook bevestigd 
door pathologisch onderzoek. Beiden hadden een opvallend mild beloop van de 
ziekte. Opvallend was echter dat 15 van de 17 patiënten geen pathologische beves-
tiging hadden gekregen van de diagnose. Aanvullend onderzoek van de dossiers 
toonde aan dat bij 14 van de 15 patiënten de diagnose herzien was, meestal naar 
een goedaardige aandoening van de alvleesklier, zoals een ontsteking. 
Er waren slechts twee patiënten met een uitgezaaide vorm van alvleesklier-
kanker die langer dan vijf jaar leefden. Een van deze twee patiënten had een 
bevestigde tumor en ontving verschillende lijnen chemotherapie. De andere 
patiënt had een niet pathologisch bevestigde tumor en bleek uiteindelijk ook 
geen alvleesklierkanker te hebben maar een ANCA-geassocieerde vasculitis, 
oftewel een ontsteking van de bloedvaten die meerdere organen treft. 
In de laatste studie van dit proefschrift hebben we onderzocht of central-
isatie van de niet-chirurgische zorg ook de overleving van patiënten met een 
uitgezaaide tumor van de alvleesklier zou kunnen verbeteren (hoofdstuk 5.4). 
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Om deze vraag te kunnen beantwoorden hebben we een drietal hoog-volume 
centra gedefinieerd. Allereerst de hoog-volume incidentiecentra (N=13), geba-
seerd op het aantal nieuw gediagnosticeerde patiënten met alvleesklierkanker 
in een bepaald ziekenhuis. Ten tweede de hoog-volume behandelcentra, geba-
seerd op het aantal patiënten met gemetastaseerde alvleesklierkanker die 
behandeling ontvingen met palliatieve chemotherapie (N=7). Ten derde de 
hoog-volume chirurgische centra, gebaseerd op het aantal resecties met een 
curatieve intentie verricht in een bepaald centrum (N=4). In onze studiepopu-
latie bestaande uit 5,385 patiënten met een uitgezaaide tumor van de alvlees-
klier bleek dat 24% behandeling met chemotherapie ontving. Dit percentage 
was niet hoger in hoog-volume incidentie centra, wat suggereert dat het zien 
van meer patiënten niet automatisch leidt tot het voorschrijven van meer 
chemotherapie. Vanzelfsprekend was het percentage met chemotherapie 
behandelde patiënten hoger in de hoog-volume behandelcentra wanneer we 
deze vergeleken met laag-volume behandelcentra. 
De mediane overleving van de gediagnosticeerde patiënten was 9.6 weken en 
daarmee vergelijkbaar met de overleving gevonden in onze eerdere studie. De met 
chemotherapie behandelde patiënten hadden mediaan genomen een overleving 
van 24 weken. We vonden een significant verschil in overleving tussen patiënten 
behandeld met chemotherapie in hoog-volume behandelcentra ten opzichte 
van patiënten behandeld in niet hoog-volume behandelcentra, 28 tegenover 23 
weken. Aangezien deze analyse enkel werd verricht op behandelde patiënten lijkt 
selectiebias een minder belangrijke rol te spelen. Het zou kunnen dat de ervaring 
met de systemische behandelingen in grote behandelingscentra leidt tot vroeg-
tijdige signalering en anticipatie op bijwerkingen. 
Ook patiënten die gediagnosticeerd werden in een van de hoog-volume 
chirurgische centra hadden een betere overleving vergeleken met patiënten 
gediagnosticeerd in een van de andere centra, 9 versus 15 weken. Deze cijfers 
dienen wel met enige nuance te worden geïnterpreteerd, het populatie-geba-
seerde karakter van onze studie kan geleid hebben tot selectiebias. Het zou 
kunnen dat de patiënten die gediagnosticeerd werden in hoog-volume chirur-
gische centra minder of kleinere metastasen hadden. Het zou ook kunnen dat 
de zorg voor deze specifieke subgroep van patiënten in hoog-volume chirurgi-
sche centra beter georganiseerd is. Naar alle waarschijnlijkheid beschikken deze 
centra bijvoorbeeld over interventieradiologen en maag-darm-leverartsen die 
meer ervaring hebben in de behandeling van deze complexe aandoening. Wat 
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ons betreft dient de gevonden relatie tussen grote centra en de verbeterde 
overleving van patiënten met uitgezaaide alvleesklierkanker in de toekomst 
verder bestudeerd te worden. 
Uiteindelijk concluderen we in dit proefschrift, waarin we trends in de behan-
deling en overleving van patiënten met uitgezaaide tumoren van het bovenste 
maag-darmkanaal hebben bestudeerd, dat het toegenomen gebruik van 
chemotherapie alleen bij patiënten met uitgezaaide slokdarmkanker heeft 
geleid tot een verbetering van de overleving. Dit betekent overigens niet dat 
we nooit meer chemotherapie zouden moeten voorschrijven. Het blijft zo dat 
de individuele patiënt nog steeds baat kan hebben bij dergelijke behandeling. 
Dit benadrukt het belang van een adequate patiëntenselectie en een behande-
ling op maat. 
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Dankjewel!
Het lezen van dit proefschrift begint voor velen van jullie met deze pagi-
na’s, de pagina’s waar het voor mij na de nodige inspanningen eindigde. 
Aangezien een ieder van jullie de totstandkoming van dit proefschrift 
mede mogelijk (of juist onmogelijk) heeft gemaakt zou ik graag een paar 
woorden van dank uitspreken. 
Allereerst Geert-Jan bedankt! Zonder jou was ik hier überhaupt nooit aan 
begonnen. Op een dag kreeg ik een mailtje van jou doorgestuurd waarin Valery 
op zoek was naar “jonge en getalenteerde mensen”. In vergelijking met jou ben 
en blijf ik inderdaad jong, maar getalenteerd? Dat vond ik een mooi compliment, 
wat me heeft doen besluiten om te solliciteren bij het Integraal Kankercentrum 
Zuid. Nu vier jaar verder en een fantastische ervaring rijker heb ik hier geen 
seconde spijt van. Samen met Valery creëerde jij de mogelijkheid om drie dagen 
per week op de oncologie polikliniek te komen werken en twee dagen per week 
onderzoek te gaan doen. 
Wat heb ik veel van je geleerd. Allereerst als arts, je feilloze klinische blik, 
je ongedwongen omgang met patiënten en je zeer zorgvuldige manier van 
werken. Daarnaast als onderzoeker, met je onuitputbare enthousiasme wist 
je zelfs mij (redelijk vaak afgeleid door andere zaken in het leven) keer op keer 
weer te motiveren, je wist de getallen steeds opnieuw weer in de juiste context 
te plaatsen en met heel veel geduld mijn (wr)Engels te corrigeren. “As well as” 
mens heb ik je bijzonder gewaardeerd, je hebt naar mij geluisterd, mij laten 
zien wat ik kan, mij altijd met open armen ontvangen en mij ontelbare keren 
aan het lachen gemaakt. Vooral dat laatste maakte mijn werkzaamheden op 
de polikliniek onbetaalbaar, het voorbespreken van mijn poli had geregeld iets 
weg van een voorstelling waar menig cabaretier nog een puntje aan kan zuigen. 
En omdat er achter iedere succesvolle man een nog succesvollere vrouw staat, 
wil ik ook jou, Inge heel graag bedanken.
Valery, ook zonder jouw vertrouwen, gewekt door een presentatie over een 
database waar ik mijn inziens toch niet echt veel informatie uit had kunnen 
halen, was dit boekje er nooit gekomen. Ik wil je bedanken voor de ontspannen 
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en informele samenwerking. Dag en nacht mocht ik je bellen, sms‘en en mailen, 
een reactie kwam er altijd de termijn was variabel. Als kritische lezer van mijn 
manuscripten, heb ik genoten van al je commentaren, die altijd verpakt in een 
goede dosis humor mijn stukken naar een hoger niveau hebben getild. Ook de 
werkoverleggen waren onvergetelijk, als we niet door de medewerkers van de 
bewaking het pand uit werden geveegd, dan waren we op eigen initiatief al 
vertrokken naar één van Eindhovense culinaire hotspots. Natuurlijk mag ook 
Madrid niet in dit verhaal ontbreken, de perfecte doelgerichte therapie voor 
onderzoekers van het wild-type. Ps. volgende keer zou ik voor de nette schoenen 
gaan in plaats van voor de strijkbout. 
Dan mijn paranimfen, wat een kanjers. Lieve Eef, dat een opleiding interne 
geneeskunde zou resulteren in zo’n waardevolle vriendschap had ik nooit 
verwacht of durven hopen. De avonturen die wij in zo’n korte tijd samen hebben 
beleefd, zijn voor mij echt goud waard. Bijvoorbeeld onze “studiereis” naar Fleix 
die na een slapeloze nacht eindigde met tien sinaasappels op het strand van 
Alicante, de weekend durende workshop losjes leven georganiseerd door de 
gezusters Vleugelman op Lowlands en DIT was me toch effe een mooi feestje 
ondanks de noodgedwongen Cinderella-tactiek. Naast een fantastische partner 
in crime ben je de afgelopen jaren een lief en bijzonder geduldig luisterend oor 
geweest. Je hebt me geleerd hoe te genieten van de kleine dingen in het leven, 
die eerder door mij onopgemerkt bleven, zoals de mooie wolken, de geur van 
een heerlijke bak koffie, de smaak van verse Limburgse asperges, de kwispelende 
kolibries en de uitgestrekte heide van de Malpie. Helaas hebben ook levensge-
nieters wel eens tegenwind, maar dan zullen wij er voor elkaar zijn, om uiteinde-
lijk die vlieger weer te doen stijgen. Bedankt dat je er was, bent en altijd zult zijn! 
Jelle, mijn allerliefste broertje. Natuurlijk bedankt voor je bijdrage aan dit proef-
schrift. Wie had gedacht dat jouw kennis, waar ik als kind al jaloers op was, ook 
mij nog ooit van pas zou komen. Naast een knappe kop, letterlijk en figuur-
lijk, heb je het talent om met een gezonde dosis humor dagelijkse struggles te 
relativeren. Zo kreeg ik bijvoorbeeld de volgende reactie van jou op een e-mail, 
die ik na anderhalf uur worstelen met netwerkinstellingen, modems, routers en 
RSA-keys eindelijk verstuurd had. “***ERROR*** This mail has not been received”. 
Op het moment dat ik bijna ontplofte las ik de toevoeging “Please go cry in the 
corner” en wist ik dat het goed zat, message delivered. Lief broertje wat ben ik 
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ongelofelijk trots op jou. Dat realiseerde ik mij in het bijzonder op de dag dat je 
in het huwelijksbootje stapte met je prachtige vrouw Shana. Tussen de tranen 
door besefte ik, dat dat kleine sulletje van vroeger plaats had gemaakt voor een 
kerel van wereldformaat. De tijd dat ik jou als grote zus nog wat kan leren zit 
erop, maar de tijd dat ik je kan waarderen nog lang niet. 
Natuurlijk ook een woord van dank voor mijn twee paar ouders. Lieve papa en 
Sylvie, ondanks dat de afstand tussen ons tijdens het schrijven van dit promotie 
onderzoek hemelsbreed significant is toegenomen, staan jullie dichterbij dan 
ooit. Ik wil jullie bedanken voor de vele fijne logeerpartijen in mijn chambre 
k’loot. Veelvuldig werd ik in mijn eigen huis verrast door jullie aanwezigheid, 
afgewassen vaat, opgevouwen wasgoed, een groene bak vol met onkruid, licht 
in de duisternis, eendenborst en de geur van camembert. Ik heb me dankzij 
jullie de afgelopen jaren heel vaak onvoorwaardelijk geliefd gevoeld! 
Lieve mam, wat een mazzel heb ik toch dat ik de jonge en geavanceerde versie 
ben van jou. Dat maakt dat jij mij als geen ander begrijpt, aan geen woord hebben 
wij genoeg. Trots ben ik dat ik je schaterlach, zorgzaamheid, fantastische humor, 
doorzettingsvermogen en mooie looks heb mogen erven! Je bent en blijft mijn 
grote voorbeeld waar ik oneindig veel van houd! En natuurlijk mag ook jij, lieve 
Walther, niet aan dit dankwoord ontbreken. Als er iemand de afgelopen jaren niet 
onder stoelen of banken heeft gestoken hoe trots hij op mij was, dan was jij dat! 
Geregeld toverde je een lach op mijn gezicht, wanneer je luidkeels riep ‘D’n deze 
had ik zelf gemaakt kunnen hebben’. Dat, lieve Walther, geloof ik ook! 
Graag wil ik alle co-auteurs bedanken die hebben meegewerkt aan de totstand-
koming van dit proefschrift, in het bijzonder Laura, de jongste telg. Ook ben ik 
de leden van de promotiecommissie dankbaar voor het aandachtig lezen van 
mijn proefschrift en “het vuur aan mijn schenen” op deze belangrijke en bijzon-
dere dag. 
 
Wie er ook niet mogen ontbreken in dit dankwoord zijn mijn collega’s van het 
IKNL, die mij met heel veel geduld wegwijs hebben gemaakt in het statistische 
oerwoud genaamd SAS en mij hebben doen inzien dat publiceren valt te leren. 
Nog steeds heb ik iedere dag om half 11 zin in koffie, koek en klets en dat zal 
nooit meer over gaan. 
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Dan mijn collega’s uit het Catharina ziekenhuis, ook zij hebben allen op hun 
eigen manier een steentje bijgedragen. Er werd creatief omgesprongen met het 
rooster en het onderwijs om mijn deadlines te halen. Zó creatief dat ik tijdens 
mijn promotietraject nooit een skireis, assistentenweekend, borrel of diner heb 
hoeven missen. Kortom ik sta bij jullie in het krijt! 
Extra credits zijn er voor de eetclub, lieve Marijk, Daph, Suus en Safiye, wat heb 
ik het heerlijk gevonden om na een dag onderzoeken onder het genot van een 
glutenvrij, zwangerschapsproof en halal bereid diner de wereldproblemen met 
jullie te bespreken. 
Ook Stephanie mag niet aan dit dankwoord ontbreken, bedankt voor de “signa-
lisatie” van mijn Nederlandstalige spelfouten en voor de strakke billen, zonder 
jou was ik wel basic, maar zeker niet zo fit. 
Lieve Tanja, ook jij verdient een lintje! Door jou kan ik de verandering zijn die ik 
in de wereld om me heel wil zien, dank voor de nieuwe bril. 
Nu zijn we aanbeland bij de categorie vrienden en kennissen die ik toch wil 
bedanken, ondanks hun vele pogingen om de totstandkoming van dit proef-
schrift onmogelijk te maken, door het organiseren van feestjes, festivals, 
concerten, diners, reizen en sportieve festiviteiten.
Allereerst mijn lieve vriendinnen, Denise, Lynn, Aniek en Kristine. Als ik afgeleid 
moest worden waren jullie er altijd. Helaas viel ik ook aan jullie ten prooi als ik 
niet afgeleid wilde worden. Onder het genot van menig alcoholische versnape-
ring werden steden zoals Parijs, Brussel en Utrecht door ons op gepaste wijze 
onveilig gemaakt. Er werd gitaar gespeeld op verkeersborden, getoerd op stof-
zuigers en getraind voor de Onlympische sport struukduken. Dames, “the next 
time you come home as drunken meat” ….. dan ben ik er gewoon weer bij. 
Dan Simone, lieve pummel, jij bent het levende bewijs: “oude liefde roest niet”. 
Wie had gedacht dat wij goed terecht zouden komen. Twee scootermeisjes, die 
wekelijks jouw vader moesten omkopen met een frikandel omdat we voor de 
zoveelste keer te laat bij de kerk stonden. Ik! Super trots ben ik, ook op jou, heer-
lijke gekke mama van Nina met je lichtgevende discoschoenen! 
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Oopsie Daisy, mijn avonturen met jou lopen always helemaal out the hand 
en daarom mag ook jij niet aan dit lijstje ontbreken. San Sebastian, Barcelona, 
Guus, Hajraa en Bourgondisch gaan allemaal te boek als verhalen om nooit te 
vergeten. Zullen we alvast een datum prikken voor “gierend achter de gera-
niums”? Op 22-09-2071 heb ik nog niks staan! 
Remco, Anne, Ferina, Em, Buuf, Mike, Mattie, Bas, Joost, Diane, Omi, Ank, Lie, 
Mees, Steef, Bart, Paul, Opa, Oma en Ilse ook, jullie waren onvergetelijk!
En last but not least, liefde van mijn leven, met je overweldigende steun, je luis-
terende oor, je aandacht voor mij, je gevoel voor humor, je zorgzaamheid, je 
fantastische kookkunsten en je warme voeten in koude winternachten ..................
waar blijf je! 
Dankwoord    7
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PhD training and teaching 
Year Workload 
(Hours)
Courses 
Cursus wetenschappelijke integriteit, Erasmus MC, Rotterdam 2016 10 hours
Cursus statistiek en SPSS, wetenschapsbureau Maxima Medisch 
Centrum, Saskia Houterman 
2013 30 hours 
Scientific writing in English for publication in Biomedical Journals, 
Lisette van Hulst
2013 30 hours 
Good Clinical practice Tapas group experts in clinical research 2013 20 hours 
Seminars 
 Nederlandse internistendagen, Maastricht, Netherlands 2016 20 hours 
Nederlandse Oncologie dagen voor Nederlands, NVMO, Arnhem 2015 16 hours 
9e gastrointestinale symposium, Vught, Netherlands 2015 4 hours 
Nederlandse Oncologie dagen voor Nederlands, NVMO, Arnhem 2014 16 hours
8e gastrointestinale symposium, Vught, Netherlands 2014 4 hours 
Presentations 
Oral presentation, 10e gastrointestinale symposium, Vught, 
Netherlands 
2016 15 hours 
Oral presentation, refeeravond “palliatieve sedatie en euthanasie” 
Eindhoven, Netherlands 
2016 20 hours 
Oral presentation, refereeravond “gemetastaseerd 
pancreascarcinoom”, Eindhoven Netherlands 
2015 20 hours 
Poster presentation European Society for Medical Oncology (ESMO), 
Madrid, Spain, 
2014 15 hours 
Poster presentation European Society for Medical Oncology (ESMO), 
Madrid, Spain 
2014 15 hours 
Poster presentation European Cancer Congress, Amsterdam, 
Netherlands 
2013 10 hours
Poster presentation European Cancer Congress (ECCO), Amsterdam, 
Netherlands 
2013 15 hours
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Year Workload 
(Hours)
Presentations  (continued)
Oral presentation, Kamerlid Michiel van Veen (VVD) Eindhoven, 
Netherlands 
2013 10 hours 
Poster presentation World Congress on Gastrointestinal Cancer 
WCGC, Barcelona, Spain 
2013 15 hours 
Oral presentation, Werkgroep Urologie Eindhoven, Netherlands 2013 10 hours 
Conferences
Werkgroepen Medische oncologie, Eindhoven, Netherlands 2012-2014 60 hours 
Projectgroepen Cytomanagement System, Eindhoven, Netherlands 2014-2015 120 hours 
Other 
Medical residency, Internal medicine 2015-2016
Total 430 hours 


